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Abstract
Flavin-containing monooxygenase 3 (FM03) is a hepatic, microsomal enzyme 
important in the Phase I metabolism of xenobiotics. Numerous single nucleotide 
polymorphisms (SNPs) in FM03 have been identified and shown to affect the 
catalytic activity of the enzyme, with some destroying the activity altogether, 
causing the distressing disorder, Trimethyalminuria (TMAU), in humans.
Genotyping was performed at the FM03 locus on several individuals 
displaying symptoms of TMAU. Two new FM03 variants, R238Q and R492Q, 
were discovered in this investigation, with kinetic studies suggesting that R238Q 
destroys FM03 catalysis.
Kinetic studies of FM03 common polymorphisms showed that the 
E158K/E308G displayed significantly reduced catalytic activity compared with 
either single variant alone. E158K/V257M also displayed significantly reduced 
catalytic activity, but not compared to either single variant alone. The 
pharmacogenetic implications are discussed with particular reference to the 
recent finding that E158K/E308G has been associated with reduced polyp 
formation in patients with familial adenomatous polyposis who were treated with 
sulindac sulphide, an FM03 substrate.
The evolutionary history of FM03 was probed using sequence data of 
genomic DNA in a Japanese cohort of potential TMAU sufferers and control 
individuals. Mutational relationships among haplotypes were inferred and time 
depth of the variation and ages of individual mutations were estimated by 
coalescent analysis, with test statistics used to detect departure from neutral 
evolution. A case of balancing selection is proposed at the FM03 locus.
In an attempt to understand the structural and biophysical consequences 
of FM03 variants, a homology model of FM03 was generated, refined and 
validated. Flavin adenine dinucleotide (FAD), an FM03 cofactor, was also 
modeled into the FM03 model and the interactions between the enzyme and 
cofactor predicted.
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1. Introduction
Xenobiotic metabolism refers to the biochemical modification in vivo of 
exogenous substances. These modifications are made through a series of enzyme 
systems, which often convert hydrophobic molecules into more readily excreted, 
polar metabolites. The primary site of xenobiotic metabolism is the liver, 
although virtually all tissues carry out xenobiotic metabolism to a greater or 
lesser extent. Xenobiotic metabolism can be considered in two phases. Phase I 
metabolism is the stage at which polar groups are either introduced or exposed in 
the xenobiotic by oxidation by Cytochrome P450 Monooxygenases (CYPs), 
Flavin-containing Monooxygenases (FMOs), Alcohol and Aldehyde 
Dehydrogenases, Monoamine Oxidase or Peroxidases or hydrolysis by Esterases, 
Amidases or Epoxide Hydrolase. Phase II metabolism is concerned with the 
conjugation of the modified product of Phase I metabolism to produce a water 
soluble conjugate, readily excreted from the body. The majority of Phase II 
reactions are catalysed by Transferases e.g. Glutathione S-Transferases, 
Sulfotransferases or UDP Glucuronyl Transferases.
After the CYPs, FMOs are the largest group of enzymes involved in 
Phase I metabolism of drugs and other xenobiotics and provide the focus for this 
investigation.
1.1. FMOs
FMOs (EC 1.14.12.8) are p-Nicotinamide adenine dinucleotide phosphate 
(reduced) (NADPH)-dependent enzymes that catalyse the oxidation of a wide 
range of compounds. Flavin adenine dinucleotide (FAD) acts as a prosthetic 
group within the FMO molecule and is reduced by NADPH. This reduced form 
of FAD readily binds molecular oxygen to generate a hydroperoxyflavin (FMO-
16
FADHOOH). When in this state, the enzyme acts in a “cocked gun” fashion, 
ready to attack the soft, nucleophilic centre of chemicals containing nitrogen, 
sulphur, selenium or phosphorus (Figure 1). This mechanism distinguishes 
FMOs from other monooxygenases as the activation of oxygen, in the form of 
the C(4a) hydroperoxide derivative of FAD, does not require binding of the 
oxygenatable substrate [1]. This is theorised to be the basis of the broad range of 
substances that are FMO substrates, including hydrazines [2], phosphines [3], 
iodine boron-containing compounds [4], sulphides [5], selenides [6] and an array 
of amines [7]. There is evidence of a number of endogenous compounds being 
FMO substrates, such as methionine [8], cysteamine and cysteine- and 
homocysteine-S-conjugates [ 1 ].
In humans, five FMO genes are known to encode protein {FMOs 1-5) [9]. 
FMOs 1,2,3 and 4 are found in a cluster with FM06, a putative pseudogene, at 
lq23-4 [10]. FMOS is located further away from this cluster at lq21. A second 
cluster on chromosome 1 contains five FMO pseudogenes[ll], FM07P to 
FMO IIP,  which are located within a cluster ~4 Mb to the centromeric side of the 
functional FMO gene cluster [11] and appear to have arisen as a result of a locus 
duplication event. FMOs 1-5 exhibit between 50 to 59% amino acid identity 
across mammalian species [12] including humans (Table 1). FMOs of other 
mammalian species have >78% sequence identity to their human orthologues 
(Table 1). Two GXGXXG motifs, characteristic of FAD- and NADPH- 
pyrophosphate-binding sites are present at identical positions (residues 9-14 and 
191-196, respectively) in mammalian FMOs. Figure 2 shows a primary 
sequence alignment of the five, functional FMOs in humans. The FAD-binding 
site is contained within a highly conserved motif that predicts a Pap secondary
17
Figure 1. Major steps in the catalytic cycle of FMO [1]
S and SO are the xenobiotic substrate and the oxygenated product respectively. 
No substrate binding is required for the cycle to begin. (1) FAD-OOH reacts 
with the nucleophile within the enzyme active site. (2) One atom of molecular 
O2 is incorporated into the substrate and the other is released as H2O. (3) The 
system regenerates.
18
Species h uman Chimpanzee Dog Rabbit Rat
FMO 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5
Human 1 - 58 53 52 51 99 58 54 53 51 89 57 55 52 51 86 58 55 52 53 82 57 53 51 51
2 58 - 57 55 55 58 99 57 57 56 58 86 58 54 56 56 86 57 55 56 57 84 58 55 57
3 53 57 - 52 56 54 57 99 54 55 55 58 83 53 54 53 58 83 53 54 54 57 81 53 54
4 52 55 52 - 54 51 55 53 99 54 53 55 53 86 52 54 54 53 84 52 50 54 53 80 53
5 51 56 56 54 - 51 57 55 54 99 52 58 52 53 89 51 57 52 52 85 51 57 54 51 84
Chimpanzee 1 99 58 54 51 51 - 57 54 50 50 88 57 55 53 50 85 58 54 52 52 82 57 53 51 51
2 58 99 57 55 57 57 - 57 57 57 58 87 58 54 56 56 87 58 55 56 57 85 58 55 57
3 54 57 99 53 55 54 57 - 54 55 55 58 83 53 54 54 58 83 54 55 54 59 81 52 53
4 53 57 54 99 54 50 57 54 - 51 54 53 55 79 51 54 56 54 85 54 51 56 54 82 53
5 51 56 55 54 99 50 57 55 51 - 51 56 53 51 89 51 56 52 52 85 50 57 51 51 84
Dog 1 89 58 55 53 52 88 58 55 54 51 - 57 56 54 51 87 57 55 53 52 87 57 56 53 52
2 57 86 58 55 58 57 87 58 53 56 57 - 58 54 56 56 87 59 57 58 57 84 58 55 57
3 55 58 83 53 52 55 58 83 55 53 56 58 - 54 54 54 59 84 55 54 55 57 83 53 54
4 52 54 53 86 53 53 54 53 79 51 54 54 54 - 53 54 53 83 53 51 54 53 78 51
5 51 56 54 52 89 50 56 54 51 89 51 56 54 - 51 55 53 52 84 51 59 52 50 83
Rabbit 1 86 56 53 54 51 85 56 54 54 51 87 56 55 53 51 - 55 54 53 52 83 56 53 52 51
2 58 86 58 54 57 58 87 58 56 56 57 87 53 54 55 55 - 58 53 57 56 86 58 52 51
3 55 57 83 53 52 54 58 83 54 52 55 59 84 53 53 54 58 - 54 56 55 57 85 52 54
4 52 55 53 84 52 52 55 54 85 52 53 57 55 83 52 53 53 54 - 51 55 53 79 52
5 53 56 54 52 85 52 56 55 54 85 52 58 54 53 84 52 57 56 52 - 52 56 56 51 83
Rat 1 82 57 54 50 51 82 57 54 51 50 87 57 55 51 51 83 56 55 51 52 - 56 53 51 51
2 57 84 57 54 57 57 85 59 56 57 57 84 57 54 59 56 86 57 55 56 56 - 57 55 57
3 53 58 81 53 54 53 58 81 54 51 56 58 83 53 52 53 58 85 53 56 53 57 - 52 52
4 51 55 53 80 51 51 55 52 82 51 53 55 53 78 50 52 52 52 79 51 51 54 52 - 51
5 51 57 54 53 84 51 57 53 53 84 52 57 54 51 83 51 51 54 52 83 51 57 52 51 -
Table 1. The primary sequence identity (%) between mammalian FMOs. Orthologues are shown in bold and paralogues are shown underlined.
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FM01 -MAKRVAIV
FM02 -MAKKVAVI
FM03 -MGKKVAI3
FMO 5 MTKKRIAV1
FM04 -MAKKVAVI
* . . * . .
GAGVS 
GAGVS 
GAGVSG 
GGGVSG 
GAGVSG
, AS IKC C LEE GLE PTC FERSDD L GGLWRFTEHVEE GRAS LYKS W SNS CKEMS CYSD FP FPED YP 79 
11SLKC CVDE GLE PTC FERTEDIGGVWRFKENVED GRAS IYQSWTHTSKEMS C FSD FPHPEDFP 79 
LAS IR S C LEE GLE PTC FEKSNDIGGLWKFSDHAEE GRAS IYKS VFSNS SKEHHC FPD FP FPDD FP 79 
L SS IKC C VEE GLE P VC FERTDDIGGLWRFQENPEE GRAS IYKS VIIHTSKEMMC FSD YP IPDHYP 80 
L S S IKC C VDED LE PTC FERSDD IGGLWKFTE S SKD GHTRVYKS LVTNVCKEMS CYSD FP FHED YP 79 
* * * * * *  * . .  * . . *  ***  * * * • . . * • * * • * . *  . •■* ■ . * . * .  * ** *  * . * . * .  ■ •*
FM01 NYVPNS Q FLEYLKMYANHFD L LKHIQ FKTKVC SVTKC SD SAVS GQWEWTMHEEKQE SAIFDAVMVCTGFLTNPYL P LD S 159
FM02 NFLHNSKLLEYFRIFAKKFD LLKYIQFQTTVLSVRKC PD FS S S GQWKWTQSNGKZQSAVFDAVMVC S GHHIL PHIP LKS 159
FMO3 NFMHNSKIQEYIIAFAKEKNL LKYIQ FKTFVS SVHKHPD FATTGQWDVTTERD GKKE SAVFDAVMVC S GHHVYPNL PKE S 159
FM05 NFMHNAQVLE YFRMYAKE FD L LKYIRFKTTVC SVKKQ PD FATS GQWEWTE SE GKKEMNVFD GVMVCTGHHTNAHL P LE S 160
FMO 4 NFMMHEKFWDYL QE FAEHFD L LKYI Q FKTTVC SITKRPD FSETGQWDWTETE GKQHRAVFDAVMVCTGHFLNPHL P LEA 159
 ^ • t* . *• i •***•*•*•* t  t ;  t  t t  • • *• • ■ t t t g ;
FM01 FP GIHAFKGQYFHSRQYKHPDIFKDKRVL V I 
FMO 2 FP GMERFKGQYFHSRQYKHPD GFE GKRIL V I 
FMO 3 FP GLNHFKGKC FHSRDYKE P GVFNGKRVLW 3 
FMO5 FP GIEKFKGQYFHSRDYKNPE GFTGKRVI11 
FM04 FP GIHKFKGQILHS QEYKIPE GFQ GKRVLVI
* * * •  * * * •  *  *  * * • • • • * • * * • *  *  • *  *  * ■
GMGNSOTDIAVEASHLAEKVFL STTGGGWVISRIFD S GYPWDMVFMTRF 239  
GMGNSG SDIAVE LSKNAAQVFISTRHGTWVMSRISED GYPWD SVFHTRF 239  
LGKSG CDIATEL SRTAEQVMIS SRS GSWVMSRVWDNGYPWDML LVTRF 239  
3IGNSG GD LAVEIS QTAKQVFLSTRRGAWILNRVGDYGYPADVL FS SRL 24 0  
3LGHT0GDIAVE L SRTAAQVL L STRTGTWVL GRS SDWGYPYMMMVTRRC 23 9
FM01 QSMLRHS L PTPIVTWLMERKINNWLNHANYGLIPEDRTQ LKE FVLHDE L P GRIITGKVFIRP SIKEVKENSVIFMHTSKE 31 9  
FMO 2 RSMLRNVL PRTAVKWMIE Q QMNRWFNHENYGLE P QNKYIMKE P VLHDDVP SRL L C GAIKVKSTVKE LTETS A I FED GTVE 31 9  
FM03 GTFLKHNL PTAI SDWLYVKQMNARFKHENYGLMP LNGVLRKE P VFHDE L P AS IL  C GI VS VKPNVKE FTETS A I FED G TIF 31 9  
FMO5 THFIWKICGQSLAHKYLEKKINQRFDHEMFGLKPKHRALSQHPTLNDDLPURI ISGLVKVKGNVKEFTETAAI FEDGSRE 32 0  
FMO 4 C S F I  AQ VL P SRFLNWIQERKLNKRFHHED YGL S -  ITKGKKAKFIVIJDE L PNC IL  C GAITMKTS V IE  FTETSAVFED GTVE 318  
: : :  : : : *  : * *  .
FM01 EPIDIIVFATGYlr: 
FMO 2 ENIDVIIFATG' 
FH03 EGIDCVIFATG" 
FM05 DDIDAVIFATG' 
FM04 EM IDW IFTTG'
FAFP FLDE SWKVEDGQ AS LYKYI FP AHL QKPTL A I IG LIK P L GSHIPTGETQARWAVRVLKGVNKL 399  
•Yfe FS FP FLED S LVKVENHMVS LYKYIFPAHLDKSTLACIGLIQ P L GSIFPTAE L QARUVTRVFKGL C S L 399
Y 3 FAYP FLDESIIKSRNNE11LFKGVFP P L LEKSTIAVIGFVQSLGAAIPTVDLQSRWAAQVIKGTCTL 399
Y 3 FD FP FLED S -  VKWKNKIS LYKKVFP P HLERPTLAII GL IQ P L GAIMPI SE L Q GRWATQ VFKGLKTL 399
Y TFSFP FFEE P LKS LCTKKIFLYKQVFP LNLERATLAI I  GL IGLKGSIL SGTELQARWVTRVFKGL CKI 398
■ * . * * * . *
FM01 P F P SVMIEEINARKENKP SWFGL C YCKAL Q SD YITYIDE L LTYINAKPHL FSML LTD PHL ALTVFFGPC S P YQ FRLTGP G 479
FH02 P SERTHMHDIIKRNEKRIDL FGE S Q S QTL QTHYVDYLDE LALEIGAKPD FC S L L FKD PKLAVRLYFGPCNSYQYRLVGPG 47 9
FMO3 P SMEDHMWDINEKMEKKRKWFG— KSETIQTDYIVYMDE L S S FIGAKPNIPUL FLTD PKLAMEVYFGPC S PYQ FRLVGP G 477
FMO 5 P SQ SEMHAEISKAQEEIDKRYVE S QRHTIQ GD YIDTMEE LAD L VGVRPNL L S LAFTD PKL ALHL L L GP CTPIHYRVQ GP G 479
FM04 P P S QKLHMEATEK-E Q LIKRGVFKDTSKDKFDYIAYMDDIAACIGTKPSIP L L FLKD PRLAWEVFFGPCTPYQYRLMGP G 47 7
*.  : :  : *: : : : : :  : : * * * . .  ***
FM01 KWEGARHAIMTQWDRTFKVIKARWQE SPSPFE SF- -  LKVFS FLAL L V A IFL IFL ----------------------------------------------------- 53 2
FMO 2 Q WE GARNAIFTQKQRILKP LKTRALKD S SNFS VS FL -  LKIL GL L AWVAFFC Q L Q WS-------------------------------------------------- 53 5
FMO 3 Q WP GARNAI LTQWDRS LKPMQTRWGRL QKP C FFFHWLKL FAI PILL IAVFL VLT------------------------------------------------------ 5 32
FMO 5 KWD GARKAILTTDDRIRKP LMTRWERS S SMTSTMTIGKFML AL AFFAI11AYF-------------------------------------------------------- 53 3
FMO 4  KWD GARNAI LTQWDRTLKP LKTRIVPD S SKP ASHSHYLKAWGAP VL LAS L L LICKS S L FLKLVRDKL QDRMS PYL VS L WRG 55 8
Figure 2. A primary sequence alignment of the five functional FMOs in 
humans.
The primary sequences of FMOs 1-5 are aligned. An asterix denotes conserved 
identical residues, a colon indicates conserved similar residues, and a dot 
indicates highly similar residues. The ‘GXGXXG' FAD and NADPH binding 
moieties are boxed (see text) along with the FMO characteristic ‘FATGY’ motif.
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structure, a Rossman fold, known to be involved in binding dinucleotides [13]. 
Phylogenetic analysis suggests that the five functional FMO genes arose from a 
common ancestral gene via a series of gene duplications, estimated to have 
occurred between 210 and 275 million years ago [11]. This is much earlier than 
the divergence of mammals, some 85 million years ago, and therefore it is 
predicted that all mammals possess the five functional FMO genes 1 to 5 [11].
Unlike CYPs, FMOs are not inducible [14, 15]. FMOs exhibit distinct 
developmental and tissue-specific expression [14, 16, 17], which are described in 
the following sections.
FMOl
FMOl, the first FMO purified, was identified as a mixed-function amine oxidase 
in porcine liver microsomes. Its substrates include nitrogen- and sulphur- 
containing compounds [18]. A cDNA for the corresponding protein of humans 
was isolated in 1991 [19] and was formally named as FMOl in 2004 [12]. 
FMOl encodes a polypeptide of 532 amino-acid residues of molecular mass 
60,306.
FMOl is expressed in abundance in the liver of all mammals examined to 
date [20-23], with the exception of the adult human liver where the mRNA [9, 
14] and the protein [24, 25] is not found. The lack of FMOl expression in the 
human adult liver is thought to be due to the insertion of several long 
interspersed nucleotide elements (LINEs), just upstream of the proximal 
promoter [26]. FMOl is expressed however in the human foetal liver [9, 14, 16, 
24, 25] where the expression is highest in the first trimester (7.8 ± 5.3 pmol/mg 
microsomal protein), then declines during foetal development and by 3 days after 
birth is completely extinguished [24]. FMOl is also expressed in the foetal 
human kidney, but this expression is increased after birth [9, 14, 19, 25, 27].
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In human, FMOl is expressed mainly in the kidney [9, 14, 19, 25] but it 
is also expressed in the intestinal mucosa, the mammary and salivary glands, and 
in a number of endocrine tissues, including pancreas, adrenal cortex and medulla, 
thyroid, thymus and testis [11]. It is thought that FMOl is likely to be the major 
contributor to renal xenobiotic metabolism as observed amounts of FMOl in 
adult human kidney (47 ± 9 pmol/mg microsomal protein) [25] are not much 
lower than that observed in the liver for the major hepatic cytochrome P450 
(CYP), CYP3A4 (96 ± 5 1  pmol/mg microsomal protein) [28] and are greater 
than that of the total content of CYPs in adult human kidney [29].
FMQ2
FM02 is expressed predominantly in the foetal and adult lung of several 
mammals including our closest evolutionary relative, the chimpanzee [23, 30, 
31], but in humans the gene encodes a truncated, non-functional protein [32], In 
comparison with FM02 of the rabbit [23], guinea pig [30] and rhesus macaque 
[31], the human enzyme lacks 64 residues from its carboxy terminus resulting 
from a C>T mutation changing a glutamine codon at position 472 to a stop 
codon. The nonsense mutation, g.23238C>T (Q472X), that gave rise to the 
truncated polypeptide is not present in non-human primates such as the 
chimpanzee (Pan troglodytes) and the gorilla (Gorilla gorilla) [32] and must 
therefore have arisen in the human lineage some time after the divergence of the 
Homo and Pan clades took place some 6 million years ago [33].
Analysis of individuals of different ethnic backgrounds, namely European 
Caucasians, Orientals (Japanese and Chinese), Africans (including African 
Americans and UK Afro-Caribbeans), New-Guinea Aboriginals, Indians and 
Maoris, revealed that the allele encoding the truncated FM02 occurred at a 
frequency of 100% in all groups investigated, with the exception of individuals
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of recent African descent, in which the ancestral allele, which encodes a full- 
length FM02, was present at a frequency of 4% [32]. Analysis of products of 
heterologously expressed cDNAs revealed that the truncated protein is inactive, 
whereas the full-length protein is catalytically active [32]
FMQ4
FM04 is 558 amino-acid residues long. Other members of the FMO family, with 
the exception of the truncated form of FM02, contain between 532 and 535 
residues [9]. Sequence comparisons reveal that the additional residues in FM04 
are contained in a single block located at the C-terminus of the polypeptide [34]. 
It has been suggested that the additional residues may have arisen as a result of a 
single point mutation in the termination codon of the ancestral FM04 gene. A 
similar extension is present in FM04s of other mammals and thus the predicted 
mutation would have occurred before the radiation of mammals. FM04 is 
expressed constitutively at low amounts in the liver, lung and kidney of the adult 
human [11, 34-37].
FMQ5
Despite the gene organization of FM05 being similar to the other FMOs, it is 
distinctive as it is not part of the FMO gene cluster on human chromosome 
lq24.3, but is located ~26Mb closer to the centromere, at 1 q21.1 [11], encoding a 
polypeptide 533 amino acids in length..
FMOS is expressed in many foetal and adult tissues, but in human its 
main site of expression is adult liver [11, 16, 36, 37], although it is not present in 
the same amounts as FM03. FM05  expression is the highest of the FMOs in the 
adult skin [16] and in the small intestine [36, 37].
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FM05 is regarded as an atypical FMO with regard to substrate 
specificity. FM05 exhibits little catalytic activity towards compounds, such as 
methimazole, that are good substrates for other FMOs [38-41]. Despite its 
expression in the adult human liver, FM05 is not thought to play a significant 
role in the metabolism of drugs, with the possible exception of esonarimod [42].
1.2. FMQ3
A cDNA for human FM03 was identified in 1992 by Lomri et al. [43] and the 
genomic location of human FM03 was subsequently mapped by Shephard et al. 
the following year [10]. FM03 encodes a polypeptide of 532 amino-acid 
residues with a molecular mass 60,047.
FM03 is the major form of FMO present in the adult human liver [9, 14] with 
expression being switched on at birth [24]. FM03 mRNA has also been detected 
in the lung, kidney, adrenal medulla and cortex, pancreas, thyroid, gut and brain 
[11]. It is thought that FMO3 expression is switched on after birth in humans 
[24], however small amounts of FM03 protein have been detected in the human 
embryonic, but not foetal, liver. The mRNA for FM03 is also not detectable in 
foetal liver [14]. The mechanisms and factors required to express the FM03 gene 
in the embryo, to silence its expression during foetal development and then to re­
activate expression of the gene after birth are unknown. Immunochemical 
analysis of 240 individuals between the ages of 8 weeks gestation and 18 years of 
age by Koukouritaki et al., (2002) [24] detected small amounts of FM03 at eight 
weeks gestation, but not in the foetus (15-40 weeks gestation). FM03 was 
undetectable, or present only in small amounts in postnatal samples during the 
first 3 weeks of life, in most individuals sampled. Subsequently, three distinct 
phases of FMO3 expression were defined. Between 3 weeks and 10 months of
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age, amounts of FM03 increased 5-fold, to 4.7 ± 5.9 pmol/mg microsomal 
protein. Between 10 months and 11 years of age another 3-fold increase in 
expression was observed (to 12.7 ± 8.0 pmol/mg microsomal protein). Between 
11 and 18 years of age, there was a further 2-fold increase (to 26.9 ± 8.6 
pmol/mg microsomal protein). The amount of FM03 was not affected by 
gender.
The age at which FM03 expression is switched on varies from birth to up 
to 2 years old. However, by 10 months of age the majority of individuals are 
expressing FM03. This contrasts with the extinction of FMOl expression in 
human liver, which is tightly linked to the process of birth, being switched off 
within a few days of birth, irrespective of gestational age [24]. This is important 
in terms of the metabolism of xenobiotics that are substrates of FM03 as, during 
the first year of life, most individuals will have no, or very small amounts of 
FMO, in their liver. The amounts of FM03 present in adult liver are comparable 
to those of the most abundant hepatic CYPs, CYP3A4, CYP2C and CYP1A2, 
with reported specific contents of 96 ± 51, 60 ± 27 and 42 ± 23 pmol/mg 
microsomal protein, respectively [28].
Inter-individual differences of up to 20-fold in the amount of FM03 have 
been reported [24, 44]. Such variation would be expected to have consequences 
for the ability of individuals to metabolize therapeutic drugs and potentially 
harmful foreign chemicals that are substrates for the enzyme. FMOs are thought 
not to be inducible by exogenous chemicals (there have been only two reported 
cases of induction in the case of FMOl and the work is yet to be verified [45, 
46]) and, therefore, inter-individual variation in their expression is more likely 
due to genetic, rather than to environmental, factors. This is supported by the 
discovery, in the 5’-flanking region of FMO 3, of single-nucleotide
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polymorphisms (SNPs) that affect the transcription of the gene, in some cases 
effectively silencing it and in others, increasing it as much as 8-fold [24]. 
However, expression of FM03 may be influenced by physiological factors, e.g. 
FM03 declines during menstruation [47-49].
FMQ3 and Trimethylaminuria
FM03 is the most abundant FMO in the human liver reaching levels as high as 
0.5% of the total microsomal protein in this organ. FM03  has previously been 
implicated in termination of pharmacological activity of primary amines and is 
therefore important in drug clearance. However, it is the involvement of FM03 
in the N-oxidation of the dietary-derived xenobiotic trimethylamine (TMA) that 
has provided the impetus for the study of this enzyme in relation to the metabolic 
disorder, Trimethylaminuria (TMAU). TMA is produced by the gut bacteria 
when they metabolise compounds such as choline and lecithin [50]. TMA is 
rapidly absorbed. Normally, FM03 catalyses the A-oxidation of dietary derived 
TMA [51], which smells of rotting fish, into the non-odorous TMA-N-oxide, 
which is readily excreted from the body in the urine. Mutations across the entire 
length of FM03 have been shown to result in the failure to catalyse the N- 
oxidation of TMA into trimethylamine 7V-oxide (Table 2 and Figure 3). TMA is 
excreted in its raw, odorous form in the bodily fluids of individuals carrying any 
one of these mutations in a homozygous state (Figure 2). Affected individuals 
have >40% unmetabolised TMA in their urine compared to 0-9% in unaffected 
individuals [52]. The first described clinical report of TMAU was in 1970 [53]. 
TMAU (or fish-odour syndrome) sufferers excrete an offensive smell of rotting 
fish within their bodily fluids. This condition can not be considered a minor 
affliction as patients often have trouble integrating into society, many are heavy
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Table 2. Mutations in FMQ3 leading to TMAU phenotype
Amino acid change Nucleic acid change exon Reference
g.-2092-10145del 1-2 [54]
E32K g.94G>A 2 [55]
I37T g.llOT>C 2 [56]
R51G g.lll45A >G 3 [57]
A52T g.l 1148G>T 3 [58]
V58I g.lll66G >A 3 [59]
N61S g.l 1177A>G 3 [35, 60]
K64KfsX2** g. 11185delA 3 [55]
M66I g.l 1192G>T 3 [54,61,62]
M82T g.l 1239T>C 3 [63]
N114S g.l5036A>G 4 [47, 64]
V143E g.l5123T>A 4 [65]
G148X g.l5137G>T 4 [66]
P153L g.l5153C>T 4 [61,67]
C197fsX g. 15526_15527delTG 5 [68]
D198E g.l5531T>A 5 [69]
I199T g.l5533T>C 5 [70]
T201K* g.l5539C>A 5 [71]
R223Q g.l8177G>A 6 [72]
R238P g.l8225G>C 6 [56]
R238Q g.l8225G>A 6 Unpublished
M260V* g.l 8290A>G 6 [71]
E305X g.21429G>T 7 [58, 73]
E314X g.21460G>T 7 [62]
R387L g.21680G>T 7 [58]
W388X g.21684G>A 7 [64]
K394KfsXll g.21702delG 7 [56]
M405IfsX + g.23580delG+ 8 [56]
M434I g.24486G>A 9 [35]
Q470X g.24592C>T 9 [64]
G475D g.24608G>A 9 [70]
R492W g.24658C>T 9 [35, 62]
R492Q g.24658G>A 9 Unpublished
R500X g.24682C>T 9 [71]
** K64KfsX2 has also been referred to as M66X
* Causative consequences of variant may be considered ambiguous because of 
variants found in Trans.
+Although this deletion occurred in exon 7, it caused a frameshift resulting in a 
truncation at amino acid 405 in exon 8.
Mutation nomenclature follows that recommended by the Human Genome 
Organization (http://www.hgvs.org/mutnomen/)
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Figure 3.The mutations of human FM 03
The genetic and corresponding amino acid substitutions are shown for the mutations causing TMAU within human FM03. Each exon is numbered and 
the FAD binding moiety within exon 2, the NADPH binding moiety within exon 7 and the FMO characteristic ‘FATGY’ motif within exon 5 are 
highlighted as solid, black bars.
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smokers in an attempt to mask the smell and in some cases they have been known to 
take their own lives rather than live on in this state [74]. Transient forms of this 
disease have been associated with childhood [75] and menstruation in females [48, 
52]. It has also been implicated in an interesting case where a 16 year old male 
displayed TMAU symptoms which manifested at the same time as seizures and 
episodes of psychotic behavioural disturbances [76]. The authors point out that in the 
early nineteenth century, odour was considered an important symptom of psychiatric 
illness, quoting “the breath of maniacal persons has been remarked by Esquirol and 
other practical authors to exhale a fetid smell, which some compare to that of stinking 
fish.” [77]. At this time, no explanation of an association, if indeed one exists which 
can be attributed to TMAU, is forthcoming. This early 19th century comment is not 
the earliest TMAU-like reference on record. Shakespere’s The Tempest [78] 
describes a character, Caliban, as a savage and deformed slave of which was written 
“What have we here? A man or a fish? Dead or alive? A fish: he smells like a fish; a 
very ancient and fish-like smell.” The earliest reference is thought to be in the Indian 
Epic, Mahabharata [79], dated -1000 B.C. which mentions a young woman 
condemned to a solitary life as a ferry-woman, cast from society because she smelled 
like “rotting fish”. The disorder has also been highlighted of late in the general 
media, with TMAU being the subjectFt of a newspaper article and a BBC 
documentary [80]. TMAU is a rare, recessively inherited [81] condition, affecting 
between 0.1-1% of the population [82-84], although this may be higher as the level of 
ignorance to this condition among the medical profession remains high. The 
condition is often diagnosed as one of ‘poor hygiene’ or an overactive imagination on 
the part of the patient. Despite the underlying genetic mechanism of the disorder, 
treatment of TMAU is limited. Antibiotics are sometimes prescribed in an attempt to 
kill gut flora that produce TMA from dietary precursors such as choline and
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lecithin.The dietary supplements copper chlorophyllin and charcoal have been 
reported to decrease the amount of TMA in the urine [85]. Strict diets that limit the 
intake of foodstuffs rich in precursors of TMA, such as meat, eggs, soya and fish, 
have been reported to help control the condition.
Catalytic consequences of the FMQ3 polymorphisms
Although TMAU is a rare condition, polymorphisms in FM03 certainly have 
implications for the wider public. Many xenobiotics are substrates of FM03 (Table 
3) including pesticides, dietary-derived compounds and a diverse range of therapeutic 
drugs such as atypical antipsychotics, anti-thyroids and anti-fungals. Polymorphisms 
exist across the entire length of FM03, which are known to affect the catalytic 
properties of the encoded enzyme (Table 4 and Figure 4), but do not cause TMAU. 
This could have implications to individuals possessing these polymorphisms. For 
instance, an individual with a polymorphism in FM03 that causes a reduction in 
oxidation activity (e.g. D132H, Table 4 and Figure 4) may be considered a poor 
metaboliser of FM03 substrates (Table 3) and therefore may have a heightened risk of 
overdose. This observation is all the more serious when considering the fact that 
adverse drug responses are suggested as the fourth leading cause of death in the 
U.S.A. [8 6 ]. Conversely, a polymorphism in FM03 leading to increased activity of 
the enzyme (e.g. L360P, Table 4 and Figure 4) may lead to lower efficacy of drugs 
metabolised by the enzyme and ineffective dose prescription due to a more rapid drug 
clearance. As displayed in Table 4, work has begun to establish the catalytic 
consequences of polymorphisms to the FM03 enzyme with regards to -N  and -S  
oxidation. These polymorphisms have been generated on the E l58 background only. 
Given that the E158K background is prevalent at a frequency of nearly 50% [87] the 
work in this thesis considers the catalytic consequences of the polymorphisms found 
in human populations on both the El 58 and K158 backgrounds in order to get an
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Table 3. FM03 substrates.
Substrate Pharmacological Agent ref
N-(3R)-1 -azabicyclo[2.2.2]oct-3-ylfuro[2,3-c]pyridine-5- 
carboxamide(l)
Receptor agonist [8 8 ]
1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine Dopaminergic
neurotoxin
[89]
5,6-dimethylxanthenone-4-acetic acid Anti-neoplastic agent [90]
Almotriptan Serotonin agonist [91]
Amphetamine CNS stimulant [92]
Arecoline Acetylcholine receptor 
agonist
[93]
Benzydamine Anti-inflammatory [94]
Bupivacaine Anesthetic [95]
Caffeine CNS stimulant [95]
Cevimeline Muscle relaxant [961
Chlorpromazine Anti-psychotic [97]
Clozapine Anti-psychotic [98]
Dapsone Anti-inflammatory [99]
Deprenyl Type B Monoamine 
oxidase inhibitor
[92]
K11777 Anti-protozoal [1 0 0 ]
Ketoconazole Anti-fungal agent [ 1 0 1 1
Fluphenazine Anti-psychotic [ 1 0 2 1
Itopride Dopamine antagonist [103]
Lidocaine Anesthetic [95]
Methamphetamine CNS stimulant [92]
MK-0457 Aurora kinase inhibitor [104]
Olanzapine Anti-psychotic [1051
Olopatadine Anti-inflammatory [1061
Perazine Anti-psychotic [107]
Phenethylamine Psychotropic agent [1081
Propranolol Adrenergic antagonist [95]
Pyrazoloacridine Anti-neoplastic agent [1091
Ranitidine Gastrointestinal H2 
receptor antagonist
[1 1 0 ]
S 16020 Topoisomerase II 
antagonist
[1 1 1 ]
(<S)-3-methyl-5-( 1 -methyl-2-pyrrolidinyl)isoxazole Anti-anxiety agent [1 1 2 ]
(iS)-Nicotine Neuronal stimulant [113]
Sulfamethoxazole Antibacterial [991
Tamoxifen Oestrogen antagonist [114]
TGI 00435 Src Kinase inhibitor [115]
Thioproperazine Anti-psychotic [1 0 2 ]
Trifluoperazine Anti-psychotic [1 0 2 ]
Trimethylamine Dietary derived amine [67]
Tyramine Dietary derived amine [116]
Verapamil Anti-arrhythmia agent [117]
Xanomeline Muscarinic agonist [118]
Zimeldine Serotonin receptor 
antagonist
[119]
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Table 3.FM03 substrates
4-chlorophenyl methyl sulphide Environmental sulphide [1 2 0 ]
7 alpha-thiomethylspironolactone Anti-mineralocorticoid [ 1 2 1 1
Aldicarb Pesticide [1 2 2 ]
Albendazole Anti-protozoal [123]
Cimetidine Histamine H2 
Antagonist
[113]
Cronetron Pesticide [1 2 2 ]
Diphenyl sulphide Environmental sulphide [1 2 0 ]
Disulfoton Pesticide [124]
Ethionamide Anti-tubercular Agents [125]
Ethyl methyl sulphide Environmental sulphide [1 2 0 ]
Famesylcysteine Posttranslationally 
modified amino acid
[126]
Fenthion Pesticide [127]
Fonofos Pesticide [128]
Methamphetamine CNS stimulant [92,
129]
Methimazole Anti-thyroid Agents [130]
Methionine Essential amino acid [131]
MK-0767 methyl sulphide Peroxisome proliferator 
receptor agonist.
[132]
Phorate Pesticide [124]
iS-methyl-esonarimod Cytokine production 
inhibitor
[42]
Sulindac sulphide Anti-neoplastic agent [5]
Tazarotenic acid Tazarotene (a retinoid) 
metabolite
[133]
Thiacetazone Anti-tubercular Agents [134]
Thiobenzamide Anti-tubercular Agents [135]
Triclabendazole Anti-protozoal [136]
Diethylphenylphosphine Pesticide [3]
Folex Defoliant [137]
2 -(methylseleno)-cinnamonitrile Pharmaceutical
intermediate
[138]
Benzyl selenide Selenium salt 
metabolite
[138]
Dimethylselenide Selenium salt 
metabolite
[139]
Ebselen Anti-inflammatory [6 ]
Methyl phenyl selenide (Selenoanisole) Heame biosynthsis 
antagonist
[6 ]
n-[2 -(methylseleno)-ethyl] benzamide Anti-oxidant (Ebselen) 
metabolite
[138]
(Phenylselenomethyl)-trimethylsilane Fuel additive [138]
Seleno-l-methionine Methionine analogue [140]
Xenobiotic substrates of FM03 are listed and highlighted according to the soft 
nucleophile attacked by the hydroperoxyflavin form of FM03 (blue -  nitrogen, red -  
sulphur, green -  phosphorus and black -  selenium).
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Figure 4.The polymorphisms of human FM 03
The genetic and corresponding amino acid substitutions are shown for the nonsynonymous polymorphisms (boxed) of human FM03. Each exon is 
numbered and the FAD binding moiety within exon 2, the NADPH binding moiety within exon 7 and the FMO characteristic ‘FATGY’ motif within 
exon 5 are highlighted as solid, black bars.
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Table 4. Polymorphic variants of FMO3
Amino Acid 
change
Nucleic Acid 
change
exon Functional
consequence
Reference
E24D g.72G>T 2 Modest reduction [60]
T108T g.15112A>C 4 Synonymous. 
No effect
[141]
D132H g.l5089G>C 4 Substrate dependent 
decrease
[142,143]
S147S g.l5136C>T 4 Synonymous. 
No effect
[141, 142, 
144]
E158K g.l5167G>A 4 Limited, substrate- 
dependent decrease
[62, 67, 
70, 73, 
142, 145]
K167K g.l5530A>G 5 Synonymous. 
No effect
[141]
G180V g.l5475G>T 5 No effect [35]
R205C g.l5550C>T 5 Moderate decrease [69]
N245N g. 18248G>C 6 Synonymous. 
No effect
[73]
V257M g.l8281G>A 6 Moderate substrate 
dependent decrease
[35, 73, 
142]
M260V g.l 8290A>G 6 n.d. [71]
V277A g.21350T>C 7 n.d. [146]
N285N g.21467C>T 7 Synonymous. 
No effect
[141, 142]
E308G g.21443A>G 7 Moderate substrate 
dependent decrease
[58, 70, 
73,147]
13501 g.21570C>T 7 Synonymous. 
No effect
[142]
L360P g.21599T>C 7 Increased activity [143]
E362Q g.21604G>C 7 n.d. [142, 146]
K416N g.23613G>T 8 Modest reduction [60]
I486M g.24642G>A 9 n.d. [146]
G503R g.24691G>C 9 n.d. [142]
* Likely to cause TMAU in a homozygous individual (included in this table because 
its frequency is reported to be > 1 % [60])
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accurate picture of the catalytic effect of polymorphisms in the population. This approach 
is supported by the finding that a homozygote individual of both the E158K and E308G 
polymorphisms display a mild TMAU phenotype, whereas the homozygote E158/E308 
shows no such phenotype [70].
FMQ3 Tertiary structure
The characterisation of any protein sequence is key to understanding the contribution of 
structure to function. The determination of the tertiary structure of a protein, whether it is 
via X-ray crystallography or NMR, can be used to learn about the mechanistic processes 
that underlie a protein’s function. Generally, when two proteins are similar at the primary 
sequence level, they tend to share a similar tertiary structure and thus similar properties and 
functions [148]. As similarity decreases, so too does the likelihood of inferring similarity 
in protein function from primary sequence. Currently there are no mammalian FMO 
structures deposited in the Protein Data Bank (PDB) [149]. However, the possibility exists 
that a theoretical model could be built of FM03 using the three-dimensional atomic 
coordinates of solved protein structures as templates, providing that the templates are of a 
high enough sequence identity to provide a meaningful guideline. Previously, two models 
of FMO have been reported [150, 151] based on the crystal structures of glutathione 
reductase (PDB 1GET, at 1.86 A resolution [152]) and NADPH peroxidase (PDB code 
1 NPX, at 2.16 A resolution [153]). However, these models were generated by merely 
threading the FMO structure onto the aC-atoms of the very low sequence identity templates 
(18% and 16% primary sequence identity to FM03, respectively and 20% identical to each 
other). Thus their use to infer biophysical significance requires extreme caution.
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1.3. Homology Modelling
The idea of generating models of proteins is not new. It was demonstrated in the 1960’s 
that when ribonuclease is denatured, it can refold into its native form and its function is not 
impaired [154, 155]. This study gave rise to the idea that a protein’s tertiary structure may 
be able to be inferred from the amino acid sequence [155]. Currently, ab initio methods of 
modelling protein structure from primary sequence are extremely unreliable, especially for 
larger proteins. The most reliable method of protein structure prediction is homology 
modelling [156-158]. Also known as comparative modelling, the basic principle of 
homology modelling is the generation of a model of a protein (the target) from a protein of 
known structure (the template) with a significant degree of primary sequence identity. The 
scientific defence of this approach is based on the observation that protein tertiary structure 
changes through evolution far more slowly, relative to the primary sequence of the 
molecule [159], and indeed the DNA sequence from which it is derived when considering 
synonymous substitutions.
Homology modelling involves five steps.
1. Identifying a known template structure to the target to be modelled.
2. Aligning the template sequence with the target sequence.
3. Building the model.
The backbone of the model is generated using the coordinates of the template file as a
guide. Loops between more highly conserved secondary structural elements are added (it
is often the case that gaps in alignment are represented as loops) or are altered in length.
4. Energy Minimisation
5. Assessing the quality of the model.
36
It is vital that the model quality is assessed. Automated modelling, although convenient, 
is not advanced enough to generate meaningful results without user input. Pre-calculated 
models from known structures are available from resources such as ModBase [160], 
which uses a PSI-BLAST and Modeller [161] (discussed in more detail below) pipeline to 
generate the results, but they are not validated or refined, nor does the template selected to 
model from undergo any analysis. Indeed, the ModBase web site itself warns that the 
database “ ...contains theoretically calculated models, which may contain significant 
errors, not experimentally determined structures”. There is also a web server version of 
Modeller, ModWeb [162], that automatically models your target sequence for you but 
does not assure the quality of alignment, selection of the correct initial template or any 
sort of assessment of model quality.
To assess the quality of a model, several factors of biophysical attributes are 
considered. As mentioned above, steric clashes of amino acid side chains are considered 
by the modelling software, but they still do happen and must be addressed. The bond 
length and angles between two alpha carbon atoms (aC) on the polypeptide backbone are 
relatively fixed. The only areas of conformational freedom are around the amino acid 
side chains from the aC atom to the C atom of the carbon of the carboxyl group and from 
the aC atom to the N of the amino group known as Psi (T) and Phi (<I>) angles 
respectively. Normally, the values of O are limited to a range of between -60 and -150 
degrees and the values of T range between -60 and 120 degrees. The predictability of 
these angle states led to Gopalasamudram Narayana Ramachandran in 1968 to propose an 
energy landscape when plotting these angles on a graph. Ramachandran plots [163] 
(Figure 5) enable the modeller to observe the possible conformations of ® and ¥  angles 
for any given protein. The plot can be thought of as areas of allowed and disallowed 
angle pairs. It is therefore possible, using Ramachandran plots, to identify unreasonable
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Figure 5. The Ramachandran Plot
A) Shows the torsion angle between the aC and the N of the amino group, denoted ® and 
the torsion angle between the aC and the C atom of the carboxyl group, denoted T. B) A 
Ramachandran plot made up of the energy landscape when pairs of ® and *P angles are 
plotted. Three small red areas denote the regions in which O/T are ‘allowed’. This area is 
expanded, denoted by the yellow areas on the plot, when the restraints are relaxed by just 
0.1 A. The majority of the plot, represented as white in colour is in the ‘disallowed’ 
regions, where dihedral angle pairs are sterically improbable and where one would look for 
poorly modelled amino acid residues. (Modified from 
http://www.cryst.bbk.ac.uk/PPS2/course/section3/rama.html)
torsion pairs of O/'F. The use of wet lab experimental data in refining homology models 
can not be understated. The catalytic cycle of FMOs is well defined and contains a 
regenerative cycle including electron donors and electron carriers (Figure 1). Models that 
can not explain experimentally observed biochemistry must be viewed critically.
6 . Refining of the model.
Processes such as loop modelling and dihedral angle modifications can be made if 
sterically poor regions are identified. For instance, in the case of dihedral angles, 
graphical packages such as Swiss-PDBViewer [164], can be used to get a more 
reasonable representation of sidechains within the polypeptide.
In the past, homology models have been built of CYPs and these have proved useful in 
generating theories to explain the consequences of polymorphisms, active site dynamics, 
ligand interactions etc., but it is notable that these have usually been built using templates 
of reasonably high primary sequence identity [165-168].
It is possible however, to produce homology models of proteins despite only having 
templates of relatively low primary sequence available. Often, the terms ‘midnight’ and 
‘twilight’ zones are used to describe the levels of 25% and 30% sequence identity. These 
thresholds represent the boundaries beyond which structural homology is so low that little 
useful information could be extrapolated from homology modelling [169], thus any model 
built using templates below this threshold would be deemed so unreliable that the 
endeavour would be of questionable value.
Modeller
Modeller [170] has been shown to be among the best modelling software available [157]. 
Essentially it is a set of Python scripts which perform all of the steps needed to produce and
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refine a homology model. Modeller automatically derives restraints from the template 
structure and the alignment with the target sequence. Modeller uses these restraints to carry 
out backbone, side chain and loop generation steps. These restraints include atomic 
distances, angles, dihedral angles, pairs of dihedral angles, rules of secondary structure 
packing and some other spatial features defined by atoms. Modeller also has a set of 
restraints that were evaluated empirically from protein X-ray crystal and NMR structures. 
Energy minimization using simulated annealing refines the special arrangements within the 
model by simulating a melting of the molecule at a high temperature, allowing the molecule 
to overcome any local minima and then cooling it slowly until an optimum global minimum 
is achieved.
A feature of Modeller which is particularly useful in modelling enzymes is the 
capacity to model heteroatoms such as enzyme cofactors in complex with a target. This can 
be done by either defining the ligand in the Modeller topology library, which is essential if 
said ligand is not present in the template structure or, more commonly, by assuming that the 
ligand interacts in a similar biophysical fashion with the target and the template Modeller 
can extrapolate all distance restraints from the interaction of the ligand to the template 
structure and then satisfying these restraints when building the model along with the ligand 
in the target.
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1.4. Evolution of FMQ3
The classic genetic dogma that for each gene there are only two alleles, a “wild-type” and a 
mutant, with the latter title referring to a deleterious state, has long since gone. We now 
appreciate, if not fully understand, multiple allelic states created by single nucleotide 
polymorphisms, not only in coding regions but also in upstream genetic elements, 
promoters and introns. The information presented as the pattern of sequence variation over 
a single chromosome in a diploid organism, termed the haplotype, is vital to understand the 
relationship of all the heterozygous positions in a gene within an individual and to 
understand the product of a haplotype.
The recent explosion of genomic information at both the inter- and intra- species 
level, both in terms of the extent of coverage and the amount of Single Nucleotide 
Polymorphism (SNP) data, specifically dbSNP [171] and the HAPMAP initiative [172], has 
also facilitated this possibility.
Features of datasets can be analysed to gain insight into the evolution of a locus 
such as SNP frequencies, haplotypes, synonymous and non-synonymous changes, 
recombinational events, association among variants such as linkage disequilibrium etc. In 
addition, allele frequency distribution can give indications as to whether natural selection 
may have had specific influence on the evolution of a locus.
Coalescent Theory
Coalescent theory refers to the idea that all alleles are ultimately inherited from a single 
ancestor. This individual can be considered as a single most recent common ancestor. 
When considering a specific allele, this allele can undergo coalescence to return to the most 
recent common ancestor, often represented graphically as a phylogenetic tree. Coalescence
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does not just refer to the arrival at the most common recent ancestor. At any point where 
two lineages converge it can be said that these lineages have coalesced.
It is possible to reconstruct the evolutionary history of a locus such as the FM03 
locus using coalescent models provided that sequence data are available over a large 
enough genomic region. Also, using coalescent based methods, where haplotypes lineages 
are traced back using mathematical models to the most common recent ancestor [173], it is 
possible to reconstruct genetic networks which make up distinct haplotypes and also answer 
questions about the SNPs themselves which make up the haplotypes, such as estimations of 
age.
Statistical tests using simulations of coalescence
Coalescent simulations can be used to compare values obtained from genetic testing of real 
data, such as genomic sequencing, to values generated from random samples of the same 
sample size and level of polymorphism as the observed data. Significant differences 
between the two values can then be interpreted. Some genetic tests which can be used with 
coalescent simulations are outlined below.
Watterson’s estimator of 0 (0w) [174] and Nei & Lei’s nucleotide diversity (7t) 
[175] are two representations of polymorphism diversity within a sample. They differ in 
that 0 w uses the number of segregating sites (the number of sites in a stretch of nucleotides 
which display a polymorphism, e.g. if 2500bp is sequenced in 1000 individuals, 100 
individuals possess a polymorphism at 456bp, 449 individuals possess a polymorphism at 
1324bp and 20 individuals possess a polymorphism at 1878bp, the number of segregating 
sites would be 3) as the basis of diversity representation whereas n uses the average number 
of pairwise differences (in the previous example of 1 0 0 0  individuals, each individual would 
be compared to the next and their number of pairwise differences recorded, with an average
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of the whole population being taken as representative of the sequence diversity within a 
population) in a sample as the basis of nucleotide diversity representation.
Tajima’s D [176] is a test of nucleotide diversity, comparing 0w and 7t in the context 
of the population size. It was proved that, assuming a constant-size neutral population, 
Tajima’s D would be near zero as 0w and 7t would be about the same. If the locus was 
undergoing a selective sweep, then a negative selection could be expected as genetic 
diversity is reduced as fixation of mutations is established. When balancing selection is 
acting, Tajima’s D can be expected to be positive owing to the excess of highly 
polymorphic sites and a deficit of low-frequency polymorphisms, compared to neutrally 
evolving sites.
Fu and Li’s F* and D* [177] uses polymorphic data to test the null hypothesis that 
all mutations are selectively neutral [178]. Fu and Li’s F* is based on the differences 
between the number of singletons (mutations appearing once) and n whereas Fu and Li’s 
D* is based on the differences between the number of singletons and the total number of 
mutations in the population sample.
Fu’s Fs statistic can be used to compare the observed number of sequence 
haplotypes to the number expected under the assumption of an infinite-sites model of 
neutral mutation with no recombination. The null hypothesis of neutral evolution would 
generate a value near zero with a paucity of haplotypes leading to a negative value and an 
intermediate to excess number indicating balancing or directional selection respectively, 
both discussed in this section.
Harpending’s raggedness statistic (r) [179] and Rogers’ mismatch distribution test 
[179] can identify the mode of distribution of pairwise differences with the former 
describing the variation about the curve generated from the latter. A smooth, unimodal 
distribution is indicative of population growth or directional selection, both discussed in
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this section whereas a ragged distribution is indicative of balancing selection or a 
population size which has remained constant.
Linkage Disequilibrium (LD), the tendency for alleles to be present in the same 
haplotype (positive LD) or not (negative LD), can be measured using a number of statistical 
tests. Wall’s B and Wall’s Q [180], based on segregating sites, examine each of the 
possible pairs of adjacent segregating sites. When adjacent sites are found to be the same 
among individuals within a population, they will be in complete disequilibrium and are 
referred to as congruent pairs. Wall’s tests examine the proportion of segregating site pairs 
that are congruent. Zns [181] is another way to measure LD, but this statistic is based on an 
average of pairwise associations between polymorphisms across the locus within the whole 
population.
Non-coalescence based statistical tests
A non-coalescent based test of neutrality was proposed by John McDonald and Martin 
Kreitman in 1991 [182]. The McDonald and Kreitman’s test compares synonymous and 
nonsynonymous variation within and between species because, under neutrality the ratio of 
replacement to synonymous fixed differences between species should be the same as the 
ratio of replacement to synonymous differences within the species. When dealing with 
human samples, it is usual to compare the human locus to that of a close relative such as 
Pan Troglodytes (chimpanzee). This particular comparison has become much more 
accessible since the completion of the chimpanzee genome sequencing project [183].
To test if genetic differentiation at a locus is due to population-subdivision, 
Wright’s fixation index (Fst) [184] can be used. This test considers the difference between 
the mean heterozygosity among subdivisions in a population and to the population as a 
whole, e.g. a Japanese cohort compared to an Irish cohort and a Japanese cohort compared
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to the human population as a whole. The fixation index ranges from 0 (indicating no 
difference at all between subpopulations and the population as a whole) and 1 (meaning 
complete differentiation).
Natural selection
As mentioned above, variability in SNP distribution can be caused by natural selection. 
Natural selection can force evolution in different directions, creating different genetic 
signatures in the form of allele frequencies. In light of this, natural selection can be 
subdivided into three categories.
Directional selection
Directional selection occurs when a certain allele confers a greater level of fitness than 
others, resulting in an increase in frequency of the allele. When this selection type is 
followed through to completion the allele is said to be completely fixed, meaning that the 
entire population expresses the fitter phenotype. Evidence of this has been presented, for 
example, in the case of triosephosphate isomerase evolution in bony fish [185] and the 
factor IX gene locus in humans [186].
Stabilising selection
More commonly a selection event occurs which lowers the frequency of alleles that have a 
deleterious effect on the phenotype. Selection will continue in this way until the allele is 
eliminated from the population. Evidence of this has been presented, for example, in the 
case of immune responsiveness in Parus caeruleus (Blue Tit) [187] and transcription 
factors in humans [188].
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Balancing selection
This type of selection maintains alleles at intermediate frequencies in a population. This 
manifests itself in a diploid species when a heterozygote has a higher fitness than 
homozygous individuals when considering a relevant loci. Evidence of this has been 
presented, for example, the major histocompatibility complex (MHC; HLA in humans) 
[189, 190], Glucose-6-phosphate dehydrogenase (G6PD) in humans [191], the 5’ cis- 
regulatory region of human chemokine (C-C motif) receptor 5 CCR5 [192], PTC [193], the 
bitter taste gene in humans, and the retroviral restriction factor, TRIM5alpha in Old World 
monkeys [194].
Given that FM03 is such an important molecule in terms of the interaction between 
humans and their chemical environment, it could be speculated that FM03 would be a 
likely target for natural selection. One might envisage a situation where the maintainance 
of a seemingly deleterious allele in a xenobiotic metabolising enzyme in terms of catalytic 
activity might be maintained at an intermediate frequency within a certain population, due 
to a selective advantage this conferred within the population’s chemical environment.
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1.2. Aims
The aims of this investigation were as follows.
• To investigate the genetic contribution of FMO 3 variation to apparent TMAU 
sufferers by sequence analysis of the FM03 locus in selected individuals and their 
families where possible.
• To assay the catalytic consequences of FM03 variation, particularly focussing on 
combinations of variation involving the E l58 site and another site, by comparing 
kinetic performance of variants using an established enzyme assay for FM03.
• To attempt to understand the consequences of amino acid variation within FM03, 
structurally and mechanistically, by building a homology model of FM03.
• To attempt to understand how FMO3 locus variation has evolved to the genotypes 
evident today, through genetic analysis of a human population cohort.
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Chapter 2 
Materials and Methods
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2.1. FM03 TMAU patient screen
2.1.1. DNA extraction from buccal swab sample
The buccal swab kit used to collect a buccal swab sample from a patient was prepared by 
Dr. Abi Jones (Department of Biology, University College London) and consisted of a 
sterile, Ultra Violet (UV)-irradiated cotton swab and a solution containing 1 mL of 0.5% 
(w/v) sodium dodecyl sulphate (SDS) and 0.05M ethylenediaminetetraacetic acid (EDTA) 
(VWR International, UK). The swab was rubbed against the inside of the patient’s cheek 
and submerged in the SDS/EDTA solution (above) by the GP. This was stored at room 
temperature and posted to University College London for DNA extraction and analysis.
The buccal swab was added to 800 pL of sterile distilled water containing 8  pg of 
Proteinase K (Roche, UK). The sample was then incubated at 56°C overnight. 0.6 mL of a 
phenol (Fisher Scientific, UK) and chloroform (May & Baker Ltd, Dagenham, UK) mixture 
was aliquoted and stored at -20°C. 0.8 mL of the SDS/EDTA/ solution was transferred 
from the mouth-swab collection tube into the tube containing the ice-cold 
phenol/chloroform mixture. The tube was inverted to mix the contents, and then 
centrifuged at 17,900 x g for 10 min. The aqueous phase was transferred to a fresh 
microcentrifuge tube containing 0.6 mL chloroform and 30 pL of 5M NaCl (VWR 
International, UK). The tube was inverted, to mix the contents, and then centrifuged at
17.900 x g for 10 min. The aqueous phase was transferred to a fresh microcentrifuge tube 
containing 0.7 mL chloroform. The tube was inverted to mix the contents, and then 
centrifuged at 17,900 x g for 10 min. The aqueous phase was transferred to a fresh 
microcentrifuge tube containing 0.7ml isopropanol (VWR International, UK), inverted to 
mix the contents and then incubated at -20°C for 2 hrs. The sample was then centrifuged at
17.900 x g for 15 min. The supernatant was decanted and the tube was placed upside down
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at an angle of 45° on tissue paper for approximately 20 min to dry the DNA pellet. 0.8 mL 
of 70% ethanol was added to the DNA sample, which was then centrifuged at 17,900 x g 
for 10 min. The DNA pellet was then air-dried, as described above. After 20 min, 400 pL 
of distilled water was added to the pellet and the sample was incubated at 56°C for 10 min 
to resuspend the DNA. The sample was then stored at -20°C.
2.1.2. DNA quantification
DNA was quantified using the NanoDrop system (NanoDrop Technologies, USA). The 
NanoDrop system was calibrated with the elution buffer used to resuspend the DNA and 
the DNA concentration was calculated automatically utilising pre-programmed extinction 
coefficients.
DNA absorbs UV light at a wavelength of 260 nm, whereas protein absorbs UV 
light at 280 nm and aromatic compounds such as phenol and other aromatic compounds 
absorb UV light at 230 nm. A260/A280 and A260/A230 ratios were compared to assess 
the quality of the DNA. A level above 1.8 was taken to represent a good quality DNA 
sample free of contaminants.
2.1.3. Polymerase Chain Reaction (PCR) amplification of FMQ3 exons and upstream 
loci from human genomic DNA
Upstream elements I (-2310 to -1716, based on assigning the ‘A’ of the ATG translation 
transcriptional start codon +1) and II (-2733 to -2162), the non-coding exon 1 (-1906 to - 
1436) and exons 2-9 of FM03 were each amplified by PCR using primers detailed in Table 
5 and synthesized by Eurogentec (Belgium). The PCR reaction mixtures contained, in a 
final volume of 50 pi, 50 ng of patient DNA , 0.5 pL of the appropriate sense (100 mM) 
and antisense (100 mM) primers, 1 pL of dNTP (10 mM), 5pl of 10X NH4 Reaction Buffer
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Table 5. Primers used to amnlil 'v each exon of FM03 bv PCR
FM03 sequence 
region
Primer Primer Sequence
Upstream 
element I
Sense 5 ’ -TTCCTGGT ACT AATAG ATC A-3 ’
Upstream 
element I
Antisense 5 ’ -TCTGTGTGTCT ACGTCCT-3 ’
Upstream 
element II
Sense 5 ’ - ATCCTCT AATCCTTGTTAAA-3 ’
Upstream 
element II
Antisense 5 ’ -CC AAT AAGG AGG ATG ACT -3 ’
Exon 1 Sense 5 ’ -TGGG AG ACTGGCCTAC AG-3 ’
Exon 1 Antisense 5 ’ -G AG ACGG AGTTTCGCTTTT A-3 ’
Exon 2 Sense 5 ’ -GTG AGCT ACC AT ACTC AGCC AGTG-3 ’
Exon 2 Antisense 5 ’ -C AC AGTGTGCTCTT AT AC ACTTCCC-3 ’
Exon 3 Sense 5 ’ -G ACCTG ATC AGT AT ACTC ATTT ACC-3 ’
Exon 3 Antisense 5 ’ - AGT AGTAG AC AT AC ACTTCTTC AGC-3 ’
Exon 4 Sense 5 ’ -CTTTTCTTTTTTC AT ACTGT ATCTGC-3 ’
Exon 4 Antisense 5’-AAAAAGAAGACATTATCAAGATATTC-3’
Exon 5 Sense 5’-TATGCTTGGTGTGTTAAAATAGCAC-3’
Exon 5 Antisense 5 ’ -C AC ACCTTTC AAACG AT AAT AACTC-3 ’
Exon 6 Sense 5 ’ -C AG AATATCC ACTAC AAATGGTC AC-3 ’
Exon 6 Antisense 5’-GCTTACAGGACATTAAGGGTTGTTG-3’
Exon 7 Sense 5 ’ -GCCTCC ATC AATTTGTTCTTC AG-3 ’
Exon 7 Anti sense 5 ’ -C AA AG ATCC AAAGTT ATTGTC ACTG-3 ’
Exon 8 Sense 5 ’ -GG A AAATT AC AGGCTGGTCCTATGC-3 ’
Exon 8 Antisense 5 ’ - AT AGCTTGT AGTTGTC ATTCC AATG-3 ’
Exon 9 Sense 5 ’ -TTCTCTGTTCTGTTTCT AC AC AG AG-3 ’
Exon 9 Antisense 5 ’ -CCCTGTCTGGGT ATTGTC AGT AAC-3 ’
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(Bioline Ltd, UK), 0.4 pL BIOTAQ Polymerase (Bioline Ltd, UK) and 1.25 pL (for 
upstream elements I and II and exons 1,2,3,5, 6  and 8 ), 2 pL (for exon 4) or 2.5 pL (for 
exons 7 and 9) of MgCL (50 mM) in thin-walled 0.5 mL Eppendorf tubes. The tubes were 
placed in a Techne Genius (Sussex, UK) thermal cycler that has a heated lid.
An initial denaturation step was performed at 95°C for five min. This was followed 
by 30 cycles of 95°C for 30 s; 58°C (for exons 2, 3, 5, 6  and 8 ), 55°C (for exon 1), 56°C 
(for exons 4 and 7) or 50°C (for upstream elements I and II and exon 9) for 30 s, and 72°C 
for 30 s. Finally, a single step of 72°C for 5 min completed the PCR amplification.
The sizes of the amplicons were confirmed by electrophoresis through a 1 % agarose 
(Invitrogen, UK) SYBR Safe (Molecular Probes, UK) gel in 0.5X TBE.
PCR reactions were cleaned-up using SureClean (Bioline Ltd, UK). An equal 
volume of SureClean was added to the PCR reaction, the mixture was vortexed briefly, then 
incubated at room temperature for 10 min. The sample was then centrifuged for 10 min at
17,900 x g. The supernatant was removed and the pellet washed with 70% ethanol (VWR 
International, UK) and vortexed for 30 s. The sample was centrifuged for 10 min and the 
supernatant was removed. The pellet was then air-dried.
2.1.4. DNA Precipitation
All chemicals were supplied by BDH (UK) except where stated. 3M sodium acetate, pH 
5.2 (0.1X vol) and 2X vol of ethanol (VWR International, UK) was added to the DNA 
solution. The sample was placed in a -70 °C freezer for 30 min. The mixture was then 
centrifuged at 17,900 x g using a bench-top centrifuge for 15 min at 4 °C. The supernatant 
was carefully removed and the DNA pellet was washed with 500 pL of 70% ethanol and 
centrifuged again at 17,900 x g using a bench-top centrifuge for 15 min at 4 °C. The 
supernatant was carefully removed and the DNA pellet was air dried for approx 5 min to
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allow the residual ethanol to evaporate. The DNA pellet was resuspended in ddH2 0  and 
stored at 4 °C.
2.1.5. DNA Sequencing
The DNA was cleaned by adding 50 pL of SureClean (Bioline, UK) to the reaction mixture, 
incubating for 10 min and then centrifuging at 17,900 x g for 15 min. The supernatant was 
removed and the pellet washed with 500 pL of 70% ethanol and the sample was then 
centrifuged at 17,900 x g. DNA was resuspended in ddlUO. DNA sequencing was 
performed by MWG-Biotech (Germany) using the “Value Read” service or by ElimBio 
(CA, USA), with both requiring 1 pg of plasmid DNA or 20 ng of PCR generated DNA per 
100 bases. Sequences were analysed by comparison to the wild-type hFM03 cDNA. DNA 
was sequenced in both forward and reverse orientations.
2.1.6. BsaWI Restriction Digest of FMQ3 exon 9 PCR amplicon
To detect the presence or destruction of the Bswl restriction endonuclease recognition site 
(5’-WCCGGW-3’) by the 1475G>A (R492Q) mutation, PCR was performed as described 
in section 2.1.3. on FM03 exon 9 from patient DNA. 500 ng of PCR amplicons was 
digested at 37 °C for 2 hrs with 5 U BsaWI, in a solution containing IX NEBuffer 2 
(10 mM Tris-HCl, 50 mM NaCl, 10 mM MgCl2 and 1 mM Dithiothreitol, pH 7.9 @ 25°C), 
supplemented with Bovine Serum Albumin (BSA) (100 mg/mL), made up to a total volume 
of 50 pL with ddH2 0 . The digested products were visualised by agarose gel 
electrophoresis as described in 2.1.3.
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2.1.7. CpG site identification
Human FM03 cDNA was submitted for sequence analysis to the Mutability (version 1.70) 
web server (http://www.hgu.mrc.ac.uk/Softdata/Mutability/).
2.2. Generation of Polymorphic variants of FMQ3
2.2.1. Site-Directed Mutagenesis (SDM)
Site-directed mutagenesis was performed to generate each desired mutation.
Template DNA (5 ng) (hFM03 cloned into the vector pET-21b(+) (Novagen, UK)); 
5 pL Accubuffer (Bioline, UK); a pair of complementary oligonucleotide primers (see 
Table 6 ), each containing the desired mutation; 1 jiL of 10 mM dNTPs (Bioline, UK); 2.5 U 
Accuzyme (Bioline, UK) and 41 pL ddH2 0  were mixed in a 0.5-mL thin-walled 
Eppendorf tube and subjected to thermal cycling in a Techne GENIUS unit (Cambridge, 
UK) featuring a heated lid. An initial denaturation step was performed at 95°C for five min 
followed by an annealing step of 1 min at 55°C. This was followed by 15 cycles of 72°C 
for 6  min; 95°C for 30 s and 55°C for 30 s,. Finally, a single step of 72°C for 9 min 
completed the SDM amplification process.
The DNA was cleaned by adding 50 p.L of SureClean (Bioline, UK) to the reaction 
mixture, incubating for 10 min and then centrifuging at 17,900 x g for 15 min. The 
supernatant was removed and the pellet washed with 500 p,L of 70% ethanol and the sample 
was then centrifuged at 17,900 x g. DNA was resuspended in 44 jiL of d d ^ O  and 5 pL of 
NEB buffer 4 (NEB, UK) and digested with 20 U of Dpnl (NEB, UK) for 2 h at 37 °C. 
Dpnl endonuclease specifically digests methylated and hemi-methylated DNA. This means 
that the template DNA is digested leaving only the newly synthesised DNA, which should 
contain the desired mutation.
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Table 6. Sequence of forward and reverse primers used to generate each mutation in
h F M 0 3  cDNA
Mutant 
(a.a. level)
Strand Primer Sequence Original
Codon
Mutated
Codon
E 158K Sense 5 ’ -CTACC AAAAAAGTCCTTTC-3 ’ GAG AAG
Antisense 5 ’ -G AAAGG ACTTTTTTGGTAG-3 ’
R 238Q * Sense 5 ’ -TCGTC ACTC A ATTTGG AACCT-3 ’ CGA CAA
Antisense 5 ’-AGGTTCCAAATTGAGTGACGA- 3 ’
V 257M Sense 5 ’ -CTGGTTGTAC ATG AAGC AG A-3 ’ GTG ATG
Antisense 5 ’ -TCTGCTTC ATGTAC AACC AG-3 ’
E 308G Sense 5 ’ -G AATTC AC AGGG ACCTCGGC-3 ’ GAG GGG
Antisense 5 ’ -GCCG AGGTCCCTGTGAATTC-3 ’
All primers were synthesized by Eurogentec (Belgium) except where marked (*) which 
were synthesized by ElimBio (CA, USA). The nucleotide change is highlighted in bold and 
underlined in the primer sequence. The codon changes are also shown.
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DpnI-digested amplification product (1 jxL) was added to 50 |liL of Alpha-Select Gold 
Efficiency E.coli competent cells (deoR endAl recAl relAl gyrA96 hsdR17(rk - mk+) 
supE44 thi-1 A(lacZYA-argFV169) O8051acZAM15 F-) (Bioline Ltd, UK) in a Falcon 
2059 tube and incubated on ice for 20 min. The transformation mixture was_heat-shocked 
at 42 °C for 45 s and then returned to ice for 2 min. 1 mL of SOC (Bacto Tryptone (20 g/L) 
(BD Diagnostic, MA, USA), Bacto Yeast Extract (5 g/L) (BD Diagnostic, MA, USA), 10 
mM NaCl (Sigma-Aldrich, St. Louis, MO, USA), 2.5 mM KC1 (Sigma-Aldrich, St. Louis, 
MO, USA), 10 mM MgCl2 (Sigma-Aldrich, St. Louis, MO, USA), 10 mM MgS04  (Sigma- 
Aldrich, St. Louis, MO, USA) and 20 mM glucose (Sigma-Aldrich, St. Louis, MO, USA)) 
was added and the transformation mixture was incubated for lhr at 37 °C in a shaking 
incubator. The mixture was then centrifuged for 5 min at 1200 x g. The bacterial pellet 
was resuspended in 100 mL of SOC (31 g (31 Capsules) per Litre 
Containing/litre: 20 g tryptone, 5 g yeast extract, 0.5 g NaCl, 5 g MgSOWFLO, 
supplemented with 20 mM Glucose (BDH, UK)) (Qbiogene, Inc., Irvine, CA) and plated 
onto a Luria-Bertani Broth (LB) ampicillin (amp) (50 |Lig/ml) agar plate (40 g (40 Capsules 
or 8  Large Capsules) per litre Contents/litre: LB Medium, 15 g Agar-B) (Qbiogene, Inc., 
Irvine, CA). The plates were incubated at 37 °C for -16 hrs.
2.2.2. Plasmid isolation
2.2.2.1. Small-scale plasmid isolation
To isolate plasmid DNA from small volumes of bacterial cells, a ChargeSwitch Plasmid ER 
Mini kit (Invitrogen, CA) was used.
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Overnight bacterial culture (1.5 mL) was pipetted into a 1.5 mL thick-walled 
Eppendorf tube. This was centrifuged at 17,000 x g for 10 min. The supernatant was 
completely removed. The pellet was resuspended in 300 pL of Resuspension Buffer 
containing RNase A (5 mg/ml). The mixture was pipetted and vortexed until no cell 
clumps were visible. 300 pL of ChargeSwitch Lysis Buffer was then added and the tube 
gently inverted until the solution became opaque. This solution was incubated for 4 min at 
room temperature. 300 pL of ChargeSwitch Precipitation Buffer was then added and the 
tube again inverted until no more precipitant was formed. The mixture was centrifuged at
17,900 x g in a bench-top microcentrifuge for 10 min, forming a compact white pellet up 
the side of the tube. The supernatant was transferred to a fresh tube containing 30 pL of 
ChargeSwitch Magnetic Beads (25 mg/ml) and incubated for 1 min at room temperature. 
The tube was applied to the MagnaRack for one min whereupon a compact pellet was 
formed consisting of DNA bound to the magnetic beads. The supernatant was removed and 
discarded and the beads were resuspended in 990 pL of ChargeSwitch Wash Buffer. The 
application to the MagnaRack and wash step was repeated and then the pellet was 
resuspended in 50-100 pL of ChargeSwitch Elution Buffer (10 mM Tris-HCl, pH 8.5) and 
incubated at room temperature for 1 min. The tube was applied to the MagnaRack for 1 
min and the supernatant, containing the plasmid DNA was recovered.
2.2.2.2. Large-scale plasmid isolation
In order to extract DNA from large volumes of bacterial cells, a QIAGEN QLAfilter™ 
Plasmid Midi Kit (QIAGEN Inc, USA) was used.
5 mL LB containing 5 pL amp (50 pg/ml) was inoculated with a single colony and 
grown for 8  hrs at 37°C in a shaking incubator at 225 rpm. 25 pL of culture was used to
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inoculate 25 mL of LB and 25 pL amp (50 fxg/ml) and grown in a 500 mL Erlenmayer flask 
for 12-16 h at 37°C in a shaking incubator at 225 rpm.
Bacterial cells were harvested in 400 mL Sorvall centrifugation bottles by 
centrifugation at 6000 x g for 15 min at 4 °C. The supernatant was removed by inverting 
the open bottle. The bacterial pellet was resuspended in 4 mL of Buffer PI containing 
RNase A (5 mg/ml). The bacterial pellet was resuspended by pipetting and vortexing until 
no cell clumps were visible. 4 mL of Buffer P2 was then added and the bottle was inverted 
6  times. The mixture was incubated at room temperature for 5 min. 4 mL of chilled Buffer 
P3 was added to the lysate and the bottle was inverted 6  times. The lysate was immediately 
poured into the barrel of a QIAGEN Midi cartridge and incubated at room temperature for 
10 min. During this incubation the QLAGEN-tip 500 was equilibrated by applying 10 mL 
of Buffer QBT and allowing the column to empty by gravity flow. The cap was removed 
from the QIAfilter outlet nozzle and the plunger was gently inserted into the cartridge. The 
lysate was filtered into the previously equilibrated QLAGEN-tip. The cleared lysate was 
allowed to enter the resin within the QIAGEN-tip by gravity flow. The QLAGEN-tip was 
washed twice with 10 mL of Buffer QC. The DNA was eluted in 5 mL of Buffer QF (10 
mM Tris-HCl, pH 8.5).
The DNA was precipitated by adding 3.5 mL of isopropanol at room temperature. 
The sample was mixed and centrifuged immediately at 15,000 x g for 30 min at 4 °C. The 
supernatant was carefully decanted and the DNA pellet was washed with 1 mL of 70% 
ethanol at room temperature. The ethanol was transferred to a 1.5 mL Eppendorf tube and 
centrifuged at 15,000 x g for 10 min at 4 °C. The supernatant was removed and the pellet 
was air dried for approx 10 min to allow residual ethanol to evaporate. The DNA pellet 
was re-dissolved in 100 pL of ddHaO, quantified and stored at -20 °C.
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2.2.3. Heterologous expression of hFMQ3
2.2.3.1. Cell growth and induction of expression
E.coli BL21 cells transformed with the appropriate cDNA were used for the expression of 
hFM03 proteins. A modified version of the pET-2 lb(+) (Novagen, UK) with the His-tag 
coing region removed was used as the expression vector as this had previously been used in 
the lab with satisfactory performance. The His-tag was removed due to concerns that it 
would interfere with catalysis of the recombinant FM03 enzyme.
A starter culture was grown in 25 mL LB and 5 |nL of amp (50 fig/ml) was 
inoculated with a single colony from a freshly streaked plate containing (E.coli) 
BL21(DE3) (F  ompT hsdS^{re ’ me ') gal dcm (DE3) pLysS (CmR)) (Novagen, UK) + 
hFM03 transformants and grown in a shaking incubator at 37 °C until the OD6 00 was 
between 0.6 and 1.0. 1 L of fresh LB medium was inoculated with 10 mL of this starter 
culture and the cells were incubated at 37 °C until an OD6 00 ° f  0.4 was reached. Expression 
of hFM03 was then induced by adding isopropyl /?D-thiogalactopyranoside (IPTG) (Sigma, 
CA, USA) to a final concentration of 0.5 mM, supplemented with riboflavin (Sigma, CA, 
USA) to a final concentration of 50 mg/L and incubated overnight in a shaking incubator at 
30 °C.
2.2.3.2. Bacterial cell harvest
The culture was transferred to an appropriate container, depending on the amount of culture 
(small culture -  50 mL Falcon Tube, large culture - Sorvall centrifugation bottle), and 
centrifuged at 1200 x g for 30 min at 4 °C. The supernatant was removed completely by 
inverting the tube/bottle.
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2.2.3.3. Cell Lvsis
Due to the variety of methods used to lyse cells in the stucy of FMOs in the literature, 
several methods were tested simultaneously, including two methods previously used in the 
lab ‘in house’ (methods III and VII below).
2.2.3.3.1. Method I f!951
The pellet was resuspended in 25 mL of lysis buffer (50 mM sodium phosphate buffer 
(pH7.5) (sodium dihydrogen orthophosphate 1-hydrate (NaKhPC^KhO) (BDH, UK) was 
added to 1M di-Sodium hydrogen orthophosphate anhydrous (Na2HP0 4 ) (BDH, UK) until 
a pH of 7.5 was reached), 100 mM KC1 (Sigma, CA, USA) and ImM EDTA (BDH, UK) (a 
chelating agent added to sequester metal ions in order to minimise proteolysis) and 
incubated on ice for 20 min. The culture was sonicated for 4 periods of 30 s, with 1 min 
cooling periods in between.
2.2.3.3.2. Method II U461
The pellet was resuspended in 25 mL of lysis buffer (50 mM sodium phosphate buffer (pH
7.5) and 0.5 mM phenylmethylsulfonyl fluoride (PMSF) (a serine protease inhibitor)) and 
incubated on ice for 20 min. The culture was sonicated for 3 periods of 2 min, with 2 min 
cooling periods in between.
2.2.3.3.3. Method III
The pellet was resuspended in 25 mL of lysis buffer (10% (v/v) glycerol (Sigma, UK), 10 
mM sodium phosphate buffer (pH 7.5) and Lyzozyme (Sigma, UK) (0.75 mg/ml) (a 
enzyme that hydrolyses peptidoglycans in bacterial cell walls, weakening them)) and
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incubated on ice for 20 min. The culture was sonicated for 3 periods of 30 s, with 30 s 
cooling periods in between.
2.2.3.3.4. Method IV [211
The pellet was resuspended in 25 mL of lysis buffer (50 mM sodium phosphate buffer (pH
7.5), 0.5% Triton X100 (v/v) (Sigma, CA, USA) (a detergent used to solubilise membrane 
proteins) and 10% (v/v) glycerol ) and incubated on ice for 20 min. The resuspended 
bacterial pellet was sonicated for 3 periods of 2 min, with 2 min cooling periods in 
between.
2.2.3.3.5. Method V 11961
The pellet was resuspended in 25 mL of lysis buffer (10 mM sodium phosphate buffer (pH
7.5), 10% (v/v) glycerol and Lysozyme (Sigma, UK) (0.75 mg/ml)) and incubated on ice 
for 20 min. The culture was sonicated for 16 periods of 15 s, with 2 min cooling periods in 
between
2.2.3.3.6. Method V I 11971
The pellet was resuspended in 25 mL of lysis buffer (100 mM KC1, 50 mM potassium 
phosphate buffer (pH 7.5) (^/-Potassium hydrogen orthophosphate (K2HPO4 ) (1 M) and 
Potassium di-Hydrogen orthophosphate (KH2PO4 ) (BDH, UK) 1 M; K2HPO4 was added to 
KH2PO4 until pH = 7.5), 20% (v/v) glycerol, 1 mM EDTA and Lysozyme (1 mg/ml) 
(Sigma, UK)) and incubated on ice for 30 min. The culture was not sonicated.
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2.2.3.3.7. Method VII
The pellet was resuspended in 25 mL of lysis buffer (150 pM KC1, 10 mM 4-(2- 
hydroxyethyl)-l-piperazineethanesulfonic acid (HEPES) (pH 7.5) (Fisher Scientific, NJ, 
USA), 1 mM EDTA and 20% (v/v) glycerol) and incubated on ice for 20 min. The culture 
was sonicated for 3 periods of 30 s, with 1 min cooling periods in between.
2.2.3.4. Cell fractionation
Sonicated cultures were centrifuged at 1200 x g for 15 min. The supernatant was recovered 
and the pellet (Inclusion Bodies) was resuspended in 2 mL 8  M Urea (Fisher Scientific, NJ, 
USA) and stored at room temperature. The supernatant was centrifuged at 100,000 x g for 
1 h at 4 °C. The supernatant (cytoplasm) was recovered and stored at -70 °C. The pellet 
(cell membrane) was resuspended in 1.5 mL of lysis buffer and stored at -70 °C.
2.2.4. Protein quantification
The method used was based on that of Lowry et al., (1951) [198]. A series of bovine serum 
albumin (BSA) (Bio-Rad, CA, USA) samples were prepared by diluting the stock solution 
(1.4mg/ml) with ddH2 0 . 100 pL of each standard was pipetted into a 13 mL test tube. 
Experimental samples were also 100 pL in volume. The DC Protein Assay Kit (Bio-Rad, 
UK) was used to perform the assay. Reagent A (alkaline copper tartrate solution) (500 pL) 
was added to both the standards and the samples, which were immediately vortexed. 
Reagent B (dilute Folin reagent) (4 mL) was added to both the standards and the samples, 
and again the tubes were vortexed immediately. The tubes were allowed to stand for 15 
min after which time the absorbance was stable for 1 hour. The absorbance was read at 750 
nm using the GeneQuant pro RNA/DNA calculator (Amersham Pharmacia, UK). The
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A750 readings of the BSA standards were used to construct a standard curve and the 
protein concentrations of the experimental samples were extrapolated from this.
2.2.5.1. SDS-Polvacrylamide Gel Electrophoresis (SDS-PAGE)
All materials and reagents were supplied by Invitrogen (USA) except where stated.
Protein (20 pg) was placed in a 0.5 pL thin-walled tube along with NuPAGE LDS 
Sample Buffer (IX), 1 pL of /Lmercaptoethanol and ddPLO to make up to a total volume of 
15 pi. The samples were heated at 95°C for 5 min. Samples were then loaded on to a 4- 
12% NuPAGE Novex Bis-Tris Gel. The gel was run in 50ml of IX NuPAGE MES SDS 
Running Buffer at 200 volts, using the XCell SureLock Mini-Cell for 35 min. Prestained 
SDS-PAGE Standard (Broad Range) (3 pL) (Bio-Rad, CA, USA) were run alongside the 
samples, to provide molecular mass reference.
2.2.5.2. SDS-PAGE Staining
The SDS-PAGE gel was removed from the disposable casings. The gel was placed in a 
small container and 200 mL of ddfLO was poured on top of it. As per manufacturer 
instruction, the gel was microwaved on full power for one min and then incubated for one 
min on a shaker. The water was removed and this step was repeated twice. The water was 
removed and 30 mL of SimplyBlue SafeStain (Invitrogen, CA, USA) was poured on top of 
the gel so the gel was submerged in the solution. The gel was microwaved on full power 
for 1 min and placed on a shaker for 10 min to incubate. The stain was removed and the gel 
was rinsed quickly with ddPLO to remove excess stain. 200 mL of ddtLO was added to the 
gel, which was then incubated for 10 min. The ddtLO was removed and 200 mL of fresh 
ddtLO was added and the gel was incubated until the desired result was achieved.
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2.2.5.3. Western Blot of SDS-PAGE gel
2.2.5.3.1. Blotting
All materials were supplied by Invitrogen (CA, USA) unless otherwise stated. 200 mL of 
IX NuPAGE Transfer Buffer was prepared by combining 10 mL NuPAGE Transfer Buffer, 
20 mL Methanol (or 40 mL Methanol if blotting from two gels), 200 pL NuPAGE 
Antioxidant and making up to the final volume with ddtLO. One nitrocellulose membrane 
filter paper sandwich per gel was soaked in the transfer buffer along with an appropriate 
number of blotting pads. A piece of pre-soaked filter paper was placed on top of the gel 
and any trapped air bubbles were removed. The gel was turned over and a pre-soaked 
transfer membrane was placed on the gel and any air bubbles were removed. Another pre- 
soaked filter paper was placed on top of the transfer membrane and any trapped air bubbles 
were removed. Two soaked blotting pads were placed into the cathode core of the XCell II 
Blot Module. The gel/membrane assembly was placed on the blotting pad, ensuring that 
the gel was closest to the cathode and the membrane closest to the anode. Enough pre- 
soaked blotting pads were added on top of the membrane assembly to rise 0.5 cm over the 
rim of the cathode. The anode was placed on top of the pads and the module was slid into 
the guide rails of the XCell SureLock Mini-Cell. The blot module was topped up with 
transfer buffer to cover the gel/membrane assembly. The outer chamber of the XCell 
SureLock Mini-Cell was filled with 650 mL of ddlLO. The transfer was performed at 150 
mA for 2 hrs.
2.2.5.3.2. Antigen detection
After protein transfer, the membrane was incubated for at least 1 hour at room temperature 
in 50 mL of blocking buffer (5% powdered non-fat milk (Safeway, CA, USA), 150 mM
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NaCl (Sigma, CA) and 25 mM Tris-HCl (pH 7.5) (Sigma, CA, USA)). The blocking 
solution was removed and replaced with 50 mL of primary antibody solution (WB-FM03 
(BD Biosciences, CA, USA) at 1:5000 dilution in 0.5% powdered non-fat milk, 150 mM 
NaCl, 25 mM Tris-HCl (pH 7.5)). The membrane was then incubated for 1 hour at room 
temperature. The nitrocellulose was rinsed 3 times with 50 mL of wash buffer (0.1% 
Tween 20 (Bio-Rad, CA, USA), 25 mM Tris-HCl (pH 7.5), 150 mM NaCl) for 15 min 
each. The nitrocellulose was then incubated at room temperature for 1 hour with 50 mL of 
secondary antibody solution (Horse Radish Peroxidase-conjugated goat anti-rabbit IgG at 
1:10,000 dilution (BD Biosciences, CA, USA) in 0.5% powdered non-fat milk, 150 mM 
NaCl, 25 mM Tris-HCl (pH 7.5)). The nitrocellulose was washed 3 times with 50 mL of 
wash buffer. The nitrocellulose was then developed using the ECL Western Blotting 
Analysis System (Amersham, UK). 1 mL of Reagent A was added to 1 mL Reagent B and 
the mixture was placed on top of the nitrocellulose, using a pipette to ensure that the whole 
membrane was in contact with the mixture. The blot was then wrapped in Saran wrap and 
placed in contact with a sheet of Kodak Biomax Light autoradiography film (Kodak, CA, 
USA). The film was exposed and developed. This procedure was repeated varying the 
exposure time until a satisfactory level of detection was observed (between 30 s and 10 
min).
2.2.6. Immunoquantification of FMQ3
Various amounts of quantified FM03 standards (BD Biosciences, CA, USA) were loaded 
on a 4-12% NuPAGE Novex Bis-Tris Gel (Invitrogen, CA, USA) along with duplicate 
samples of 5 pg and 10 pg of bacterial extract containing an unknown amount of expressed 
recombinant protein. SDS-Page was performed as described in Section 2.2.5 and a western 
blot was performed on these gels as described in Section 2.2.5.3. The developed western
65
blot film was scanned using a Hewlett Packard Scanjet 4850 Flatbed Scanner (Hewlett 
Packard, NJ, USA) and the results were saved in TIFF format. The amount of FM03 in the 
recombinant bacterial protein sample was quantified densitometrically, using ImageJ 
software [199], by comparison with a standard curve of FM03 standards.
2.2.7. Methimazole Assay of FMO activity ri301
Bacterial membrane protein fractions containing quantified human FM03 were obtained 
using cell lysis method VII (2.23.3.1.). All other methods of lysis tested yielded protein 
deemed inactive as no activity was observed spectroscopically. FM03 was activity was 
assayed as follows. 2 mL of assay mixture was prepared as follows. A mixture containing 
4 mM Dithiothreitol (DTT) (Sigma, CA, USA), 12 mM 5,5’-Dithio-bis(2-nitrobenzoic 
acid) (DTNB) (Sigma, CA, USA), 20 mM p-Nicotinamide adenine dinucleotide phosphate 
(reduced form) (NADPH) (Sigma, CA, USA) was made up in Assay Buffer (Tris-HCl (pH 
8.4), 1 mM EDTA). The mixture was divided between two clear 2 mL plastic cuvettes 
(Sarstedt, Germany). All reagents and protein were equilibrated to 37 °C during 
preparation of the assay. Both cuvettes were placed inside a Cary Split-beam 
Spectrophotometer 3000 (Varian, CA, USA), with the 1 mL mixture acting as a reference. 
The mixtures were incubated at 37 °C before the non-reference cuvette was spiked with 2- 
Mercapto-1-methylimidazole (Methimazole) (Lancaster Synthesis, NH, USA) to a range 
(1000-3 pM) of final concentrations in a final volume of 1 mL. The absorbance at 412 nm 
(the disappearance of the yellow coloured TNB to DTNB (colourless)) was followed for 5 
min after the baseline had settled. Enzyme velocities were calculated using the TNB 
extinction coefficient of 13,600 M' 1 cm’1. The enzyme kinetic parameters, Km, Vmax were 
estimated from Hanes-Woolf [200] linear transformations of the Michaelis-Menton 
equation using the Enzyme Kinetics module (v. 1.3.) of the SigmaPlot (v 10.0.) program
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(Systat Software Inc., CA, USA). This transformation has been shown to be superior to 
others such as the Eadie-Hofstee [201] and Lineweaver-Burk [202], because it applies the 
same weights to all substrate concentrations, unlike the Eadie-Hofstee and Lineweaver- 
Burk which place a high weight on low concentration values causing a bias in the data 
towards reflecting the enzyme behaviour at these lower concentrations as representative of 
the enzyme behaviour as a whole [203]. Km, Kcat and Kcat/ Km values were calculated for 
each FM03 variant tested and these were compared with those of wild type FM03 (n=3 for 
each protein). Statistical significance was assessed using an unpaired t-test performed 
using GraphPad Prism 4.0 (GraphPad Software, CA, USA).
2.3. Generation of a homology model of FMQ3
2.3.1. Template Identification
The blastp function of the Basic Local Alignment Search Tool (BLAST) [204] was used to 
search the Protein Data Bank (PDB) for homologues similar at a global primary sequence 
level to human FM03. GenTHREADER [205] was used to look for structural homologues 
similar at a fold-level, inferred from sequence-sequence alignment against library of known 
folds derived from solved protein structures. This latter step was especially important in 
this case as it has been shown that as the sequence identity drops into the twilight zone (see 
section 1.3.), there may be insufficient signal in the sequence-based methods (e.g. BLAST) 
to detect distant relationships [206]. Threading methods (e.g. GenTHREADER) have the 
ability to detect common folds that may be present even in the absence of significant 
sequence homology [207].
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2.3.2. Homology Modelling
Homology Modelling was performed using MODELLER [161].
2.3.2.1. Homology Modelling hFMQ3
The FM03 (target) sequence and the template sequence(s) were aligned using the ClustalW 
algorithm [208] web server at the European Bioinformatics Institute (EBI) 
(http://www.ebi.ac.uk/clustalw). The Blosum scoring matrix [209] was used with penalty 
values set at 10 for opening or closing a gap, and 0.05, for extending a gap. The output was 
saved in .pir format. The ‘model-default.py’ python script was modified to insert the 
location of the .ali file (the renamed PIR file), the location of the template PDB file and the 
number of models to build. The ‘model-default.py’ python script was executed using a 
1700 Advent PC with a Mobile Intel Pentium processor 4 (3.20GHz) and 512 MB of RAM 
within the DOS command line, to generate the models. The ‘model-loop.py’ python script 
was used in an attempt to improve the accuracy of loop predictions generated by the 
previous script.
2.3.2.2. Model scorine
Regions of probable inaccuracy were defined by positive ProSa [210] profiles or negative 
VERIFY_3D [211] profiles. The stereochemical quality of the models was also assessed 
using WHAT_CHECK [212] to assess the side-chain environment and PROCHECK [213] 
to validate the backbone and side-chain conformation and Swiss-PDBViewer v.3.7 [164] 
was used to generate Ramachandran plots (Figure 5, section 1.3.).
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2.3.2.3. Model refinement
The ‘dope_loopmodel.py’ python script was modified to direct it to the models generated 
and then executed using a 1700 Advent PC with a Mobile Intel Pentium 4 processor 
(3.20GHz) and 512 MB of RAM within the DOS command line. This method uses the 
more advanced ‘Discrete Optimised Protein Energy’ (DOPE) method to assess the spacing 
of the atoms in the model and refine them at the cost of computational time rather than 
simply using ‘loopmodel.py’. Additionally, the regions of probable inaccuracy identified in 
Section 2.3.2.2., which corresponded to loop regions, were targeted specifically for loop 
modelling. Several versions of any model are returned with various loop arrangements, the 
one with the lowest energy being taken as the ‘best’ orientation (see Section 1.3.).
Dihedral angles within the polypeptide model were modified using the 
Ramachandran plot within Swiss-PDBViewer v.3.7, which has click-and-drag capabilities 
allowing side chains to be moved within the plot, from unlikely positions to more 
favourable positions as determined by their proximity to the favoured regions of the 
ramachandran plot (see Figure 5), resulting in a more robust biophysical model.
2.3.2.4. Modelling FAD into the FMQ3 model
In the case of the FM03 model generated using the structure “Crystal structure of a protein 
with similarity to flavin-containing monooxygenases and to mammalian dimethylalanine 
monooxygenases” (PDB code, 1VQW) [2141, the FAD molecule present in the template 
was modelled into the putative active site of the FM03 model. The atomic coordinates of 
the FAD molecule within the PDB file of 1VQW were assigned a chain identifier manually 
using a text editor. A ‘blk’ character was added to the .ali file at the end of both the target 
and template sequences to represent the ligand. This effort was performed in an attempt to
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gain insight into the possible interactions of the FAD molecule within the FM03 homology 
model.
The ‘model-ligand.py’ script was executed using a 1700 Advent PC with a Mobile 
Intel Pentium 4 processor (3.20GHz) and 512 MB of RAM within the DOS command line 
to generate a model that included the FAD molecule in the structure.
2.3.2.5. Putative Active Site assignment
Models based on the PDB crystal structure of “Phenylacetone Monooxygenase, a Baeyer- 
Villiger Monooxygenase” (PDB code, 1W4X) [215] were examined for hydrophobic 
pockets, initially using Q-SiteFinder [216] which uses the interaction energy between the 
protein and a van der Waals probe to locate energetically favourable binding sites within 
the molecule. FAD- and NADPH- binding motifs were highlighted on the model, which 
provided evidence, when found in the proximity of known enzyme catalytic residues 
identified using the Catalytic Site Atlas [217], that the model made sense in terms of the 
FM03 catalytic cycle (Figure 1). Finally, the CAVER [218] module of the PyMol 
visualisation tool was used to identify buried cavities within the model to show the possible 
physical contact between substrates within the molecule.
Models based on 1VQW were assessed by eye as the active site of the ligand 
(methimazole) bound state of the template model had been deposited in the PDB, named 
“Crystal structure of flavin-containing monooxygenase (FMO)from S.pombe and substrate 
(methimazole) complex” (PDB code, 2GVC).
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2.3.2.6. Examination of FAD-FMQ3 interactions
The hydrophobic and hydrophilic interactions between the modelled FAD molecule within 
the FM03 homology model was examined using the Ligand Explorer tool within the 
Molecular Biology Toolkit (MBT) suite [219].
2.3.2.I. Tertiary Model Alignment
Tertiary models of FM03 generated by Modeller were aligned using FATCAT [220] 
(http://fatcat.bumham.org/), for pairwise alignment, or POSA [221] 
(http://fatcat.bumham.org/POSA/), for multiple structure alignment.
2.3.3. Visualization of molecules
Molecules were visualised using PyMol (www.pymol.org).
2.5. Evolution studies of the FMQ3 locus
Previously, DNA had been obtained by the Yamazaki group at Showa Pharmaceutical 
University, Japan, from 23 unrelated Japanese (18 male and 5 female ranging in age from 
19 to 52 years old) who had responded to an internet article because of self-perception of 
TMAU symptoms, specifically a body odour smelling strongly of rotten fish. Urinary 
TMA/TMA /V-oxide was examined by the Yamazaki group and DNA was also obtained 
from 45 Japanese non-TMAU sufferers. Coding exons, together with 3.4 kb of upstream 
sequence and 2.9 kb of flanking intron and 3’ untranslated gene regions were amplified by 
PCR and sequenced. Haplotypes were inferred by the Yamazaki group. For details of the 
haplotypes inference and PCR conditions, see Allerston et al., 2007 [222].
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2.5.1. Data Analysis
2.5.1.1. Mutational relationship between haplotypes
All pairwise comparisons between SNPs were analysed for evidence of linkage 
disequilibrium (measured as R2) using DnaSP (version 4.10.3) [223]. Any significant 
associations between SNPs were identified using %2 tests with a Bonferroni correction for 
multiple comparisons. The minimum number of recombination events (Rm) within the 
samples was estimated by the four-gamete test [224]. To visualise mutational relationships 
between haplotypes, the Reduced Median (RM) Network algorithm [225], as implemented 
by Network 4.1.1.2 (http://www.fluxus-engineering.com), was used.
2.5.1.2. Probing the time depths of FM03 variants
In an attempt to estimate the time to the most recent common ancestral sequence ( T m r c a )  
and the ages of some of the mutations in our sample, we used the program GENETREE 
(version 9.0), which uses maximum-likelihood coalescent analysis [226]. The method is 
based on a standard coalescent model, which assumes an infinite-sites model of mutation (a 
model where each new mutation occurs at a site that has not mutated before) with no 
recombination. Thus, only infinite-sites-compatible data were used for this analysis. Under 
the coalescent model, mutations are assumed to occur along ancestral lineages according to 
a Poisson process of rate 0/2, where 0 (the population mutation parameter) = 4Nep. Ne is 
the effective population size (the size of a theoretical, randomly mating, isolated and 
stationary population, which would have the same distribution and type of polymorphism as 
the population examined) and p is the neutral mutation rate per locus per generation, which 
can be calculated from the equation p = vgL, where v is the neutral mutation rate per 
nucleotide per year, g is the generation time in years and L is the number of silent sites in
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the sequence. An estimate of the parameter 0 was obtained through the use of the mL 
function of GENETREE and was refined by using the surface option of the program. This, 
together with our estimate of the neutral locus mutation rate, enabled Ne to be determined, 
from the equation 0 = 4Ne|i. Coalescent simulations performed using GENETREE gave 
estimates for T mrca and the ages of SNPs in coalescent units of 2Ne generations, which 
were converted to years by using our estimate of Ne and a generation time of 20 years.
2.5.1.3. Testing FMQ3 for departures from neutrality
DnaSP was used to calculate two estimates of sequence diversity, Watterson’s estimator of 
0 (0w) [174] and nucleotide diversity (7t) [175], and to determine a number of test statistics: 
Tajima’s D [176], Fu and Li’s F* and D* [177], the expected number of haplotypes (h) 
[227], Fu’s Fs [228], raggedness (r) [179], Z„s [181] and Wall’s B and Q [180]. 
Significance values for the test statistics were assessed by comparison with a distribution of 
estimates obtained from coalescent simulations of 5,000 random samples of the same 
sample size and level of polymorphism as the observed data. Simulations were performed 
assuming constant population size and no recombination (making tests conservative) or for 
the level of recombination in the observed data. DnaSP was also used to analyse the allele 
frequency spectrum and the pairwise differences among FM03 haplotypes, via Rogers’ 
mismatch test [179], performed using Arlequin (version 3.01) [229]
(http://lgb.unige.ch/arlequin/). The ratio of replacement to silent polymorphisms within 
humans was compared with the ratio of replacement to silent fixed differences between 
humans and chimpanzee, by means of a McDonald-Kreitman test [182], using a Fisher’s 
exact test of independence. Wright’s fixation index ( F s t )  [184] was used to measure 
population subdivision by comparing genetic diversity within subpopulations to that of the
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whole population by comparing the FM03 SNPs of the Japanese cohort to population 
panels provided in dbSNP [171].
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Chapter 3 
Results and Discussion
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3. Results and discussion
3.1. TMAU Patient studies 
Introduction
This section describes the analysis of the DNA from several suspected TMAurics. In each 
case the individual concerned had been diagnosed, through TMArTMA A-Oxide ratio 
anaysis through urine testing, as having suspected primary TMAuria. The FM03 locus was 
examined for mutations that would provide evidence for a TMAuria diagnosis and provide 
further insight into the genetics and molecular biology of this disease. Exons 2 to 9 were 
sequenced along with three flanking upstream regions of FM03 analysed (-2310 to -1716, - 
2733 to -2162 and -1906 to -1436 (containing the non-coding exon 1) where the ‘A’ of the 
ATG start codon of FM03 is considered +1) by sequencing in any of the suspected 
patients.
Subject one
A medical doctor from Northern Norway contacted us after the parents of a female child (2 
years old) had complained about a strong bodily odour, reminiscent of rotten fish, 
emanating periodically from the child. Neither parent complained of a similar problem, but 
after further questioning, the mother did report of an uncle who lived alone, has never 
married and she remembered that he had an odd smell. The parents were not 
consanguineous.
The parents were reluctant to bleed the child and so their blood was obtained first in 
order to check their DNA, after which time, if anything interesting was found, the child 
would then be bled for DNA extraction. In the meantime the mother contacted her uncle 
and introduced him to the doctor. His DNA was also obtained. DNA samples were sent
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from the Norwegian doctor to UCL, where the sequencing analysis was of the FM03 locus 
(mentioned above and described in detail in 2 .1 .).
A previously unreported mutation was found in exon 6  in a heterozygous state in the 
mother and in the subject. This same mutation was found in a homozygous state in the 
great uncle confirming a Primary TMAU diagnosis for this individual.
A relatively common FM03 haplotype was discovered in the father, but this was 
not found to have been inherited by the subject and so did not contribute to the TMAU 
phenotype.
No other mutations were observed in the regions amplified.
Mother of subject one
The sequencing trace indicated that the mother was homozygous for the E l58 background 
(Figure 6  A). The trace also indicated that the mother was a heterozygote for the 713G>A 
(R238Q) mutation (Figure 6  B).
Father of sub ject one
The sequencing trace indicates that the father is heterozygous for the 472G>A (E158K) 
polymorphism (Figure 7 A) and for the 923A>G (E308G) (Figure 7 B). From this 
information it was not possible to deduce if these polymorphisms were in cis or trans.
Great Uncle of subject one
The sequencing trace indicated that the great uncle was homozygous for the 713G>A 
(R238Q) polymorphism (Figure 8 ).
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Mother
Wild-type
470
A A G A G
Figure 6  A). A sequence trace from a PCR amplification of exon 4 of the FM 03  gene 
from the mother of subject one
1 ro
The trace indicated that the mother of subject one was homozygous for the Glu 
background.
Control Mother
713G>A
Wild-type R238Q
710 715 710 715
Figure 6  B). A sequence trace from a PCR amplification of exon 6  of the FM 03  gene 
from the mother of subject one
The trace indicates that the mother is heterozygous for the 713G>A (Arg Gin) 
polymorphism.
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Figure 7 A). A sequence trace from a PCR amplification of exon 4 of the FM 03  gene 
from the father of subject one
1The trace indicates that the father is heterozygous for the 472G>A variant (Glu Lys).
920
E gc A G A C C  A G
Control
W ild - t y p e
i
Father
V a r ia n t
Figure 7 B). A sequence trace from a PCR amplification of exon 7 of the FM 03  gene 
from the father of subject one
The trace indicates that the father is heterozygous for the 923A>G variant (Glu308Gly).
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Figure 8 . A sequence trace from a PCR amplification of exon 6  of the FM 03  gene 
from the great uncle of subject one
The trace indicated that the great uncle of subject one is homozygous for the 713G>A 
(Arg Gin) polymorphism.
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Subject one - Norwegian child
The sequencing trace indicated that the female subject (bom 1999) was heterozygous for 
the 713G>A (R238Q) polymorphism (Figure 9 A). The trace also showed that the subject 
was a homozygous for the E l58 background (Figure 9 B) and homozygous for the E308 
background (Figure 9 C). This indicated that the heterozygous polymorphisms present in 
the father (E158K and E308G) were in a cis state. This was an important experiment as it 
has previously been shown that having the E158K and E308G polymorphisms, either alone 
[70] or in concert with another polymorphism [62], can cause a TMAU phenotype if in cis. 
Both polymorphisms had previously been shown to be present in the paternal FM03 in a 
heterozygous state, but the phase of these polymorphisms was unknown. This experiment 
showed that the polymorphisms were in cis and that this allele had not been inherited by the 
subject.
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R238Q
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Figure 9 A). A sequence trace from a PCR amplification of exon 6 of the FM 03  gene 
from subject one
The trace indicates that subject one is heterozygous for the 713G>A (Arg238Gln) 
polymorphism.
Subject one
i i
470
A A A G A G T
Figure 9 B). A sequence trace from a PCR amplification of exon 4 of the FM 03  gene 
from subject one
The trace indicates that subject one is homozygous for the Glu variant.
Subject one
9 2 0
C A G A G A C
Figure 9 C). A sequence trace from a PCR amplification of exon 7 of the FM 03  gene 
from subject one
The trace indicates that subject one is homozygous for the Glu308 variant.
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Subject two
A 1 year old child from Northern Ireland was presented to the local General Practitioner 
displaying a TMAU-like phenotype. DNA was collected from the child and sent to UCL 
for analysis.
No mutations were found in the FM03 locus.
Subject 2 - Northern Irish patient 1
Analysis revealed there were no mutations in the subject’s FM03 gene or in the upstream 
regions sequenced.
Subject three
A 4 year old female child from Northern Ireland was presented to the local General 
Practitioner displaying a TMAU-like phenotype. DNA was collected from the child and 
sent to UCL for analysis.
Analysis of the FM03 locus revealed that the child was homozygous for a mutation 
in exon 7 leading to a truncation of the FM03 protein, which has previously been reported 
to destroy FM03 activity. No other mutations were observed in the regions amplified.
A previously unreported mutation was found in exon 9 in a heterozygous state. No other 
mutations were observed in the regions amplified.
Subject 3 - Northern Irish patient 2
The DNA sequencing trace indicated that the subject was homozygous for the 913G>T 
polymorphism (Figure 10) which results in a premature termination at codon 305 in exon 7.
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wild-type
E 305X
c.913G >T
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Figure 10. A sequence trace from a PCR amplification of exon 7 of the FM 03  gene 
from subject three
The trace indicated that the subject is homozygous for the 913G>T (Glu305X) 
polymorphism.
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Subject 4 - Sheffield, England patient
The sequencing traces indicated that the 4 year old subject was heterozygous for a 
1475G>A (R492Q) polymorphism (Figure 11). A restriction digest assay of a PCR 
amplified exon 9 of subject FM03 also indicated that this was this case (Figure 12).
Subject four
A 4 year old female child from Sheffield, England presented with a TMAU phenotype to 
their general medical practitioner. A buccal swab kit was prepared at UCL (by Dr. Abi 
Jones, Dept, of Biology) and sent to the GP in Sheffield in order to obtain a buccal swab of 
the child. This was returned to UCL for DNA extraction, FM03 locus amplification, and 
sequencing and restriction analysis (see section 2.1. for details).
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Figure 11. Sequencing trace showing the region of FM 03  exon 9 containing the 
1475G>A polymorphism of subject four
When comparing sequencing trace of subject four (right) to the wild-type trace (left) a 
distinct G/A double peak can be observed in the subject. This indicated that the subject was 
heterozygous for the 1475G>A (Arg492 Gin) polymorphism.
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Figure 12. Restriction digest analysis of FM 03  exon 9 from subject 4 DNA with BsaWI
A) A wild-type PCR product of FM03 exon 9 yield a 619bp product containing a single 
restriction site 280bp from the start of the exon, whereas the 1475G>A mutant contains no 
such restriction site. B) A BsaWI digest of a wild-type homozygote would therefore yield 
a 339bp and a 280bp fragment. A 1475G>A homozygous mutant would not cut at all and a 
heterozygote digest yield a 339bp fragment, a 280bp fragment and a 619bp uncut fragment. 
C) The subject’s restriction digest generated restriction fragments suggesting that subject 
four was indeed a heterozygote for the 1475G>A (Arg492 Gin) mutation.
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TMAU Patient studies - discussion
The finding that none of the TMAU patients and their family members studied (n=7) 
contained any genetic variation in the upstream regions of FM03 analysed is perhaps 
surprising. The same upstream regions were analysed in a study by Koukouritaki et al., 
(2005) [141] in a population group of 200 individuals (400 chromosomes) each from three 
different population groups; Caucasian American (Cauc), African American (Afr) and 
Hispanic American (Hisp). Seven variants were discovered with 3 occurring at relatively 
high frequencies in all 3 population groups; -2650C>G (dbSNP [230] Build 127 id# 
rs 1736560) 0.303 (Cauc), 0.259 (Afr) and 0.438 (Hisp); -2543T>A (dbSNP id# 
rs 12404218) 0.205 (Cauc), 0.192 (Afr) and 0.291 (Hisp); -2177G>C (dbSNP id# 
rs3754491) 0.068 (Cauc), 0.124 (Afr) and 0.286 (Hisp). The same study showed that - 
2650C>G on its own and together with 2543T>A has been shown to increase luciferase 
reporter expression, with the double variant resulting in an 8-fold increase in reporter 
activity. It is conceivable that the lack of these variants in our patient cohort may be a 
compounding, were other mutations or polymorphisms were found within the coding 
regions, or causative, where no mutations were found with regards to the TMAU 
phenotypes reported. However, our own investigation of the sequencing information from 
the 22 putative TMAU sufferers (TMAU) (44 chromosomes) and 45 control individuals 
(Con) (90 chromosomes) from a Japanese population featured all three of the upstream 
SNPs at relatively high frequencies in both groups; -2650C>G 0.545 (TMAU) and 0.578 
(Con); ~2543T>A 0.114 (TMAU) and 0.100 (Con); -2177G>C 0.114 (TMAU) and 0.110 
(Con) (Table 10, section 3.4.). It is possible that the lack of variants in the Norwegian 
family cohort (see section 3.1.) is due to population differences. This seems unintuitive 
though, both because of the otherwise global occurrence at high frequency detailed above 
and due to the subject and her family being of European ancestry, perhaps represented
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genetically in the Caucasian American group of Koukouritaki et al’s study and recent data 
from the HapMap [1721 project. SNP information deposited from this project in dbSNP 
found the allele frequencies for the 3 SNPs in a European panel of 120 chromosomes to be 
0.308 (-2650OG), 0.100 (-2543T>A) and 0.100 (-2177G>C).
Sequencing a control group from specific populations from which the patients 
belong to in tandem with a patient population could shed more light on this observation.
Norwegian Cohort -  Subject one
Initially, an infant with a phenotype typical of TMAU was presented to a genetic councillor 
(Dr. Hildegunn Hoeberg Vetti, Center for Medical Genetics and Molecular Medicine, 
Haukeland University Hospital, Norway). The parents wanted to confirm this TMAU via a 
genetic screen, but were reluctant to bleed the child. Therefore, both parents agreed to be 
screened instead, from which the genotype of the child could be inferred. The results 
(detailed in sections 3.1. and 3.1.) were interesting. The father is heterozygous for the 
E158K and E308G variants in cis (see section 3.1.2.1.2 and Figure 13). When found in cis, 
these relatively common polymorphisms can result in a reduction in FM03 activity [21, 24, 
147]. When the mother was shown to be heterozygous for a new variant, R238Q (see 
section 3.1. and Figure 13), a residue shown to cause TMAU when changed to tryptophan 
[56], it led to the postulation that the child had inherited the E158K and E308G variants in 
cis allele from the father and the allele containing the R238Q variant from the mother, 
reducing levels of FM03 activity to cause the observed TMAU phenotype. To confirm this 
idea, DNA was extracted from the child and analysed. In the meantime the mother of 
subject one had relayed information to the genetic councillor regarding her uncle whom she 
remembered as always having a strong smell of fish and had led a somewhat
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Figure 13. A representation of the 2 alleles of FM 03  present in the great uncle, 
mother, father and subject one, with the mutations highlighted
The great uncle is homozygous for the R238Q mutation. The mother is heterozygous for 
this mutation. The father is heterozygous the E158K and E308G polymorphisms in cis. 
Subject one has inherited the R238Q mutation from the mother and the allele without the 
polymorphism in exon 4 and exon 6 from the father. The white sections indicate regions, in 
subject one and great uncle, which have not been sequenced.
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reclusive life. After a telephone conversation with the gentleman, the doctor suggested he 
take a TMA-challenge meal, after which he reported his odour problem was exacerbated. 
His DNA was then sent to University College London for analysis.
Contrary to our postulated idea, subject one had not inherited the expected alleles 
from her parents. The child had indeed inherited the R238Q allele from the mother, but she 
had not inherited the E158K and E308G in cis variant allele from the father (see section
3.1. and Figure 13). Instead, she had inherited what appears to be a functional FM03 allele 
from her father and is thus heterozygous. Thus, the prognosis for the child is improved 
because of this as, with a functional FM03 allele, the chances of being able to manage the 
TMAU phenotype is vastly increased. Indeed, because the child has the identical FM03 
protein-coding sequence to her mother who shows no signs of TMAU, it may be that the 
condition will prove transient and dissipate with age. There have been reported cases in the 
literature to support the transient nature of TMAU in some children [75]. It would be 
interesting to analyse the urine TMA/TMA N-oxide ratio of the mother of subject one to 
confirm whether the effect of being heterozygous for the variant R238Q is indeed devoid of 
a TMAU phenotype as she reports.
In contrast, the great uncle of the child is homozygous for the R238Q variant of 
FM03 and as such would be considered as a TMAU sufferer (see section 3.1. and Figure 
13). The great uncle has since received genetic counselling.
The genetic pedigree of this family paints an interesting genetic lineage not least 
because it contained a consanguineous relationship in the family; with the great uncle being 
the offspring of two first cousins (see Figure 14). The documented high levels of 
consanguinity in northern Norway [231], where the family are from, may have given rise to 
the prevalence of this, otherwise rare allele (it is not present in dbSNP) in this isolated 
population.This investigation has revealed a previously unreported mutation in FM03,
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oo Great Uncle 
DOB 1960
O
Infant
OOB1999
^ ^ 1  TMAU symptoms reported 
( ^ )  | | No TMAU symptoms reported
Figure 14. A genetic pedigree of the Norwegian family in this study
The great uncle, offspring of consanguineous relationship (first cousins), is homozygous for 
the 713G>A (R238Q) polymorphism and displays TMAU symptoms. Subject one displays 
TMAU symptoms despite being merely heterozygous for the 713G>A (R238Q) 
polymorphism. The mother does not report TMAU symptoms despite being genotypically 
identical to her daughter at the FM03 locus.
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713G>A (R238Q) which reportedly causes a TMAU phenotype. As mentioned above, this 
represents the second reported case of TMAU caused by the mutation of R238, and the first 
time two different mutations have been implicated in TMAU at the same nucleotide leading 
to two separate amino acid changes. Previously, Teresa et al., (2006) [56] had reported an 
Italian cohort that featured a TMAU patient with the R238P amino acid change, resulting 
from a 713G>C mutation. The importance of this highly conserved residue is thus 
highlighted further. Possible structural changes associated with the residue are discussed 
later (section 4) as are the catalytic consequences of the variant (section 3.2.).
Sub ject two - Northern Irish Patient one
The lack of mutations in the FM03 gene of subject two (section 3.1) means that primary 
TMAU is an unlikely diagnosis. Subject two may have Secondary Trimethylaminuria, 
which can be transient and so may disappear with age [75]. This is unlikely however as 
reported cases of this usually manifest in children with heterozygous variations in FM03. 
It is possible that the child has a problem involving gut flora, rendering digestion of TMA 
rich foods more difficult, leading to a TMAU-like phenotype. Current treatment regimes 
include dietary restrictions to cut out choline (a TMA precursor) and TMA rich foods and 
treatment with antibiotics such as Neomycin and Metronidazole, which has previously 
proved moderately successful in TMAU patients [232, 233]. The development of antibiotic 
resistance has been suggested as a problem which may be overcome by bi-weekly therapy 
of different antibiotics [233]. Management of TMA production and sequestration of free 
TMA by consuming the dietary supplement chlorophyllin-copper complex is a suggested 
alternative therapy to alleviate symptoms of TMAU [47, 85]. Individual patients report 
mixed responses to these different treatments. It has also been suggested that the use of
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soaps with lower pH (5.5-6.5) could be used to try and neutralise the odorous TMA from 
the skin surface.
Subject three - Northern Irish Patient two
The DNA analysis indicates that the patient is homozygous for the 913G>T (E305X) 
polymorphism (section 3.1.) (Figure 10). This polymorphism encodes a truncated form of 
FM03 which does not include the final 227 amino acids of the 532 amino acid molecule. 
This stretch of the enzyme is predicted to contain important residues involving linkage 
between NADPH and active site domains, a binding site for FAD flavin moiety, the FAD 
domain side of a substrate cleft-isoalloxazine ring, an active site to active site linkage of 
monomers, a dimer interface (important only if FM03 exists as a dimer, it is not known in 
what state the enzyme exists in vivo) and active site of the substrate cleft and a predicted 
membrane anchoring domain [40]. The loss of such protein domains may be academic as a 
truncation of this size would most probably have destructive consequences in terms of 
protein folding and protein localisation.
The 913G>T polymorphism has been reported before [73] in patients displaying 
TMA N-oxidd TMA ratios indicating Primary Trimethylaminuria (Table 7). The 
polymorphism was found in a homozygous state in a single individual (Family 2 in the 
paper) who, although having TMA concentrations close to that of the control level, had 
extremely elevated TMANO/TMA ratios. It has been shown in vitro that the E305X 
truncation totally destroys the catalytic activity of FM03 in terms of A-oxidation of TMA 
[73].
Where this polymorphism was found in the other individuals it was found in a heterozygous 
state along with 551C>T (P153L) which has been shown to destroy FM03 catalytic activity 
in terms of A-oxidation [62, 67, 73]. Furthermore, a polymorphism has been reported
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Table 7. - Clinical characterization of index cases with TMAU (adapted from Treacv et al.. 
(1998) T731)__________________________________________________________________
Case Ancestry Age at DX 
(years)
TMAa TMANO/TMAb Genotype
1 English-Irish 15 60.4 ± 11.7 21.9/78.1 P153LAE305X
2 English-Irish 14 19.7 ±2.8 11.8/88.2 E305X\E305X
5 English-Irish 
German-Spanish
58 501.2 ±
280.3
NT P153L\E305X
6 English-Irish 4 40.2 ± 7.8 NT P153LVE305X
7 English-Scottish 18 48.1 ±7.5 NT P153L\E305X
aThe normal level is <18 pmol/mmol creatinine. 
bThe normal ratio is >97:3.
NT, not tested.
DX, Diagnosis
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leading to a premature termination codon only nine residues downstream from E305X, 
E314X (940G>T) which has also been shown in vitro to destroy catalytic activity in terms 
of A-oxidation [62].
At this stage there is no genotypic evidence to suggest Secondary 
Trimethylaminuria and the presence of a mutation in a homozygous state, previously shown 
to destroy FM03 catalysis of /V-oxidation, indicate that a Primary Trimethylaminuria 
phenotype would be expected.
Subject four -  Sheffield, England subject.
Subject four was found to be heterozygous for thel475G>A (R492Q) variant (section 3.1.). 
Thus, two different mutations have been implicated in TMAU leading to two separate 
amino acid changes, the other being 1474C>T (R492W). This is the first time two different 
mutations have been implicated in TMAU at the same codon, but not due to a mutation at 
the same nucleotide, leading to two separate amino acid changes
Previously the R492W has been reported in a compound heterozygote TMAU 
patient. Akerman et al., (1999) [62] first described the 1474C>T mutation (leading to a 
R492W amino acid change) in a compound heterozygote with another novel mutation, 
198G>T (M66I). Akerman et al., (1999) [58] also investigated an 8 year old French 
Canadian girl displaying a classic TMAU biochemical phenotype, who was a compound 
heterozygote for the R492W mutation along with a P153L (458C>T) mutation. This latter 
mutation was shown to segregate with TMAU [67] and has been shown to destroy the 
activity of FM03 in a recombinant protein. Dolphin et al., (2000) [35] investigated a 
patient with compound heterozygosity for the R492W and a previously unreported 
mutation, M434I (1302G>A). Both mutations were generated individually in a 
baculovirus-mediated insect cell protein expression system and assayed for activity. The
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M434I mutation was found to severely decrease FM03 activity and the R492W mutation 
was found to destroy enzyme function completely.
It is probable that the structural change produced by the R492W substitution 
destroys (or greatly reduces) the protein activity, due to the proximity of the amino acid 492 
to the predicted active site of the substrate cleft [40]. As subject four is heterozygous for 
this mutation, it is possible that TMAU will prove transient. The subject was 4 years old 
when she was first examined by the GP. Transient TMAU has been reported previously 
with the TAMU phenotype disappearing completely in these cases as the child reaches 7-8 
years old [75]. Here, the transient TMAU phenotype was postulated to have been caused 
by . .a transient overproduction in the gut or an overloading of the gut-generated substrate 
overwhelming the hepatic enzymes’ [FM03] oxidizing capacity.” However, it is more 
probable that rather than being the “cause”, the gut-overload was compounded because the 
child had only a single FM03 allele able to generate a functional FM03 enzyme.
Because this subject possesses one functional FM03 gene, it would be reasonable to 
predict that the TMAU phenotype will be a transient one, and once adult expression of 
FM03 is established, the phenotype would be predicted to dissipate (discussed in section 
1.2 .).
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3.2. Kinetic parameters of FMQ3 polymorphic variants 
Introduction
To assess the catalytic consequences of FM03 amino acid variation, kinetic parameters 
were assessed using an established assay for FMO activity (described in section 2.2.7.)- Of 
particular interest were two double amino acid variants, E158K/V257M and 
E158K/E308G. It has been shown previously that in combination with E158K, the E308G 
variant was catalytically impaired, compared with either variant present alone. Also, the 
R238Q variant discovered in the TMAU Norwegian cohort discussed earlier (section 3.1.) 
was also assayed for FM03 activity.
Kinetic parameters of FMQ3 polymorphic variants - Results
Variant FM03 cDNAs were created as described in section 2.1.1. Analysis of the DNA 
sequencing traces, for both strands, confirmed the presence of the mutation in the cDNA on 
the E158 (Figure 15) and K158 (Figure 16) backgrounds. The DNA traces were also used 
to confirm the absence of undesired mutations that might have been inadvertently 
introduced, that would cause premature stop codons or unwanted amino acid variants.
All FM03 variants were readily expressed in bacteria according to the protocol 
detailed in section 2.2.3.1. Only cell lysis method VII (detailed in section 2.2.3.3.7.) was 
amenable to maintaining catalytically active FM03 during the cell protein preparation 
protocol.
FM03 activity was assessed by the Methimazole assay, detailed in section 2.2.7. A 
hyperbolic Michaelis-Menton relationship between enzyme rate and substrate concentration 
was observed for all variants of FM03 tested, except the R238Q form of the enzyme which 
was catalytically inactive. A Hanes-Woolf linear transformation of the Michaelis-Menton
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Figure 15. DNA sequencing traces of FM 03 cDNA on the E158 background
Sequencing traces of FM03 cDNA generated via site-directed mutagenesis on the E l58 background are shown. 
A) E158K, B) V257M, C) E308G and D) R238Q.
variant
713G>A
R238Q
i
i i » i
710
C T C 0 A T  T
99
A)
wild-type
i
470
472G>A
E158K
A A A G A G T
472G>A
E158K
470
A A A 0 A  G T
923A>G
E308G
920
C A G 0 G A C
Figure 16. DNA sequencing traces of FM 03 cDNA variants on the K158 background
Sequencing traces of FM03 cDNA generated via site directed mutagenesis on the K158 background are shown. A) The E158K/V257M double 
variant and B) the E158K/E308G double variant.
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equation was used to determine the kinetic parameters, Km and /feat and Kcat/KM (Figure 
17). /feat and Km/ ATcat were also calculated for each catalytically active variant (Table 8). 
Only the E158K/V257M and E158K/E308G double mutants were significantly catalytically 
deficient when compared to the wild-type FM03, as measured by the decrease in catalytic 
efficiency, Acat/KM- The E158K/V257M double mutant was 71.4% as efficient (P < 0.05) 
and the E158K/E308G double mutant was 42.7% as efficient (P < 0.005) (see appendix 1 
for details). Interestingly, while the V257M single mutant was not significantly 
catalytically different from the E158K/V257M double mutant, the catalytic activity of the 
E158K/E308G double mutant was significantly reduced to that of the E308G single mutant 
(P < 0.05) (see Appendix 1 for details). The Km of wild-type FM03, 143 ± 17 pM, is 
similar to that reported earlier for the protein expressed in bacterial systems [197].
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Figure 17. A Hanes-Woolf linear transformation plot of the Michaelis-Menton 
equation for each catalytically active variant of FM 03, measuring methimazole 
concentration (pM)/ Assay product formed (nmol/min) as a function of Methimazole 
concentration (pM)
Wild-type (black), E158K (Green), V257M (blue), E308G (pink), E158K/V257M (orange) 
and E158K/E308G (red) FM03 variants are plotted. A plot showing ony wild-type 
(unbroken line) and E158K/E308G (dashed line) is also presented for clarity. All data 
display a good linearity, indicative of obeying classical Michaelis-Menton kinetics.
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Table 8. 5-oxygenation of methimazole bv human FMQ3 variants
FM03 variant Km (pM) Kcat (s -1) Kcat/KM (pM '1 s -1) Relative activity (%)
Wild type 143 ± 17 0.0704 ±0.00219 4.9 04 ±6.0 ~Ui 100
E158K 170 ±24 0.0704 ± 0.00278 4.1 _U4 ± 6.0 u;> 84.1
V257M 179 ± 27 0.0715 ±0.00308 3.9 _U4± 6.3 'u:> 79.9
E308G 166 ±29 0.0672 ± 0.00326 4.0 04 ± 7.0 81.8
E158K / V257M 183 ±30 0.0643 ±0.00301 3.5 _U4± 6.1 'u:> 71.4*
E158K / E308G 292 ± 59 0.0615 ±0.00402 2.1 4)4 ± 4.4 42.7 **
R238Q N.D. N.D. N.D. N.D.
The 5-oxygenation of methimazole was determined as described in section 2.2.7. 
Data are mean ± standard deviation obtained from three independent experiments. 
Km (pM), Kcat (s '), Kcat/KM (pM'1 s '*) and catalytic activity relative to wild-type 
FM03 are displayed (%).
* P < 0.05 compared to the result obtained from wild-type FM03 (see Appendix 1 for 
details).
** P < 0.005 compared to the result obtained from wild-type FM03 (see Appendix 1 
for details).
N.D. Enzyme activity was not detected.
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Kinetic parameters of FMQ3 polymorphic variants - Discussion
The impact of pharmacogenetics of monooxygenases on the drug metabolism and 
distribution of certain drugs has been established. Variant alleles of CYP2C8*3 have 
been implicated in altered oxidation of the mitotic inhibitor paclitaxel [234, 235]. 
Patients carrying amino acid variants of CYP2C9 have been implicated in warfarin 
sensitivity, e.g. CYP2C9*2 R144C and CYP2C9*3 I359L, requiring lower doses of 
warfarin [236, 237] due to lowered catalytic activity of the enzyme [238-240]. 
CYP2D6 polymorphism has been implicated in the impaired metabolism of the anti­
hypertensive debrisoquine [241-243] and the anti-convulsant mephenytoin [244, 245]. 
The allelic frequency of CYP variants vary widely from population to population 
[246], which is important when considering the clinical significance of 
pharmacogenetic studies. Given the extremely broad range of FM03 substrates, any 
frequent polymorphisms that alter FM03 catalytic efficiency would be relevant to 
pharmacogenetic considerations for therapeutic strategies.
E158K is the most common FM03 polymorphism with an allelic frequency 
ranging from 39-50% depending on the population sampled. [65, 66, 70, 87, 143, 147, 
222, 247-251]. Heterozygotes have shown no significant increase in free TMA in 
urine [70]. In vitro studies by other groups have also shown the lack of significant 
effect on FM03 catalysis by this common polymorphism, as confirmed in this 
investigation (section 3.2.) [248, 252].
The allelic frequency of V257M has been reported to range from 3-25% 
depending on the ethnicity of the population [35, 142, 222, 247-249, 253, 254]. The 
lack of significant reduction in recombinant FM03 enzyme efficiency due to the 
V257M polymorphism presented in this investigation (section 3.2.) has also been
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demonstrated by other groups [35, 255]. Another group has also reported a lack of 
significant reduction, but in a substrate specific manner [256].
E308G has been shown to be a relatively common polymorphism with an 
allelic frequency of 6-26% depending on the population sampled [62, 70, 147, 248- 
251, 257]. In vivo [249, 258] and in vitro [255, 259] methods have shown the variant 
to have little consequence catalytically to FM03 efficiency and this is supported by 
the work presented in this investigation with an insignificant reduction in enzyme 
efficiency, as a measure of ^cat/KM.
Little data on the frequency of E158K and V257M being found in cis exists. 
E158K and V257M were found in cis at an allelic frequency of 4-6% in a Han 
Chinese population [254]. In a different study, E158K/V257M was found at an allelic 
frequency of 1% in a study of Hispanic Americans, but was not present in any other 
population in the study (Caucasian American, African American and Asian 
American) [248]. Surprisingly, this E158K/V257M double mutant was found with 
the E308G mutation in cis also, with the other allele of the individual unknown. 
Because the source of the DNA was a blood bank, it was not possible to test the 
individual for symptoms of TMAU and, to date, this E158K/V257M/E308G triple 
mutant has not been assayed and it may be of interest to see what the catalytic 
consequence would be to FM03. This investigation suggests that the E158K/V257M 
double mutant does cause a significant reduction in FM03 catalytic efficiency (P < 
0.05) with efficiency dropping to 71.48% of that of the wild-type enzyme. It is 
interesting to note that the E158K/V257M double mutant has relatively similar 
catalytic parameters, as does the single V257M mutation on its own.
E158K and E308G occur in cis at an allelic frequency ranging from 1-16% 
depending on the source population [248, 250, 254]. The E158K/E308G double
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variant when found in cis (featured earlier in the Norwegian cohort, section 3.2.) has 
previously been shown to reduce FM03 activity by around 50% in vivo (as a measure 
of free TMA in urine samples compared with control subjects) [58, 70]. The activity 
of in vitro expressed FM03 have shown a dramatic reduction in catalytic efficiency of 
the E158K/E308G variant when compared to either the E158K or E308G single 
variants [21, 143, 147]. The kinetic study presented as part of this investigation 
supports a reduced catalytic efficiency in the E158K/E308G double mutant of 42.7% 
compared to wild-type FM03, which represents a significant reduction (P < 0.005). 
That the E158K/E308G double mutant significantly disrupts FM03 catalysis, 
compared with either the E158K or E308G single mutants, is made all the more 
interesting when we consider that the E158K/V257M double mutant has a relatively 
similar catalytic activity to either of the single mutations alone. FM03-substrate 
metabolism shown to be affected by the reduction in catalytic efficiency of the 
E158K/E308G variant occurring in cis includes the histamine F^-receptor antagonist 
ranitidine [147], the anti-tubercular agent thiobenzamide [147] and the non-narcotic, 
non-steroidal anti-inflammatory drug, sulindac [5]. Interestingly, in the latter case, 
the E158K/E308G variants were found to have a protective effect on the development 
of polyps in familial adenomatous polyposis patients who received sulindac as a 
means of primary chemoprevention, presumably reducing the ability of the enzyme to 
inactivate the drug, leading to prolonged exposure to the active form of sulindac, 
sulindac sulphide [260, 261]. Therefore, the relationship between the E158K and 
E308G variants has the potential to be important from a pharmacogentic standpoint 
when considering FM03 substrates as therapeutic treatments.
The finding that the R238Q variant of FM03 was catalytically inactive is 
consistent with the finding in this investigation that individuals with a FM03 allele
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containing this variant have compromised TMA metabolism. In chapter 3, a case 
study was presented of a Norwegian cohort that was screened for TMAU-associated 
mutations at the FM03 locus (see section 3.2. for details). A child showing 
symptoms of TMAU was found to be heterozygous for the 713G>A (R238Q) 
mutation. Her great uncle was found to be homozygous for this mutation and 
consequently received genetic counselling after being diagnosed as having TMAU. 
With no other mutations present, R238Q was suggested as the cause of the TMAU 
phenotype. Evidence of importance of arginine at amino acid 238 for FM03 catalysis 
is also presented by Teresa et al., (2006) who describe the mutation 713 G>C (R238P) 
in an Italian TMAU cohort with a TMAU phenotype [56].
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3.3. Generating a homology model of FMQ3
Introduction
To theorise about the structural consequences of the variants of FM03, homology 
modelling of FM03 was performed.
Modelling FMQ3
The two closest homologues to human FM03 in the PDB at present, in terms of 
identity at the primary sequence level, are the crystal structure of Baeyer-Villiger 
Monooxygenase from the moderate thermophilic bacterium, Thermobifida fusca 
(T.fusca) [215] (26% identity) at 2.40 A resolution (PDB accession code 1W4X) and 
the crystal structure of FMO from Schizosaccharomyces pombe (S.pombe) [214] 
(29% identity) at 1.70 A resolution (PDB accession code 1VQW) (see Figure 18 for 
ClustalW primary sequence alignments). The next nearest homologues are of 
extremely low sequence identity (<15%).
Using the homology modelling software ‘Modeller’ it was possible to generate 
models of FM03 from the crystal structure templates 1W4X and 1VQW.
Homology model of FMQ3 using 1VOW as a template
The crystal structure 1VQW was co-crystallised with ligands and the coenzyme FAD. 
Using a python script within the suite of scripts that make up Modeller, it was 
possible to model this coenzyme along with the rest of the target from the template.
The model displays two main bundles of secondary structure (Figure 19). The 
larger of the two seems to be where the FAD and NADPH molecules are predicted to
bind. It consists of a bundle of six a-helixes, one, four-stranded parallel [3-sheet and
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Figure 18. ClustalW alignments of 1W4X vs hFM03 and 1VQW vs hFM03.
An asterix denotes conserved identical residues, a colon indicates conserved similar residues, and a dot indicates highly similar residues.
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Figure 19. A cartoon representation of the homology model, based on 1VQW, of 
FM 03
The model displays two main bundles of secondary structure. The larger of the two 
seems to be where the FAD (shown in blue) and NADPH (not shown) molecules are
predicted to bind. It consists of a bundle of six a-helixes (red), one, four-stranded 
parallel (3-sheet (yellow) and one, three stranded anti-parallel (3-sheet. In the model,
the flavin moiety is bound within the a-helix bundle, with the adenine dinucleotide 
moiety of the molecule penetrating deep into the protein, poking between an anti­
parallel (3-sheet and with the tip of the moiety residing near a parallel (3-sheet, 
one, three stranded anti-parallel (3-sheet. In the model, the flavin moiety is bound
within the a-helix bundle, with the adenine dinuceotide moiety of the molecule
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penetrating deep into the protein, poking between an anti-parallel p-sheet and with the
tip of the moiety residing near a parallel P-sheet.
The crystal structure of 1VQW [214] have helped to give further insights into 
the mechanism of FMO action. The correct orientation of the isoalloxazine ring of 
the FAD molecule is predicted to be vital in order for it to act as an efficient 
prosthetic group, namely to accept a hydride ion from NADPH, accept molecular 
oxygen and for oxygenation of the substrate (Figure 20 A). The flavin moiety is 
visible from the surface image of the protein, residing in a pocket, readily accessible 
and solvent-exposed. The orientation of the FAD molecule within the FM03 model 
was examined and shown to be positioned in a reasonable orientation (Figure 20 B) 
with the Asn 61 residue in close proximity to the FAD isoalloxazine ring. This 
residue is equivalent to Asn 91 in the 1VQW structure, which has been shown to be a 
key residue in binding molecular oxygen, and is thought to be the only FMO residue 
directly involved in substrate catalysis.
In the FM03 model, the adenine dinucleotide moiety of FAD is buried deep 
within the protein (Figure 21 A). There are several residues known to be involved in 
TMAU, where FM03 catalysis is severely disrupted or destroyed, that reside 
proximal to the modelled FAD molecule within the FM03 model, namely E32K, 
A52T, V58I and N61S (Figure 21 B). The residues predicted to interact with the 
FAD molecule within the FM03 homology model were investigated further using 
MBT Ligand Explorer (Figure 22). Hydrophobic and hydrophilic interactions were 
predicted, measured and tabulated (Table 9).
A)
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Figure 20. FAD isoalloxazine ring orientation within FMO
A) The isoalloxazine ring of the FAD molecule within the active site of S.pombe 
FMO solved crystal structure (1VQW) is shown (red) along with a molecule of FMO 
substrate Methimazole (blue). Asn 91 is highlighted in orange. Asn 91 in 1VQW has 
been shown to be a key residue in binding molecular oxygen and is thought to be the 
only FMO residue directly involved in substrate catalysis.
B) The isoalloxazine ring of the modelled FAD molecule within the FM03 model 
based on 1VQW is shown (red). The Asn 61 residue is highlighted in yellow, which 
is the equivalent residue to Asn91 in 1 VQW.
1 1 2
A)
N61S,
Figure 21. FAD modelling within the homology Model of FM 03 based on 1VQW
A) A cartoon representation of FM03 (green) with FAD represented as red spheres.
B) A close up view of FAD within FM03, with the local amino acid residues known 
to be associated with TMAU represented by blue spheres.
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Figure 22. MBT Ligand Explorer view of the modelled FM 03 association with 
FAD
A) A cartoon representation of FM03 with FAD shown as ball-and-sticks. FM03 
residues predicted to interact with FAD are labelled and their hydrophobic (purple) 
and hydrophilic (green) interactions are shown as dashed lines along with their 
distance, measured in Angstroms, which is labelled.
B) A close up view.
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Table 9. A tabulation of all interactions predicted from the model of FMQ3 along 
with an incorporated FAD molecule, by MBT Ligand Explorer
FM03 
amino acid 
residue
u
Interaction(s) (distance (A)) Catalytic effect reported at 
residue
Ile8 Hydrophobic (3.48, 3.53)
Gly 9 Hydrophilic (2.77) 
Hydrophobic (2.77)
Val 12 Hydrophilic (2.54, 3.08)
Ser 13 Hydrophilic (2.68, 3.21)
Phe 31 Hydrophilic (2.92)
Glu 32 Hydrophilic (2.65, 2.83) TMAU E32K [55]
Lys 33 Hydrophobic (3.59, 3.88) Within 1 residue of 
TMAU causing E32K
Leu 40 Hydrophobic (2.90, 3.83, 3.88) 
Hydrophilic (2.88)
Trp 41 Hydrophobic (2.85, 2.92, 3.67, 3.72, 3.79)
Ser 60 Hydrophilic (3.05) Within 1 residue of 
TMAU causing N61S
Asn 61 Hydrophilic (3.0) TMAU N61S [35, 60]
Met 67 Hydrophobic (3.61) Within 1 residue of 
TMAU causing M66I
Phe 109 Hydrophobic (3.08, 3.56)
Val 110 Hydrophilic (3.04, 3.26)
Cys 146 Hydrophilic (3.02)
Ser 147 Hydrophilic (2.72) 
Hydrophobic (3.12, 3.42, 3.65)
Ala 378 Hydrophobic (3.79)
The FM03 residue is detailed along with any hydrophobic and/or hydrophilic 
interactions, with their distances measured in Angstroms shown in parentheses. 
Hydrophilic interactions are H-H measurements and hydrophobic interactions are H-C 
measurements. Also shown is any implication in TMAU of an amino acid change.
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Seventeen FM03 residues were predicted to contribute to the binding of FAD, 
including 2 of the residues associated with TMAU above, E32K and N61S. Met 67, 
which is one residue away from Met 66 and shown to be a causative mutation in 
TMAU when mutated to isoleucine [54, 61, 62], was shown to interact with the FAD 
molecule.
FMOs are known to have a hydrophobic 'FATGY' sequence motif common to 
most FMOs (it is ‘FTTGY in FM 04’), and an 'identifying sequence' 
FXGXXXHXXXF. Despite being known for quite some time, the actual role of these 
two highly conserved motifs has remained elusive. Both motifs were mapped onto 
the FM03 model to try to gain some insight into their possible roles. The FATGY 
motif was shown to map to a region around the rim of the pocket containing the 
putative active site of FM03 (Figure 23 A). The FMO identifying sequence maps to 
the 'top' of the FM03 model (Figure 23 B).
The catalytic site atlas did not identify any probable catalytic residues from its 
database of enzyme active sites, within the putative active site of the FM 03 model 
based on 1VQW.
Mutations and Polymorphisms of FMQ3
In an attempt to try and understand possible insights that may be gleaned from a 
structural standpoint, the residues known to be variant in FM03 were mapped on to 
the model (Figure 24). The variants included all residues known to destroy (or 
severely disrupt) FM03 activity, those residues known to alter FM03 catalytic 
activity and the two residues for which novel mutations were discovered in this 
investigation (see section 3.2.). The amino acid residues affected are shown in Figure 
24 and the consequences for these changed are discussed later in this chapter.
116
A)
B)
Figure 23. The FMO identifying sequences
FMOs are known to have a hydrophobic sequence motif common to all FMOs, 
'FATGY' and an 'identifying sequence' FXGXXXHXXXF.
A) The FATGY motif is shown (yellow) to map to a region around the 'mouth' of the 
pocket containing the putative active site of FM03. A FAD molecule can be seen 
within the pocket (red).
B) The FXGXXXHXXXF FMO identifying sequence (orange) maps to the 'top' of 
the FM03 model, with the FATGY motif shown in yellow to emphasise the relative 
position of the two motifs.
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Figure 24. The homology model, based on 1VQW, of FM 03 with amino acid variants highlighted
The model is shown as a cartoon (A) and as a surface view (B) with residues known to be variant in FM03 were mapped on to the model. 
Residues known to destroy (or severely disrupt) FM03 activity are shown as red spheres, residues known to alter but not severely disrupt FM03 
catalytic activity are shown in blue and the two sites of allelic variation shown to destroy catalytic activity where two novel variants were 
discovered in this investigation (R238Q and R492Q) are shown as yellow spheres and labelled.
Model scoring FMQ3 homology model based on 1VOW
The programme Verify 3D considers the 3D compatibility of the protein model to its ID 
primary sequence. The residues in the 3D model are characterized by the environment 
surrounding it, defined by the area of the residue that is buried, the proportion of side-chain 
area covered by polar atoms and the local secondary structure. The likelihood of finding a 
specific amino acid in the environment defined is then scored, e.g. finding a charged 
residue buried in a non-polar environment would be assigned a poor score reflecting the 
improbable nature of such an occurrence [262]. Models that are largely wrong have a low 
overall score, whereas models that contain small numbers of improperly built segments can 
be detected by low scoring regions in the profile plot. A single region (residue 223 to 
residue 267) was defined as a low scoring region, and can be considered to be an 
improperly built segment of the FM03 model based on 1VQW.
ProSA analyses the energy distribution in proteins as a function of sequence 
position, with native structures typically having a balanced energy distribution devoid of 
high energy peaks or 'strained' areas littering the protein, such features being typical of 
unlikely regions in terms of amino acid 3D position. The ProSA plot of residue scores 
identified two areas of concern in the model (Figure 25 A). One area was the C-terminal 
region and the other was the region around 223 - 267 that verify 3D also identified. Despite 
these regions of uncertainty, ProSA indicated that the model generated was of good overall 
quality with a z-score within the range of scores typically found for native proteins of a 
similar size with solved structures in the PDB (Figure 25 B).
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Figure 25. ProSA output for FM 03 model generated using 1 VQW as a template
A) An energy distribution plot of FM03. The thin green line considers the energy distribution over a 10-residue stretch, whereas the thick green 
line considers the energy distribution over a 40-residue stretch. The plot suggests two areas of concern with the model, indicated by peaks of 
positive energy, at the C-terminus and in the middle of the protein around 220-270 amino acids.
B) A plot of the z-scores of all solved structures currently in the PDB as a function of their length, solved either by NMR (dark blue) or X-ray 
crystallography (light blue). The position of the z-score of the FM03 model as a function of the length of the model is indicated by a black dot. 
This shows that the model is generally within the range of the z-score expected for a molecule of that size and indicates that the model is of a 
general good quality.
The Ramachandran plot for the FM03 model, generated using 1VQW as a template, 
showed 41/532 (7.7%) of amino acid residues in sterically improbable regions of the energy 
landscape (Figure 26 A). One measure of a good model is having more than 90% of the 
amino acide residues in the sterically 'allowed' regions [263]. The number of amino acids 
in the improbable areas was reduced to 33/532 (6.2%) by moving residue sidechains very 
close to ‘allowed’ regions into the region by breaking the aC-backbone either side of the 
residue, dragging the side chain into the region and then ligating the aC-backbone within 
Swiss-PDBViewer v.3.7, as displayed in the Ramachandran plot (Figure 26 B). 6/33
(18.1%) of the residues remaining in the disallowed regions of the Ramchandran plot reside 
within the region identified by Verify3D and ProSA as being a region that may not have 
been built correctly. 8/33 residues (24.2%) of these residues within the disallowed regions 
of the Ramachandran plot reside in the C-terminal region of the model, highlighted as an 
area of concern by Verify3D and ProSA. The residues suggested by MBT Ligand Explorer 
(Table 9) as being important in binding to the FAD prosthetic group were highlighted on a 
Ramachandran plot (Figure 26 C). All residues were found to be in the ‘allowed’ regions, 
suggesting that the model is reasonable in these important areas.
Finally, the packing quality of each residue was assessed using the WHATIF web 
server (Figure 27). A threshold value of -5 was used, below which level a residue can be 
considered poorly packed. The results indicated that there were two main areas of poorly 
packed amino acid residues. One corresponds to the area around amino acids 220-270, 
previously identified as a poorly built region by Verify3D and ProSA. The C-terminus, 
although not containing as many or as poorly packed residues, still stands out as an area of 
poor packing. The rest of the model, on the whole, was reasonably well packed.
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Figure 26. Ramachandran plots of the FM 03 model generated using 1 VQW as a template
A) The Ramachandran plot for the FM03 model generated using 1VQW as a template showing 41/532 (7.7%) of amino acid residues in 
sterically improbable regions of the energy landscape (points outside the defined rings boundries of allowed regions, shown in blue and yellow).
B) The number of amino acids in the improbable areas was reduced to 33/532 (6.2%) by moving residue sidechains very close to ‘allowed’ 
regions into the region by breaking the aC-backbone either side of the residue, dragging the side chain into the region and then ligating the aC- 
backbone within Swiss-PDBViewer v.3.7, as displayed in the Ramachandran plot. 6/33 (18.1%) residues are within the region identified by 
Verify3D and ProSA as being a region that may not have been built correctly (see section), highlighted in pink. 8/33 residues (24.2%) of these 
residues within the disallowed regions of the Ramachandran plot reside in the C-terminal region of the model, highlighted as an area of concern 
by Verify3D and ProSA and are highlighted in green.
C) The residues suggested by MBT Ligand Explorer (see Table 9) as being important in binding to the FAD prosthetic group are highlighted as 
red dots in the Ramachandran plot. All residues were found to be in the ‘allowed’ regions, suggesting that the model is reasonable in these 
important areas
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Figure 27. WHATIF assessment of the amino acid packing quality of the FM 03 model generated using 1VQW as a template
A threshold value of -5 was used, below which level a residue can be considered poorly packed. For clarity, a horizontal, black bar indicates the 
threshold. It is apparent that there are two main areas of poorly packed amino acid residues. One corresponds to the area around amino acids 
220-270, previously identified as a poorly built region by Verify3D and ProSA. The C-terminus, although not containing as many or as poorly 
packed residues, still stands out as and area of poor packing.
123
Homology model of FMQ3 using 1W4X as a template
A homology model of FM03 was also built using the Baeyer-Villiger Monooxygenase 
from the moderate thermophilic bacterium, Thermobifida fusca (1W4X) as a template. The 
hydrophobic network highlighted in the model (Figures 28 A and B) based on 1W4X was 
shown to consist of two channels, one containing predicated binding motifs for FAD and 
the other a predicted binding motif for NADPH. Indeed, the crystal structure of 1W4X 
included FAD bound to the protein corresponding to the predicted FAD binding site 
derived from the motifs. A Q-site finder probing of the model (Figure 28 C) showed 
various hydrophobic sites, but the deepest hydrophobic pocket (incidentally, where 
NADPH was predicted to bind) contained several hits classified as ‘Probable’ (E-value < 
le-5) from the Catalytic Site Atlas (Figure.28 D).
The FM03 model built using 1W4X was aligned with the model generated using 
1VQW as a template and compared using the FATCAT server. The alignment of the two 
models generated using 1W4X and 1VQW showed that they were significantly similar (P <
o
0.05) with an RMSD of 3.22 A (Figure 29), with the majority of the difference occurring in 
the difficult C-terminal area where the template coverage was extremely low. Indeed, when 
the last 37 amino acids are removed from both homology models, the pairwise alignment 
lowers to 2.3 A which is significantly similar (P < 0.005). Despite this, for reasons 
discussed later, it was decided not to continue with more detailed studies of the model, built 
using 1W4X as a template.
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Figure 28. Buried cavities within the homology model of FM 03 based on 1W4X
A) Two buried cavities are highlighted (white) within the model of FM03 generated 
using 1W4X as a template. B) The buried cavities are shown with the FM03 model 
stripped away to emphasise their association. C) The meshed features within the 
model are Q-site Finder predictions of predicted buried protein-ligand interaction 
sites. D) The highlighted residues on the FM03 model represent the top hits reported 
by the Catalytic Site Atlas (1 being the top hit).
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Figure 29. A superimposition of the two models of FM 03 generated by homology 
modelling
A cartoon view of the two models of FM03 are shown, generated using 1W4X as a 
template (blue) and the model of FM03 generated using 1VQW a template (red).
The models are significantly similar (P < 0.05) with an RMSD of 3.22 A.
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Homology Modelling of FMQ3 - Discussion
When employing homology modelling in an attempt to understand protein structure 
and biophysical consequences of structural changes, it is important to understand the 
molecular biology of the protein template. This is especially important when dealing 
with enzymes, where catalytic properties are a consideration. Homology models of 
FM03 were made using the FMO from S.pombe (1VQW) and the Baeyer-Villiger 
monooxygenase (BMO) from T.fusca (1W4X). In many respects, FMOs and BMOs 
are similar. Both are flavoenzymes that require NADPH as an electron donor and 
both react with molecular oxygen to form a flavin-peroxide intermediate, which then 
attacks soft-nucleophilic centres of substrates. Crucially, however, the BMO 
undergoes a conformational change executed via a domain rotation event during 
catalysis [215]. This occurs once the FAD molecule is reduced by NADPH. In order 
for molecular oxygen to bind, the enzyme must undergo a conformational change. 
The domain rotation occurs around a molecular ‘hinge’ consisting of a domain linker 
in the form of two antiparallel /?-strands which are higly conserved in BMOs [215]. 
Domain rotations have been shown before in xenobiotic metabolism enzymes during 
catalysis, such as thioredoxin reductase [264]. Indeed, the antiparallel ^-strand 
domain linker is present in several proteins that exhibit domain motions, including 
thioredoxin reductase [265], but not in FMOs. In all three states of FMO crystallised 
(with no ligand bound, with substrate bound and with NADPH bound), no 
conformational change is present [214]. Despite the high degree of similarity of the 
two homology models generated, due to the different mode of action of catalysis by 
the two enzymes, only the model generated using the FMO from S.pombe (1VQW) 
was selected for further study.
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Homology modelling of FMQ3 based on the FMO from S.pombe (1VOW)
Despite domain assignment software such as DomPred [266] consistently predicting 
FM03 existing as a single domain unit, the homology model of FM03 displays two 
distinct regions of secondary structure bundles. Although these regions may well not 
qualify as being true protein domains (independent or, at the least, semi-independent 
units, able to fold and, in some cases, retain function if separated from the parent 
chain [267]) their seemingly distinct nature is interesting. It may well be that these 
regions are true domains, with automatic domain assignment methods being fallible 
due to the complexity of the task [268] and the the paucity of domain definitions 
already in the databases for FMOs. The C-terminal region of the FM03 model exists 
essentially as a long, floppy loop, devoid of more complex secondary structure. In 
many ways this region is meaningless due to the lack of coverage by the template 
protein and therefore very little structural information can be gained from analysis of 
this region.
The larger of the two domains is where the NADPH and FAD molecules are 
predicted to bind and where a molecule of the latter is modelled. In the model, the
flavin moiety is bound within the a-helix bundle, with the adenine dinuceotide moiety 
of the molecule penetrating deep into the protein, poking between an anti-parallel p-
sheet and with the tip of the moiety residing near a parallel P-sheet. It is perhaps not
unreasonable to speculate that this region of secondary structure may be involved in 
maintaining core stability around this vital region of catalysis. Despite the proposed 
catalytic region residing in a large, deep pocket, we theorise that the actual 
metabolism of substrates takes place relatively near the solvent exposed opening of 
the pocket, where the isoalloxazine ring of the flavin moiety of the FAD molecule 
resides.
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The crystal structures of 1VQW [214] have helped to give further insights into 
the mechanism of FMO action. The correct orientation of the isoalloxazine ring of the 
FAD molecule is predicted to be vital in order for it to act as an efficient prosthetic 
group, namely to accept a hydride ion from NADPH, accept molecular oxygen and for 
oxygenation of the substrate. Therefore, it was judged to be important for the 
modelled FAD molecule within the FM03 model to be in a reasonable orientation. A 
cursory examination of the FAD molecule orientation seemed to suggest that the ring 
was in a reasonable orientation when compared to the 1VQW template. Further 
examination of the model revealed that the relative distance and orientation of Asn 61 
to the FAD isoalloxazine ring (Figure 20 and Table 9) was comparable to Asn 91 and 
the FAD isoalloxazine ring within 1VQW. This is encouraging as Asn 61 is the 
human FM03 equivalent to S.pombe Asn 91, and Asn 91 has been shown to be a key 
residue in binding molecular oxygen and is thought to be the only FMO residue 
directly involved in substrate catalysis. Protein sequence alignment of all mammalian 
FMOs available at the time, an FMO from Saccharomyces cerevisiae (S.cerevisiae) 
and four putative FMOs from Caenorhabditis elegans (C.elegans) showed that the 
asparigine at this position was conserved in all sequences. This calls into question the 
previous theory of Asn 61 involvement in a conserved secondary structure of a 
conserved membrane interaction domain [141].
FAD is a relatively large molecule and, within the FM03 model, most of the 
molecule would not be visible, with the adenine dinucleotide moiety of FAD buried 
deep within the protein (Figures 21 and 24). Several residues are known to be 
involved in TMAU, where FM03 catalysis is severely disrupted or destroyed, that 
reside proximal to the modelled FAD molecule within the FM03 model, namely 
E32K, A52T, V58I and N61S (Figure 21 B). It was therefore decided to probe the
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involvement of other FM03 residues in FAD binding. The hydrophobic and 
hydrophilic interactions were predicted, measured and tabulated using MBT Ligand 
Explorer (Figure 22 and Table 9). 17 FM03 residues were predicted to contribute to 
the binding of FAD (Table 9), including two of the residues associated with TMAU, 
E32K and N61S (Figure 30). Asn 61, discussed above, was predicted to be vital for 
the catalytic cycle of FM03 with the other residues associated with FAD binding, and 
was presumably important in FAD stability and molecule accessibility. Other 
interacting residues reported by MBT Explorer, although, not associated with FM03 
catalytic reduction to date, were proximal to residues known to be so. Lys 33 (Figure 
30), which is one residue away from Glu 32 (Figure 30) and known to be associated 
with TMAU, was predicted to have hydrophilic interactions with FAD. Ser 60 is one 
residue away from the important Asn 61 (Figure 30), discussed above, and associated 
with TMAU, and is predicted to have a hydrophilic association with FAD. Met 67 
(Figure 30) is one residue away from Met 66 (Figure 30), known to be associated with 
TMAU, and is predicted to have a hydrophobic association with FAD.
In order to probe the involvement and importance of each residue predicted to 
be involved with FAD binding and stability in vitro FM03 codons could be altered by 
mutagenesis, the protein expressed and relative FAD content assayed, to see how 
much FAD binding is disrupted. Recently, a group showed that the M66I FM03 
variant failed to incorporate or retain FAD, despite expressing to comparable protein 
levels [259]. M66 (Figure 30) is highlighted on the homology model of FM03 in 
Figure 24. Interestingly, a variant of the 492 residue (Figure 30), R492W was also 
shown to lack FAD. This residue is also highlighted in Figure 24. This residue was
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Figure 30. Homology model of FM 03 with residues implicated in FAD 
incorporation and/or retention.
The FM03 homology model is shown with Glu 32 (orange), Lys 33 (pink), Ser 60 
(magenta), Asn 61 (cyan), Met 67 (yellow) and R492 (blue) displayed as spheres. 
The FAD molecule is displayed in as sticks (red).
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found to be variant in the English subject studied in this investigation (see section 
3.1.), albeit in the Q492 state. The finding that this residue caused the enzyme to be 
unable to incorporate or retain FAD is curious, as the residue does not reside near the 
catalytic core near the FAD molecule. Unfortunately, very little information about 
this region is forthcoming from the homology model due to lack of template coverage, 
discussed above. No other residues predicted to be involved with FAD incorporation 
or stability (Table 9) were investigated by this group, although other variants shown 
to be involved in TMAU were and had FAD levels comparable to wild-type enzyme, 
showing that FAD presence required but not sufficient for FM03 catalytic efficacy.
Mapping the two FMO identifying sequences, ‘F(A/T)TGY’ and 
‘FXGXXXHXXXF’, onto the model does not reveal an obvious reason for their high 
level of conservation. Due to the highly conserved nature of the ‘FATGY’ motif, it 
would be reasonable to assume that this motif is important to the molecule. A 'fishy 
taint' in the eggs of chickens has been associated with a mutation in Fmo3 which 
changes the threonine to a serine [269]. The position of the motif on the model of 
FM03 does not instantly give a clue as to the role of this motif. The ‘FATGY’ motif 
on the FM03 model maps to just above the putative active site pocket (Figure 23 A). 
Undoubtedly, the integrity of this pocket would be very important to the maintenance 
of an environment suitable for redox reactions to take place, but any specific reason as 
to why this region is so highly conserved is open to speculation. This is also the case 
for the ‘FXGXXXHXXXF’ motif, perhaps even more so, as it maps to a position in 
the larger domain but with little obvious function (Figure 23 B). It may be that these 
motifs are important in order for proper protein folding to take place or for 
maintenance of structural stability.
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The catalytic site atlas did not identify any probable catalytic residues from its 
database of enzyme active sites, within the putative active site of the FM03 model 
based on 1VQW. This may be due to the Atlas' bias towards enzymes that have had 
their mechanisms solved; hence any enzyme without a family member in the PDB 
would be less likely to be represented.
Mutations and Polymorphisms of FMQ3
The residues known to be variant in FM03 were mapped on to the homology model 
of FM03 to try and understand any structural consequences of their variance. The 
variants included all residues known to destroy (or severely disrupt) FM03 activity, 
those residues known to alter FM03 catalytic activity and the two residues for which 
novel mutations were discovered in this investigation.
The majority of the amino acid variants shown to be destructive in FM03 
seem to cluster in the larger domain, with a significant concentration around the FAD 
coenzyme (Figure 24). The majority of polymorphic sites shown to affect, but not 
destroy, FM03 activities seem to cluster in the smaller bundle of secondary structure 
(Figure 24). Other than disrupting protein folding or stability, it is not obvious as to 
how many of the variants that map away from the catalytic core are responsible for 
the lack of FM03 activity associated with their presence. R238 is positioned near, but 
not within the putative active site. A variant of this residue, R238Q, was discovered 
by a patient study in this investigation (see section 3.1.). As shown in this 
investigation, when this residue is mutated to glutamine, FM03 activity is destroyed 
(see section 3.2.). It has also been shown that when this residue is found as a proline, 
FM03 activity is destroyed [56]. The proximity of the residue to the active site courts 
speculation that the variants may prevent proper access to the active site for the
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coenzyme, electron donor, -substrate or a combination of the three. Any and all of 
these situations would prevent FM03 catalysis. The second variant, discovered for 
the first time in this investigation, was R492Q (see section 3.1.). It has been shown 
previously to destroy FM03 activity when changed to a tryptophan at this position 
[35, 62]. It is difficult to hypothesise about the possible structural consequences of 
this mutation, as it resides on the poorly modelled C-terminal region, discussed in 
more detail below.
Homology model validation
The observations so far assume that the model of FM03 resembles the actual structure 
of human FM03. There is no way of knowing this until the structure is solved by 
crystallographic methods, but the quality of the homology model was assessed to try 
and give some sort of indication of how much faith one can place in this model of 
FM03.
Four well-established and widely cited methods of structure validation were 
used to assess the homology model of FM03; Verify 3D (assesses residue packing 
environment), ProSA (assesses packing based on special separation of Cp residues), 
WHATIF (assesses residue packing quality) and Ramachandran Plot (examines the 
psi and phi backbone conformational angles for each residue in a protein.) analyses, 
generated using Swiss-PDB Viewer.
Generally, Verify 3D, ProSA and WHATIF agreed that the model of FM03 
was a good one in terms of residue environment, energy distribution and atomic 
packing quality. However, all three methods identified two areas of concern with the 
model, the first around a 50 amino acid stretch ranging from around amino acids 220- 
270 and the second region located at the C-terminal portion of the model. It is not
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surprising that the C-terminal region was flagged as being unrealistically built. This 
region was always going to be difficult to model due to the lack of template coverage 
(see Appendix 2 for details). A possible way of improving the model of this C- 
terminal region into a more realistic conformation would be to consider this tail region 
in isolation, BLAST the PDB for more suitable templates, and then build a chimeric 
model incorporating the top hit. This would require a reasonable level of primary 
sequence homology to expect an improvement. Such homology templates are not 
available in the PDB at this time. It is not clear as to why the region around amino 
acids 220-270 has not been built correctly. The template provided to Modeller as a 
basis of structural comparison had coverage in the majority of this area (see Appendix 
2 for details). Despite the classification of this region as being poorly modelled, the 
general topology of the model would be expected to be generally correct, so one can 
draw some sort of gross observations, such as, the proximity of the residue to the 
active site may possibly of interest. Both regions of poor quality do not seem to be 
directly involved in the catalytic core of the molecule and do not contain many 
mutations and/or polymorphisms known to destroy FM03 activity, although the R238 
residue mentioned above does reside in this area. We can not dismiss the importance 
of the C-terminal region of FM03, with several truncation mutations and three residue 
mutations in this region known to perturb FM03 activity (Table 2), including the 
residue R492, mentioned earlier. Mutations in this area may have more to do with the 
importance of the C-terminal region with regards to cellular localisation, rather than 
catalytic activity of protein folding/stability.
One measure of a good model is having more than 90% of the amino acid 
residues in the sterically 'allowed' regions of a Ramachandran plot [263]. This was 
found to be the case in the FM03 homology model before refinement and was
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subsequently improved during refinement. Almost half of the residues in poorly 
defined regions of the Ramachandran plot had also been previously identified as being 
present in the two areas of concern discussed above. Crucially, the residues identified 
by MBT Ligand Explorer (Table 9) as being important in binding to the FAD 
prosthetic group were found to be in the ‘allowed’ regions, suggesting that the model 
is reasonable in these important areas.
Comparison of FMQ3 model built with others recently published
Recently, Borbas et al., (2006) [270] described a model of human FM03 that they had 
created to help describe the consequences of the L360P polymorphism, discovered in 
their lab. This model was generated using the SWISS-MODEL system [164] which is 
a fully automated modelling program with absolutely no human intervention during 
model building or model scoring or refinement afterwards, much like ModWeb (see 
section 1.3.). More recently, Yeung et al., (2007) [259] presented a homology model 
of FM03 using proprietary software (Molecular Operating Environment (available 
from http://www.chemcorp.com)) which was not refined or scored.
The general topology of the two recently published models of FM03 and the 
one built in this investigation are similar (Figure 31). This is unsurprising as all three 
use the same template, 1VQW, to generate the majority of the molecule, with the 
Yeung et al., (2007) [259] model having the added feature of a C-terminal tail 
segment modelled on cytochrome C oxidase from Rhodobactor sphaeroides [271] 
(PDB code 1M56). The value of this feature could be questioned however, 
considering the low template coverage in terms of primary sequence identity being 
only 22% to human FM03, below the ‘midnight zone’ cut-off point (see section 1.3.).
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All three models seem to have two bundles of secondary structure, with the 
largest forming the core, catalytic centre with the FAD binding domain. More 
detailed comparison of the structures would require the PDB coordinates of all three, 
not presently available.
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A) B)
Figure 31. Homology models recently published of FM 03
Both models are based on the S.pombe FMO, 1VQW, the template used to generate the homology model in this investigation. A) Borbas et al., 
(2006) [270] presented a model highlighting the location of FAD (pink) and NAPDH (purple) binding sites. The variant site 360 is also 
highlighted (yellow). B) Yeung et al., (2007) [259] presented a model highlighting several variant sites (single spheres), regions most similar to 
yeast FMO (white), additional residues at C terminus (red), FATGY motif (cyan), nucleotide binding motifs (yellow) and FMO ‘identifying’ and 
signature motifs (purple).
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FMQ3 model -  Active site of FMQ3
The literature surrounding the biochemical activities catalysed by the active site of 
FMOs has been built up since the early pioneering work of Daniel Ziegler in the 1960’s 
right up to the present day. Since there is no structure of a mammalian FMO and no 
homologue of high enough sequence identity to infer function, the active site and the 
consequences of alterations to the active site, i.e. through amino acid substitutions, have 
been shrouded in mystery. Having a refined model of FM03 means it would be possible to 
probe the biophysical environment of any putative active site through protein-ligand 
docking. A good starting point in protein-ligand docking would be AutoDock, which is a 
free-to-academia suite of computer programs used to model protein-ligand interactions. It 
is the most highly cited docking algorithm in the peer-reviewed literature (correct as of 10th 
October, 2006) [272]. AutoDock has been shown to be more accurate than other free-to- 
academia, protein-ligand software such as FlexX [273] and Dock [274] in benchmarking 
tests [275]. AutoDock uses a protein molecule (such as the homology model of FM03) and 
a ligand (such as FM03 substrate, methimazole or FM03 cofactor, FAD) as input files. 
The program then probes a user-defined space, e.g. the putative FM03 active site, using 
simulated annealing techniques for a low energy conformation. This process is an iterative 
one and the results can be viewed by the user. Models can also be mutated and then 
subsequently subjected to docking studies in an attempt to understand the biophysical 
consequences of amino acid substitutions at the tertiary level. This sort of study could give 
fresh insight into the impact of the mutations underlying TMAU and the polymorphisms 
known to cause changes in the catalytic capacity of FM03.
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FMQ3 model -  insieht to the structural chanees which lead to TMAU
The mutations leading to TMAU are more likely to cause perturbations in FAD binding or 
orientation, leading to FAD being completely displaced from the molecule or bound in a 
state which renders the prosthetic capacity of the molecule inefficient, or indeed, lost. This 
could be assayed in vitro by generating mutations predicted to perturb FAD binding by site 
directed mutagenesis and then assessing FAD content compared to wild-type protein. This 
approach is supported by the recent work by Yeung et al., (2007) [259] who showed that 
M66I, a residue known to cause TMAU and one residue away from M67 which was 
predicted in section 3.3. Table 9, to interact with FAD, failed to incorporate FAD forming 
the FM03 holoenzyme in vitro [259]. It would be interesting, and possible, to 
systematically generate the FM03 variants predicted to interact with FAD and then assay 
the molecules for FAD incorporation. To complement this, having a refined FM03 
homology model allows protein-ligand docking studies to be performed. Where docking 
studies suggested that FAD may well be able to bind to FM03 but does so in such a manner 
that the correct orientation of the isoalloxazine ring can not be achieved, then FAD content 
would be expected to be maintained at a wild-type level, but catalysis would be perturbed.
Other variant sites are more difficult to theorise as to the causes of FM03 activity 
perturbation, other than protein folding, structural integrity maintenance and perhaps cell 
localisation.
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3.4. Evolution of the FMQ3 locus
The work in this section has been published.
Allerston, C.K., Shimizu, M., Fujieda, M., Shephard, E. A., Yamazaki, H. and Phillips, I. R. 
(2007) Molecular evolution and balancing selection in the flavin-containing 
monooxygenase 3 gene (FM03). Pharmacogenetics and Genomics. 17(10):827-839.
FMQ3 nucleotide sequence variation
6,274 bp of the FMO3 gene were sequenced from 23 Japanese potential TMAU sufferers. 
This comprised 3,358 bp of contiguous 5’ flanking sequence (extending from -5144 to - 
1786, relative to the A of the ATG translational initiation codon), the entire coding 
sequence (1,599 bp, 533 codons, including the stop codon, in exons 2-9) and 1,317 bp of 
partial intronic and 3’-untranslated region. The sequencing was performed by the Yamazaki 
group in Japan. Haplotype phases were inferred by the Yamazaki group using the software 
packages SNPAlyze (DYNACOM, Chiba, Japan) and HAP [276]. Results from one 
individual were ambiguous and thus were excluded from the data set. Sixteen diallelic 
SNPs were identified, 12 in the 5’-flanking region and 4 in the coding region (Table 10). 
Twelve of the SNPs were transitions and 4 were transversions. Three of the SNPs, all in the 
5’flanking region, at -4600, -4488 and -3788, are novel. All of the coding-region SNPs 
were nonsynonymous substitutions: at positions +15167G>A in exon 4 (Glu>Lys change at 
amino-acid residue 158), +15549C>T in exon 5 (Arg>Cys change at residue 205), 
+18281G>A in exon 6 (Val>Met change at residue 257) and +21443A>G in exon 7 
(Glu>Gly change at residue 308). The SNPs at codons 158, 257 and 308 are polymorphic 
variants that individually have a limited effect on enzyme activity [35, 67, 255]. None of 
the SNPs were present as a singleton, i.e. occurred in only one sequence of the sample, and 
only one (+15549C>T) was present as a doubleton. Comparison with the FM03 sequence 
of chimpanzee (Pan troglodytes) (Genbank accession no. NM_001009092.1) showed that 
for each diallelic SNP observed in humans, one of the two alleles was present at the
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Table 10. SNPs and their frequencies
dbSNP
Accession
Number
Allele Frequency of derived variant in
Potential TMAU 
sufferers0 
(n=44)
Controlsd
(n=90)
Position Ancestral3 Derived1*
rs6608461 -5109 G C 0 .11 4 (0 .0 5 1 ,0 .2 0 6 ) 0 .10 0 (0 .0 6 1 ,0 .1 5 1 )
-4600 T C 0 .11 4 (0 .0 5 1 ,0 .2 0 6 ) 0 .10 0 (0 .0 6 1 ,0 .1 5 1 )
rs 12402693 -4488 C T 0.114 (0 .0 5 1 ,0 .2 0 6 ) 0 .1 0 0 (0 .0 6 1 ,0 .1 5 1 )
-3788 T C 0 .11 4 (0 .0 5 1 ,0 .2 0 6 ) 0 .10 0 (0 .0 6 1 ,0 .1 5 1 )
rs 1736554 -3606 G A 0.11 4 (0 .0 5 1 ,0 .2 0 6 ) 0.211 (0.163, 0.266)
rs3754487 -3549 C T 0 .31 8 (0 .2 2 8 ,0 .4 1 9 ) 0.267 (0.216, 0.321)
rs 1736555 -3548 A G 0.545 (0.446, 0.643) 0.578 (0 .524 ,0 .631)
rs3754489 -3544 C T 0 .114 (0 .0 5 1 ,0 .2 0 6 ) 0 .10 0 (0 .0 6 1 ,0 .1 5 1 )
rs 12404183 -2854 T C 0 .114 (0 .0 5 1 ,0 .2 0 6 ) 0 .1 0 0 (0 .0 6 1 ,0 .1 5 1 )
rs 1736560 -2650 C G 0.545 (0.446, 0.643) 0.578 (0 .524 ,0 .631)
rs 12404218 -2543 T A 0.11 4 (0 .0 5 1 ,0 .2 0 6 ) 0 .10 0 (0 .0 6 1 ,0 .1 5 1 )
rs3754491 -2177 G C 0 .1 1 4 (0 .0 5 1 ,0 .2 0 6 ) 0 .1 0 0 (0 .0 6 1 ,0 .1 5 1 )
rs2266782 15167(E158K) G A 0.364 (0.270, 0.464)
rs28363549 15549(R205C) C T 0.045 (0.009, 0.128)
rs 1736557 1828KV257M) G A 0.068 (0 .021 ,0 .155)
rs2266780 21443(E308G) A G 0.318(0 .228 , 0.419)
“The positions of the SNPs are given relative to the ‘A’ of the ‘ATG’ translational initiation 
codon. For each codon-region SNP, the codon position is also given. 
bThe ancestral state of each SNP was inferred from the chimpanzee sequence. 
cNumbers in parenthesis are 95% confidence intervals.
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corresponding position in chimpanzee (Table 11). The ancestral state of each SNP was 
inferred from the chimpanzee sequence. With the exception of SNPs at -3548 and -2650, 
the more common human variant corresponded to the inferred ancestral allele.
Calculations of measures of nucleotide diversity were based on the number of 
effectively silent sites in the sequenced region. For the potential TMAU sufferers this was 
estimated to be 5,065 and is the sum of all 5’flanking and 3’-untranslated sites, plus all 
intronic sites (with the exception of the two conserved splice sites at the 5’ and 3’ end of 
each intron) and exon sites that are silent. Although the 5’-flanking region undoubtedly 
contains some sites that are functionally constrained, the identity of these is not known and 
intuitively they would constitute a very small proportion of the 3,358 bp of 5’-flanking 
region sequenced. For the control group, all 3,358 bp of 5’-flanking region were considered 
silent.
Two estimates of sequence diversity were calculated: the average expected per-site 
nucleotide heterozygosity (0W), estimated from the observed number of polymorphic sites 
[174], and nucleotide diversity (7t), a direct estimate of per-site heterozygosity, derived 
from the average pairwise sequence difference between two random sequences in a sample 
[227]. For the potential TMAU sufferers, 0W is 0.00054 and n is 0.00065 (Table 12). For the 
control group, both estimates of diversity are higher, 0W being 0.00070 and n 0.00095. The 
estimates of nucleotide sequence diversity (n) for FM03 are similar to the average value of 
n (0.00075) for human genetic loci [277, 278]. There were no mutations at silent sites in the 
coding region.
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Table 11. Haplotvpes and their estimated frequencies in the potential TMA patient group
N ucleotic
Haplotype
e position
1 1 1
5 4 4 3 3 3 3 3 "> -> 5 5 8 1
I 6 4 n 6 5 5 5 8 6 5 1 1 5 2 4
0 0 8 8 0 4 4 4 5 5 4 7 6 4 8 4
9 0 8 8 6 9 8 4 4 0 3 7 7 9 1 3
Codon
1 2 2 3
5 0 5 0
8 5 7 8
G T C T G C A C T C T G G C G A
Frequency
Chimp
1
2
3
4
5
6 
7
C T C
G
G
G
G
T C G A C
C.
G
A
A G
A
0.364
0.045
0.114
0.045
0.045
0 .318
0 .068
The positions of the SNPs are given relative to the ‘A’ of the ‘ATG’ translational initiation 
codon. For each codon-region SNP, the codon position is also given. Bases identical to the 
chimpanzee sequence are indicated with a dash and are inferred as the ancestral state. 
Haplotype 1 is identical at each SNP position and thus represents the ancestral haplotype. 
Polymorphisms are derived from this state and the base change is indicated.
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Table 12. Diversity estimates and neutrality tests for FMO3
Potential TMAU sufferers Control group
Sample summaries
na 44 90
Sb 16 12
sc 0 0
Rmd 1 0
P values P values
he 7 < 0.05* 4 <0.01
Expected no. of 
haplotypesf
11.6 9.6
Parameter estimates
0wg 0.00055 0.0070
7^ 0.00066 0.00095
Test statistics
Tajima’s D "'”' 0.66 - 0.92 -
Fu and Li’s F * ""1 1.59 <0.05 1.47 < 0.001
Fu and Li’s D*1' " 1 1.51 <0.05 1.52 <0.05
Fu’s Fs[m 3.50 < 0.05* 7.38 <0.01
Raggedness (r)11 /V| 0.16 - 0.37 <0.02
zJS" 0.32 < 0.05* 0.48 <0.02
Wall’s fi1'80' 0.33 < 0.05* 0.45 <0.05
Wall’s e 11801 0.38 - 0.50 <0.02
A total of 6,274 sites (5,033 silent sites) were analysed in potential TMAU sufferers and
3,358 silent sites in control individuals.
aNumber of chromosomes surveyed
bNumber of segregating sites
cNumber of singleton sites
dMinimum number of recombination events, based on the four-gamete test [224] 
eNumber of haplotypes
fGiven the extent of nucleotide diversity in the sample and assuming no recombination
events have taken place
gExpected heterozygosity per nucleotide [174]
hAverage pair-wise sequence difference per nucleotide [227]
P values are given within the potential TMAU sufferer group when significant (P < 0.05) 
and are based on comparisons to estimates obtained from coalescent simulations performed 
assuming constant populations size and no recombination, except where marked which 
were significant only when simulations were performed for the level of recombination 
observed in the sample.
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Haplotypes
The 16 SNPs in the sample of 44 chromosomes were found to segregate as 7 distinct 
haplotypes. These haplotypes, together with the haplotype composed of the ancestral state 
of each allele, inferred from chimpanzee, are shown in Table 11. The most frequent 
haplotype in the sample (haplotype 1), with a frequency of 0.363, is identical to the 
chimpanzee sequence at all 16 SNP positions and thus represents the inferred ancestral 
haplotype. One of the haplotypes (haplotype 4) appears to have arisen as the result of a 
recombination event (see section 3.4.).
Although individuals in the TMAU cohort were self-selected on the basis of an 
apparent fishy body odour, only seven were diagnosed as suffering from mild TMAU, as 
judged by urinary secretion of 70-90% of total TMA as TMA A-oxide, with two more 
being classed as borderline (excretion of 90% of total TMA as the A-oxide) [85]. Of the 
seven mild TMAU sufferers, six have a haplotype pair that is the same as that present in 
one of the unaffected individuals (Table 13). If only the 5’-flanking region is considered the 
12 SNPs present in this region segregate as four distinct haplotypes. The identity of these 
haplotypes is the same, and their frequencies are similar, in the potential TMAU sufferers 
and control groups. This is also the case for the haplotype pairs in the two groups. 
Therefore, with the exception of R205C (see section 3.4.), none of the SNPs or haplotypes 
identified in the 44 chromosomes of the potential TMAU group is apparently causative of 
the disorder. Some affected individuals may possess mutations, in unsequenced regions of 
the gene, which would compromise gene expression or RNA processing. Alternatively, the 
mild TMAU may be the result of dietary intake of relatively large amounts of TMA 
precursors, e.g. choline, or to factors that affect the metabolism of such compounds, for 
instance, gut flora composition or functional polymorphisms of endogenous enzymes.
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Table 13. Genotypes and their occurrences in potential TMAU sufferers
Genotype 
(haplotype pair)
Occurrences in
Diagnosed 
TMAU sufferers
Borderline cases Non-affected
individuals
1-1 1 1
1-2 1 1
1-3 1 1
1-5 1 1
1-6 2 4
3-4 1
3-6 2
4-7 1
6-6 2
6-7 2
Total 7 2 13
The number of ocurrances of each haplotype pair in diagnosed TMAU sufferers, borderline 
cases and non-affected individuals is presented. Of note is the finding that six of the 
individuals diagnosed as suffering for TMAU (albeit mild cases) have a haplotype pair that 
is also found in non-affected individuals.
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Recombination and linkage disequilibrium
The presence in haplotypes of diallelic SNPs of pairs of sites with four gamete 
combinations is indicative of recombination (crossing-over between the two sites or gene 
conversion) or repeated mutation. The probability of repeated mutation at the same site is 
very small. The four-gamete test (Table 12) [224] reveals that only 2 out of 120 pairs of 
SNP sites compared (-3548, 158 and -2650, 158) have all four gametes. The presence of 
these two four-gamete site pairs can be accounted for by a single recombination event 
(between variant sites -2650 and 158).
Of the 120 pairwise comparisons of variant sites, 37 show significant LD (P < 
0.001) (Figure 32 A). A plot of pairwise LD (measured as R2) against physical distance 
indicates that strong LD extends to a distance of 25 kb (Figure 32 B), e.g. between the SNP 
at -3549 and that at 308, which lies 21.5 kb downstream of the translation initiation codon.
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Figure 32. Pairwise linkage disequilibrium
A) A plot of the association among 16 SNPs within 22 Japanese individuals. Blackened 
boxes indicate 37 out of 120 possible associations that display significant LD at the 0.001% 
level by a %2 test and Bonferroni correction. Numbers denote the nucleotide positions of the 
SNPs relative to the A of the ATG translational initiation codon.
B) The relationship between pairwise LD, measured as R2, and physical distance, in 
kilobase pairs (kb), for the 37 associations significant at the 0.001% level.
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Evolutionary history of FMQ3 allelic divergence
The mutational relationship among the haplotypes was visualised by construction of a RM 
network [225] (Figure 33). In a RM network, circles correspond to distinct haplotypes. The 
size of each circle is proportional to the relative frequency of the haplotype in the sample. 
Haplotypes are connected by branches (lines) along which mutations are indicated. Where 
multiple mutations occur along a single branch, e.g. between the central node and haplotype 
3, the order in which these occurred is not known and hence their sequence along the 
branch is arbitrary.
Haplotype 1 corresponds to the ancestral sequence and thus is the root haplotype of 
the network. By tracing the connections that link the route haplotype to the other 
haplotypes, the evolutionary history of genetic changes at the FM03 locus can be inferred. 
The FM03 haplotypes fall into four major clades. One of these comprises the ancestral 
haplotype (haplotype 1) and haplotype 5, which are separated from each other by a single 
cSNP that causes an Arg>Cys substitution at residue 205 of the protein. The three other 
haplotype clades comprise of phylogenetically distinct lineages radiating from a central 
node, separated from the ancestral haplotype by two mutations (at -2650 and -3548): 
haplotype 3 has undergone eight further mutations in the 5’-flanking region; haplotypes 2 
and 7 both have an additional single mutation (at -3606) and are separated from each other 
by a single SNP that causes a Val > Met substitution at residue 257; haplotype 6 is 
separated from the central node by three mutations, one (at -3549) in the 5’-flanking region 
and two SNPs that cause Glu > Lys and Glu > Gly substitutions at residues 158 and 308, 
respectively.
The placement of one haplotype, haplotype 4, is ambiguous, as indicated by a 
reticulation in the network. This is due to homoplasy (the inferred occurrence of multiple 
independent evolutionary events giving rise to the same allelic state at a variable site) that
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Figure 33. Reduced-median network of FM03 haplotypes.
Each of the seven unique haplotypes is represented by a circle, the size of which is 
proportional to the relative frequency of the haplotype. Mutational relationships are 
indicated by lines linking the haplotypes. Mutational differences between haplotypes are 
indicated on the branches of the network. Mutations in the 5’-flanking region of the gene 
are identified by their nucleotide position relative to the A of the ATG translational 
initiation codon. Coding-region mutations leading to an amino acid change, 15167 
(E158K), 15549 (R205C), 18281 (V257M) and 21443 (E308G), are boxed. Where 
mutations occur along a branch, their order is arbitrary.
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affects sites -3548, -2650 and 158.
Time depth of FMQ3 variation and ages of mutations
To investigate the length of time over which the sequence differences have arisen and of the 
ages of individual mutations, something which can’t be done using a RM network, the 
sequence haplotypes were analysed through the use of the program GENETREE, which 
uses maximum-likelihood coalescent analyses [226], under assumptions of neutrality and 
an infinite-sites model of evolution, i.e. no recombination. Thus haplotype 4, which appears 
to have arisen via a recombination event, was excluded from this analysis. The method uses 
all of the information in the infinite-sites-compatible sequence data set.
The maximum-likelihood estimate of the population mutation parameter (0m l) per 
locus, conditional on the FM03 gene tree and determined by using the GENETREE 
program, is 3.30. This is slightly larger than 0w, the estimate of the parameter from the 
number of polymorphic sites, which is 2.74 for the locus.
The gene tree for FM03 is shown in Figure 34. To estimate the neutral mutation 
rate of FM03 we used the net silent-site sequence divergence between humans and 
chimpanzee (i.e. divergence between species minus divergence within species) and a 
human-chimp divergence time of ~6 million years before present (BP) [33]. The net 
sequence divergence was estimated as 47.31. This gave a neutral mutation rate (v) of 7.78 x 
10'10 per site per year. Assuming a generation time of 20 years, the locus-specific neutral 
mutation rate (p) is 7.88 x 10'5 per locus per generation. Using the GENETREE maximum 
likelihood estimate of the parameter 0 and our estimate of the locus-specific mutation rate 
p, the effective population size (N e) was calculated, from the relationship 0 = 4Nep, as 
10,463.
The estimated time to the most recent common ancestral sequence (T m rca ), i.e. the
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Figure 34. A genetree for FM 03, estimated through maximum-likelihood coalescent 
simulation
The tree shows the inferred genealogical history of the 6 haplotypes compatible with the 
infinite sites model of mutation. Mutations in the 5’-flanking region of the gene are 
identified by their nucleotide position relative to the A of the ATG translational initiation 
codon. Coding-region mutations leading to an amino acid change, 15167 (E158K), 15549 
(R205C), 18281 (V257M) and 21443 (E308G), are boxed. Where branches contain 
multiple mutations, with the exception of 15167 (see text), the order of mutations through 
time is arbitrary. The scale is presented as millions of years before present (Myr BP).
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total time depth of the tree, derived from the maximum-likelihood coalescent analysis, was 
calculated as 2.08 in units of 2Ne generations. This value was substituted using the estimate 
of Ne and assuming 20 years per generation, to years. This corresponds to 872 thousand 
years (kyr) BP (SD = 226 kyr BP). This corresponds closely to the coalescence time 
expected for a neutrally evolving human nuclear locus, assuming random mating and a 
long-term constant effective population size, i.e. 4Ne generations ago [279]. In a coalescent 
model assuming constant effective population size, average pairwise divergence is 
dominated by the time taken for the last two lineages to coalesce, which is expected to take 
2Ne generations, or half the total time back to the most recent common ancestral sequence. 
From the net sequence divergence between human and chimp FM03 genes (47.31) and the 
average pairwise sequence difference among human haplotypes in the same region (3.32), 
the average pairwise age of sequence diversity is estimated as 6 x l06x 3.32/47.31 = 421 kyr 
BP. This indicated a TMRCAof 842 kyr BP.
The maximum-likelihood coalescent analysis of GENETREE also enables 
estimation of the ages of individual mutations and the coalescent times of various 
haplotypes. The coalescent time for haplotypes 2, 3, 6 and 7, which corresponds to the point 
at which these evolutionary lineages coalesce to a common ancestor, is estimated as 674 
kyr BP (SD = 182 kyr BP). Similarly, the coalescent time of haplotypes 2 and 3 is 
estimated as 283 kyr BP. In cases where multiple mutations have occurred along a single 
branch, e.g. that leading to haplotype 3, the order in which they arose is unknown and 
consequently the dates of individual mutations can not be estimated. However, in the case 
of the branch leading to haplotype 6, which contains three mutations, the single 
recombination event that, from the RM network (Figure 33) and the four gamete test, was 
predicted to give rise to haplotype 4 (see above), indicates that the mutation at 158 predated 
those at -3549 and 308. This allows the SNP at 158 (Gly > Lys) to be dated. The mutation
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is estimated to have occurred 371 kyr BP (SD =132 kyr BP). Although the order in which 
mutations at -3549 and 308 occurred is not known, the SNP at 308 (Glu > Gly) is 
estimated to have occurred some 200 kyr BP and thus it, too, is relatively old. The SNPs at 
257 (Val > Met) and 205 (Arg > Cys) occurred more recently, with estimated ages of 62 
kyr (SD = 52 kyr) and 52 kyr (SD = 59 kyr), respectively.
Evidence for balancing selection at the FMQ3 locus
To examine the possibility that balancing selection, suggested by the relatively long branch 
lengths separating intermediate-frequency haplotypes on both the RM network (Figure 33) 
and the genetree (Figure 34), has acted on the FM03 locus, several tests were performed. 
These tests fell into four classes based on (1) the frequency spectrum of alleles within the 
FM03 locus, (2) the number and diversity of haplotypes in the sample, (3) LD and finally 
(4) interspecific comparison of sequence variation. To address the possibility of bias that 
might arise from analysis of sequences derived from potential TMAU sufferers, all tests 
were also performed independently, on 3,356 bp of 5 -flanking region of FM03 from 45 
unaffected Japanese individuals.
A summary of the tests carried out on the FM03 population samples is presented in 
Table 12.
Allele frequency spectrum
Under neutrality, and assuming random mating and a constant population size, the two 
estimates of nucleotide variation, 0W and 7t, should be equal and Tajima’s D, which 
compares these values, should be zero. The two neutrality tests are not equal in both the 
potential TMAU group and the control group leading to a positive Tajima’s D value.
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Fu and Li’s F* and D* statistics were used to compare the observed number of 
singleton polymorphic sites with that expected under a neutral model. Fu and Li’s F * and 
D* were positive for both the potential TMAU sufferers (P > 0.05) and the control group (P 
> 0.001 and P > 0.05, respectively).
Wrights fixation index, Fst, which measures population subdivision by comparing 
genetic diversity within subpopulations to that of the whole population, was used to analyse 
the FM03 SNPs. Only Japanese individuals were sequenced in this investigation, but SNP 
coverage in the genotyped panels of dbSNP contained details of four of the SNPs featured 
in the Japanese group, -3606, -2854, 15167 (E158K) and 18281 (V257M), in panels of 
European, Asian and African origin. The average Fst value four the four SNPs among 
these populations were found to be 0.050.
The allele frequency spectrum (Figure 35 A) showed an excess of intermediate- 
frequency SNPs compared to the number expected under a neutral model of evolution.
The Number and diversity of haplotypes
The number and diversity of haplotypes was examined to investigate departures from 
neutrality. Fu’s Fs statistic was used to compare the observed number of sequence 
haplotypes to the number expected under the assumption of an infinite-sites model of 
neutral mutation with no recombination. The significantly positive value of Fs (P > 0.02) 
(Table 12) indicated an excess of intermediate-frequency haplotypes.
As mentioned earlier, analysis of DNA sequences from the potential TMAU 
sufferers indicated that the sample has undergone a single recombination event. When 
coalescent simulations were performed for the level of recombination observed in this data 
set, the number of haplotypes and Fs for the TMAU group were significantly different from 
those expected under neutrality (P < 0.05)
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Figure 35. SNP frequency spectrum and Pairwise mismatch distribution histograms
A) A frequency spectrum of SNP alleles. Bars represent the observed frequency of SNP alleles and the line indicates the frequency expected 
under a model of neutral evolution.
B) Pairwise mismatch distribution among FM03 haplotypes. Bars show the observed frequencies of the numbers of differences between all 
pairs of the 44 haplotypes in the Japanese potential TMAU sufferers.
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The pairwise difference distribution among FM03 haplotypes was examined using the 
Rogers’ mismatch distribution test [179]. The result showed a multimodal, also known 
as ragged, distribution (Figure 35 B) with a raggedness index of 0.16 for the potential 
TMAU sufferer group and 0.37 (P < 0.02) for the control group (Table 12).
Linkage disequilibrium
Zns [181], Wall’s B and Wall’s Q [180], were used to assess whether the strong LD which 
occurred throughout the FM03 locus (Figure 32) was consistent with a neutral model of 
evolution. In the control group, values of Z„$, Wall’s B and Wall’s Q were all significantly 
higher than expected under neutrality (Table 12). Z„s and Wall’s B for the potential TMAU 
sufferers was significantly high when compared with estimates obtained from simulations 
performed for the level of recombination observed in this group (P < 0.05).
Inter-specific comparisons of the FMQ3 locus
Comparison of the sequenced regions of the human and chimpanzee (Pan troglodytes) 
(Ensembl [280] genebuild (August 2006 PanTro 1.0)) FM03 locus revealed 49 fixed 
differences. Eight of these were in coding regions of which two were non-synonymous 
variants (247G>A in exon four generating a R116H variant and 1421A>T in exon 9 
generating a D474V variant). The average nucleotide divergence per silent site between 
human and chimpanzee within the sequenced regions of the FM03 locus was found to be 
0 .010.
The McDonald-Kreitman test, a test of neutrality that is not dependent on 
assumptions about population history, was used to compare the ratio of replacement to 
silent polymorphisms within humans with the ratio of replacement to silent fixed 
differences between humans and chimpanzee (Table 14). The test indicated that the
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Table 14. McDonald-Kreitman test of neutrality
S ilent R ep lacem en t F ish er 's  ex a c t test
F ixed
P olym orphic
4 7  2 P < 0.05  
12 4
Numbers of polymorphisms and fixed difference founds at both silent and replacement 
(those that change amino acid residue) sites in the 44 chromosomes are contrasted with a 
2 x 2  Fisher’s exact test of independence.
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number of replacement SNPs in human FM03 is significantly more than would be expected 
under a neutral model of evolution (P > 0.05).
Evolution of the FMQ3 locus - Discussion 
FMQ3 nucleotide sequence variation
There was a marked paucity of low-frequency variance with regards to the SNPs present in 
the population sample of FM03. The finding that of the seven mild TMAU sufferers, six 
have a haplotype pair that is the same as present in unaffected individuals is perhaps not as 
surprising when one considers that those six individuals had haplotype 1 as one of the 
haplotypes. This haplotype is the ancestral haplotype and as such can be considered to 
code for a wild-type FM03. TMAU is a recessive condition, where severely affected 
individuals have both of their FM03 alleles containing mutations leading to perturbation or 
destruction of FM03 activity. The individuals in this study were assessed biochemically 
and diagnosed as having borderline or mild TMAU (Table 15).
Evidence that the sample has undergone only one recombination event (see 3.4.) is 
indicative of strong linkage disequilibrium (LD).
Evolutionary History of FMQ3
The presence of homoplasic sites is indicative either of recurrent mutations or 
recombination events. Haplotype 4 may have arisen via a recurrent mutation of the 
ancestral haplotype at position 158. However, the mutation at the 15167 (G>A) (encoding 
amino acid 158) site is not a CpG site and thus would not be subject to a markedly higher 
rate of mutation. A more likely origin is via a single recombination event that took place 
between sites -2650 and 15167 on an ancestral haplotype and a haplotype corresponding to
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Table 15. Genotype and biochemical phenotype of individuals potentially suffering from
TMAU
Genotype
(haplotype
pair)
Total TMA
(mmol/mol
creatinine)
Free TMA 
(mmol/mol 
creatinine)
TMA A/-oxide 
(% of total 
TMA)
Diagnosis
1-1 123.7 4.7 96 Unaffected
1-1 88.7 11.0 88 Mild
1-2 70.1 12.9 82 Mild
1-2 44.0 2.6 94 Unaffected
1 -3 71.7 21.0 71 Mild
1 -3 69.0 4.0 94 Unaffected
1-5 60.7 1.8 97 Unaffected
1 -5 85.1 22.2 74 Mild
1 -6 127.5 13.0 90 Borderline
1-6 32.8 1.6 95 Unaffected
1 -6 156.0 0.8 99 Unaffected
1 -6 70.0 14.0 80 Mild
1 -6 36.9 1.0 97 Unaffected
1 -6 110.0 1.1 99 Unaffected
3 -4 116.5 10.6 91 Borderline
3 -6 64.6 0.8 99 Unaffected
3 -6 157.1 2.2 99 Unaffected
4-7 121.2 16.0 87 Mild
6 -6 119.4 13.0 89 Mild
6 -6 109.8 10.1 91 Borderline
6-7 117.0 6.2 95 Unaffected
6-7 49.1 0.5 99 Unaffected
Free TMA and TMA A-oxide were measured in the first void urine of the morning of each 
individual. The haplotype pair of each individual is shown along with the diagnostic urine 
analysis, which was carried out by the Yamazaki Group, Showa Pharmaceutical University, 
Japan.
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the node located on the branch linking the central node to haplotype 6. The haplotype 
corresponding to this node would have contained a mutation at site 158, but not sites -3549 
or 21448 (encoding amino acid 308), indicating that the mutation at site 15167 (encoding 
amino acid 158) pre-dated the occurrence of the latter two mutations. The recombination 
event inferred from the RM network corresponds to that predicted by the four-gamete test 
(see above). Data from dbSNP [230], which indicate that the SNP at codon 158 occurs 
more frequently than that at codon 308, supports the conclusion that the former mutation 
occurred before the latter.
Time depth
The net sequence divergence was estimated as 47.31. This gave a neutral mutation rate (v) 
of 7.78 x 10'10 per site per year which is similar to estimates for many other human nuclear 
loci [281]. The effective population size (Ne) was calculated, from the relationship 0 = 
4Nep, as 10,463 (very close to the average value determined from other genes [281-286]). 
The calculated value of the T m rca  of 842 kyr BP from the coalescent model was very close 
to the estimate obtained from the maximum-likelihood coalescent analysis of 872 thousand 
years (kyr) BP (S.D. = 226 kyr BP). Thus two independent methods of calculation give 
very similar estimates for the time-depth of the FM03 gene tree, which correspond to that 
expected for nuclear genes. Thus most of the mutations in the sample, including the SNPs 
at 158 and 308, probably arose before the origin of modem humans some 150-200 kyr ago 
[281, 287] and almost all probably predated the migration out of Africa, estimated to have 
occurred 50-100 kyr ago [281, 287]. Of the identified SNPs that are present in dbSNP (- 
3606, -2854, 158 and 257), all occur in African, European and Asian populations, as does 
the SNP at 308 [248], which supports their pre-out-of-Africa origin. The estimated age of
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the most recent mutation in this study at nucleotide 15549 (R205C) indicated that it may 
have arisen after migration out of Africa and thus may be restricted to Eurasian or Asian 
populations. This is supported by the presence of the mutation in Asian, but not African or 
European, populations.
Tests for departure from neutrality -  a case for balancing selection
A higher value of 0w and tt, for both the potential TMAU sufferers and control groups 
(Table 12) and, consequently, a positive Tajima’s D, implies an excess of moderate 
frequency compared to low-frequency variants, though the excess is not statistically 
significant.
Positive Fu and Li’s F* and D* values indicate a significantly high proportion of 
‘old’ versus ‘young’ mutations, suggesting balancing selection or population subdivision. 
The Fst value of 0.050 among the populations in the dbSNP panels for the four SNPs 
covered indicated that only 5% of the observed variation was due to differences among 
populations. This value is lower than that typically observed for nuclear genes -0.15 [281, 
288-290], and is lower than the values reported for 80% of 25,549 SNPs [291]. This trend 
of FM03 haplotype diversity has been reported recently in African Americans, non-Latino 
whites and Hispanics of Mexican descent [60]. The low Fst values estimated for the FM03 
SNPs suggests that little genetic differentiation of FM03 has occurred among continental 
populations and suggests that the positive Fu and Li’s D* and F* are more likely due to 
balancing selection than to population subdivision.
The excess of intermediate-frequency SNPs, in both the patient and control groups, 
compared to the number expected under a neutral model of evolution are suggestive of 
balancing selection. Most genes studied to date differ from this in that they contain an 
excess of rare alleles, which has been interpreted as either being due to positive selection or
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population growth [292]. The significantly positive value of Fu’s Fs (P>0.02) indicated an 
excess of intermediate-frequency haplotypes, supporting the earlier findings that this may 
be due to balancing selection acting on the FM03 locus. This paucity of haplotypes was 
significant (P>0.01), considering the extent of nucleotide diversity of the sample, which 
futher supports this interpretation.
The multimodel distribution observed by the Rogers’ mismatch test and 
Harpending’s Raggedness test is typical for a distribution observed when balancing 
selection is in effect or where the population size has remained constant over a long period 
[179]. This is in contrast to a unimodel, also known as smooth, distribution, which is 
typical of a population growth or directional selection [179] and which is exhibited by the 
majority of genes studied to date [292].
The results of significant Zns, Wall’s B and Wall’s Q tests are compatible with 
balancing selection acting on the FM03 locus, which would be expected to result in LD 
among selectively neutral polymorphic sites closely linked to the sites under selection.
The average nucleotide divergence per silent site between human and chimpanzee 
within the sequenced regions of the FM03 locus was consistent with that of other genes 
[191,288, 293].
The McDonald-Kreitman test, indicating that the number of replacement SNPs in 
human FM03 is significantly more than would be expected under a neutral model of 
evolution, could be construed as balancing selection or slightly deleterious selection. In the 
latter case, although purifying selection would prevent a slightly deleterious amino acid 
variant from attaining a high frequency, it may be weak enough to allow the variant to be 
maintained at a low frequency. However, replacement polymorphisms of FM03 are not all 
rare, with two of the four having a moderate frequency (>30%), which would favour 
balancing rather than slightly deleterious selection.
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The analysis of the FM03 samples from the two cohorts of Japanese individuals 
generated results based on phylogenetics, allele frequency spectrum, the number, frequency 
and mismatch distribution of haplotypes, linkage disequilibrium and inter-specific sequence 
comparisons, which all provide evidence for the FM03 locus undergoing a period of 
balancing selection. The failure of several of the test statistics used in this investigation to 
detect selection where there is independent, compelling evidence of such (as in the cases of 
the p-globin [282] and Duffy blood group loci [294]) underscored the strength of the signal 
of detection for the departure from neutrality in the FM03 locus where significant values 
were attained for all tests. It has been shown that the vast majority of human genes 
investigated display negative Tajima’s D [295], an allele frequency spectrum skewed to the 
left due to an excess of rare alleles [296] and a haplotype mismatch distribution that is 
unimodal [296], interpreted as evidence of the expansion of the human population, which 
would obscure any affects of balancing selection. Therefore, our results represent strong 
evidence for balancing selection at the FM03 locus.
Balancing selection can maintain variation in the population for longer than would 
be expected under a neutral model of evolution. It is characterised by an excess of alleles at 
intermediate frequency and a phylogeny in which > 2 lineages are separated by relatively 
large branching, giving the network an old coalescence. These characteristics have been 
presented describing the FM03 locus. The variants being maintained would be expected to 
confer a selective advantage in order to be maintained in a population, of which the 
determination of the identity and phenotypic consequences are extremely difficult to 
determine. In the case of the FM03 locus, two haplotypes, 1 and 6, have been maintained 
at an intermediate frequency over long periods. Haplotype 1 is the ancestral form whereas 
Haplotype 6 contains three SNPs in the 5’-flanking region and two coding region SNPs 
(corresponding to amino acid variants E158K and E308G) (Figures 33 and 34). Both
165
coding region SNPs are relatively old, with ages estimated as 363,000 years and 200,000 
years respectively (see section 3.4.). The coincidence of the two variants is interesting as 
they have been reported clinically and in the FMO community for several years. As 
mentioned earlier (section 3.2.), although E158K and E308G individually have little affect, 
when found in cis this study has shown (and others in the past have also shown) that this 
can result in a reduction in FM03 activity [21, 147]. The FM03 substrate metabolism 
shown to be affected by this double variant also mentioned earlier (see section 3.2., 
ranitidine [147], thiobenzamide [147] sulindac [5]), is of great interest. Of particular 
interest is the sulindac case, where the E158K/E308G variants were found to have a 
protective effect on the development of polyps in familial adenomatous polyposis patients 
who received sulindac as a means of primary chemoprevention, presumably reducing the 
ability of the enzyme to inactivate the drug, leading to prolonged exposure [260]. This 
instance gives rise to the possibility that the maintenance of haplotypes that encode versions 
of enzymes displaying substrate-dependent differences in catalytic activity may confer an 
evolutionary advantage, enabling polymorphic individuals to retain the ability to detoxify 
harmful xenobiotics while reducing their metabolic capacity to inactivate a natural 
compound that has a beneficial effect.
Although not present at such a high frequency as Haplotypes 1 and 6, Hapotype 3 
coalesced with other haplotypes some 675,000 years ago. Evidence exists for three of the 
ten upstream SNPs that make up Haplotype 3, that their presence increases FM03 
promotion 8-fold [141]. These SNPs (-2650, -2543 and -2177) presumably lie in the FM03 
promoter region, which is poorly defined at present. Sequences upstream of -2714 were not 
investigated by these authors, so the effect on promoter activity of the other SNPs in 
Haplotype 3 is not known at this time. However, it is still reasonable to speculate that 
individuals possessing Haplotype 3 would express greater amounts of FM03 and thus, on
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the one hand are able to detoxify harmful foreign chemicals more quickly but on the other 
hand also metabolise therapeutic agents that are substrates of this enzyme more quickly, 
possibly lowering drug efficacy and thus therapeutic benefit.
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4. Summary
Evolution is shaped by differences at a genetic level between and among species, with 
SNPs contributing a significant potion of these differences. This investigation has 
considered the SNPs of FM03 and their importance to the molecule in terms if its 
evolution, biophysical properties, structure and catalytic efficiency. This is of importance 
to human health not only because of the importance of FM03 in clearing potentially 
harmful xenobiotics from the body, but also because of the variation in SNP and allelic 
frequencies of the haplotypes they make up, between populations. In the case of 
therapeutic drugs, the likely efficacy of such drugs in patients with perturbed xenobiotic 
metabolism would depend on the population with which you are dealing. On an individual 
case basis, the genotype of the individual could be used to predict the likely outcome of 
administering a drug. Such pharmacogenetic considerations are becoming more important 
in the development phase of drug-development [297, 298] and any information that can be 
learned in this area is of interest.
This study considered the rare mutations in FM03 that cause the disease TMAU. 
The distress and strain that this disorder puts on the individual and their loved ones can not 
be understated and research into this disease is important. This investigation presented 
patient studies including one family study which resulted in the discovery of two novel 
variants of FM03, R492Q and R238Q. R238Q was generated, assessed in vitro for
catalytic efficiency and found to be catalytically inactive.
This study also considered the relevance of commonly occurring polymorphisms of 
FM03. Of particular interest was of the occurrence of two common polymorphism in cis, 
E158K and E308G. When found together, these variants cause a significant reduction in 
enzyme efficiency, when compared to when found alone and also compared to 
E158K/V257M, another relatively common polymorphism pairing found in cis. The
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outcome of the kinetic investigation of this study supported the consequences of the double 
mutant. This is of pharmacogenetic interest due to the case of the E158K/E308G variant 
having a protective effect on the development of polyps in familial adenomatous polyposis 
patients who received sulindac as a chemotherapy agent, presumably by reducing the ability 
of FM03 to catalyse the metabolism of sulindac 5-sulphide to the sulindac 5-sulphoxide 
thus reducing the capacity of FM03 to inactivate the drug. The maintenance of such a 
seemingly destructive haplotype in the population at relatively high frequencies is 
consistent with this investigation’s proposal that FM03 is under balancing selection, 
presented in section 3.4., along with an in-depth evolutionary study of the FM03 locus.
To try and understand the mechanistic consequences of the amino acid changes 
caused by these common SNPs and to understand the FM03 molecule as a whole, a 
homology model was generated. Figure 36 shows the homology model with the variants 
tested for catalytic activity highlighted. The physical proximity of the amino acid residues 
at sites 158 and 308 compared to that of 158 and 257 may offer some kind of clue as to why 
the consequences of there being variations in the amino acids at both sites have such 
different consequences. Both polymorphisms have been shown to cause limited catalytic 
change individually, but when both are changed to K158 and G308, it could be imagined 
that the physical proximity of the two residues would become critically close to a threshold 
that a double mutation breaches, lowering catalytic activity. Why the double variant 
E158K/V257M seemingly caused a significant lowering in catalytic activity is not obvious. 
The two residues are extremely far apart on the model generated in this study. The exact 
nature of the V257 residue’s contribution is difficult to show from this model as this area 
was of low coverage in the template used to build the model. The same can be said of 
R238. Why this residue, when changed to R238Q, seems to destroy catalytic activity, 
shown in vivo and in vitro in this investigation, is not clear.
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Figure 36. A cartoon representation of the homology model built of FM 03, built as 
part of this investigation
The FM03 polymorphisms E158K (blue), V257M (orange) and E308G (cyan), generated 
and probed as part of a kinetic study (section 3.2.), featured within both an evolutionary 
(section 3.4.) and TMAU patient screen (section 3.1.) are highlighted as spheres. Also 
highlighted as spheres is the R238Q variant (pink) which is a novel FM03 variant 
described in section.3.1. and also investigated by kinetic studies, in section 3.2.
FM03 is a fascinating molecule. Such an important molecule, found at abundant 
levels in the liver, yet with so much ancient variation at a genetic level, contributes to a 
diverse genotypic and phenotypic distribution spread among the populations of the planet. 
The broad range of xenobiotics from our increasingly harmful environments, not to mention 
the many that we introduce willingly that FM03 metabolises, means that anything we can 
learn about it is of value. It has been recognised that drug-designers and pharmaceutical 
development as a whole have not appreciated FMOs as major contributors to drug 
metabolism. Because FMOs are seemingly not inducible, unlike the CYPs, the drug-drug 
interactions involving induction are not an issue, though those involving enzyme inhibition 
are still of importance to pharmaceutical licensing. This means that a case where one drug 
is taken which, perhaps as a side-effect, induces expression of an FMO, which in turn, due 
to the abundance of the enzyme, metabolises a second drug taken concurrently by a patient 
thus lowering the efficacy, is not a scenario which needs to be considered, unlike with the 
CYPs which are inducible. As mentioned earlier, a pharmacogenetic case involving FM03 
variation has been reported in the metabolism of the chemotherapy agent, sulindac (see 
sections 3.2. and 3.4.).
Pharmacogenetic information has the potential to improve therapeutic efficacy as 
we learn more about the genetic contribution to drug metabolism. Whether this potential is 
realised remains to be seen.
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